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The accumulation of Amyloid beta peptide 1–42 (Aβ1–42) in extracellular plaques is one of the 
pathological hallmarks of Alzheimer’s disease (AD). Several studies have suggested that a 
cellular reuptake of Aβ1–42 may be a crucial step in its cytotoxicity, but mechanisms of Aβ–
membrane interaction and subsequent cellular uptake are not yet understood. Aβ may be 
present in an aggregated form prior to cellular uptake. Alternatively, monomeric peptide 
may enter the endocytotic pathway and conditions in the endocytotic compartments may 
induce the aggregation process. The first aim of the present study is therefore to answer the 
question whether aggregate formation is a prerequisite or a consequence of Aβ–membrane 
interaction and of Aβ endocytosis. We visualized aggregate formation of fluorescently 
labeled Aβ1–42 by Förster resonance energy transfer (FRET) and tracked its internalization by 
human neuroblastoma cells. Both aggregated and monomeric Aβ1–42 entered the cells, 
however, monomer uptake faced a concentration threshold and occurred only at 
concentrations and time scales that allowed β–sheet–rich aggregates to form. By uncoupling 
membrane binding from internalization, we found that Aβ1–42 monomers as well as small 
aggregate species bound rapidly to the plasma membrane and formed β–sheet–rich 
aggregates. These structures were subsequently taken up and accumulated in endocytic 
vesicles. This process correlated with inhibition of cellular metabolism activities. Our data 
therefore imply that the formation of β–sheet–rich aggregates at the cell membrane is a 
prerequisite for Aβ1–42 uptake and cytotoxicity. The second aim of the study is to investigate 
the Aβ–membrane interaction in vitro by using giant unilamellar vesicles (GUVs) and giant 
plasma membrane vesicles (GPMVs) as model membrane systems. We found that both Aβ 
isoforms, Aβ1–42 and Aβ1–40, interacted with the liquid disordered (Ld) phase of model 
membranes. Early aggregation intermediates of Aβ, which did not yet bind to the 
amyloiddophilic dye Thioflavin T (ThT), induced negative membrane (lipidbilayer) curvature. 
The ability of Aβ to induce membrane deformation suggests that Aβ may facilitate its own 
endocytosis. It also hints at a possible physiological function of non–toxic Aβ aggregate 
species.   
 









Das Amyloid–beta Peptid (Aβ) ist der Hauptbestandteil der extrazellulären Plaques bei der 
Alzheimerschen Krankheit (AD). Die Aufnahme von Aβ aus dem extrazellulären in den 
intrazellulären Raum, die wahrscheinlich durch Endozytose erfolgt, könnte eine 
entscheidende Rolle bei der zytotoxischen Aktivitätvon Aβ spielen. Das Ziel der vorliegenden 
Arbeit ist es, die Mechanismen der Wechselwirkungen des Aβ Peptids, insbesondere von  
Aβ1–42, mit der Plasmamembran und der nachfolgenden zellulären Aufnahme aufzuklären. 
Die Aggregation, die zelluläre Aufnahme und die Zytotoxizität von Aβ1–42 wurden durch 
Verwendung von fluoreszenzmarkierten Aβ1–42 in einem Neuroblastomzellkulturmodell 
untersucht. Sowohl bei Inkubation mit Monomeren als auch mit Aggregaten wurde in den 
Zellen fluoreszenzmarkiertes Aβ1–42 detektiert. Dabei binden Aβ1–42 Monomere und kleine 
Aggregate zunächst an die Zellmembran. Allerdings erfolgt keine direkte Aufnahme von 
Monomeren in die Zelle. Erst nach Ausbildung von Aggregaten mit geordneter 
Sekundärstruktur wurde Aβ1–42 in den endozytotischen Vesikel mittels konfokaler 
Mikroskopie detektiert. Dieser vorangehende Aggregationsprozess von an der Zellmembran 
gebundenem Aβ1–42 wurde durch Förster–Resonanzenergietransfer (FRET) nachgewiesen. 
Voraussetzung für den an der Membran ablaufenden Aggregationsprozess ist, dass die 
Monomere oberhalb einer kritischen Konzentration anwesend sind, um nach ausreichender 
Inkubationszeit eine Bildung von β–Faltblatt–Strukturen und entsprechenden Aggregaten zu 
ermöglichen. Aβ1–42 Aggregate, die sich durch eine β–Faltblatt–Strukturenauszeichneten, 
benötigten keine kritische Schwellenkonzentration für die endozytotische Aufnahme. D.h., 
eine vorangegangene Bildung entsprechender Aggregate, deren β–Faltblatt–Struktur durch 
das Fluorophor ThioflavinT und/ oder ThioflavinS (ThT, ThS) nachgewiesen werden konnte, 
beschleunigt die zelluläre Aufnahme von Aβ1–42. Eng mit der Aufnahme von Aβ1–42 
Aggregaten war die Veränderung des zellulären Metabolismus verbunden. Um die 
Wechselwirkung zwischen Aβ und der Membrannäher zu charakterisieren, wurden 
Modellmembransystemen einschl. riesigen Membranvesikeln (giant unilamellar 
vesicles(GUVs) und giantplasmamembranevesicles(GPMVs)) genutzt. Dabei wurde 
beobachtet, dass sowohl Aβ1–42 als auch Aβ1–40 Einstülpungen in der Membran induzieren 
können. Kleine Aggregate beider Isoformen, die noch keine β–Faltblatt–Struktur aufweisen, 
interagierten bevorzugt mit der ungeordneten Lipidphase (liquid disordered, Ld) und 




Schluss nahe, dass möglicherweise das Aβ Peptid selbst den endozytotischen Prozess 
unterstützt oder diesen sogar einleiten könnte. Dies könnte auch auf eine mögliche 
physiologische Funktion von Aβ Aggregaten, die nicht toxisch sind, hindeuten. 
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AD Alzheimer’s disease 
APP amyloid precursor protein 
Aß1–40 amyloid beta 1–40 peptide 
Aß1–42 amyloid beta 1–42 peptide 
BACE β–site APP–cleaving enzyme 
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BT Bleed–Through  
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DOPC dioleoyl phosphatidylcholine 
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DTT dithiothreitol 
EEA early edosome antigen 
EM electron microscopy 
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FRET Förster resonance energy transfer 
GEEC glycosyl phosphatidylinositol–anchored protein enriched early endosomal 
compartments 
GPMV giant plasma membrane vesicles 
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LAMP2 lysosome–associated membrane protein 2 
Ld liquid–disordered 
LDL low–density lipoprotein 
LDLR low–density–lipoprotein receptor 
Lo liquid–ordered 
LUV large unilamellar vesicle 
MLV multilamellar vesicle 
MTT 3–(4,5–dimethylthiazol–2–yl)–2,5–diphenyltetrazolium bromide 
MW molecular weight 
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RT room temperature 
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SSM n–stearoyl–D–sphingomyelin 
SUV small unilamellar vesicle 
TCEP tris(2–carboxyethyl)phosphine 
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1.1  Overview of neurodegenerative diseases 
Neurodegeneration relates to the pathological condition primarily affecting neurons, that 
results in a progressive loss of neuronal structure, function and neuronal death (Martin 1999; 
Przedborski et al. 2003; Dickson 2010). The loss of specific populations of neurons affects 
various functional systems, like pyramidal and extrapyramidal motor system or the higher 
order association and limbic cortices (Dickson 2011). The neuronal loss and damage of 
neurons in the function area of brain can lead to many different clinical symptoms, such as 
dementia, reduced motor control and psychological abnormalities.  
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Traditionally classification of the neurodegenerative disorders was according to the clinical 
syndromes and the anatomical distribution of neuropathology, e.g. Alzheimer’s disease (AD), 
Parkinson’s disease, Huntington’s disease, Spinocerebellar ataxia and Amyotrophic lateral 
sclerosis as listed in Table 1–1 (Martin 1999; Dickson 2011).  
The developments of molecular genetics, biochemical immunocytochemical and biophysical 
techniques (Burke et al. 2013), allowed to characterize the neurodegenerative disorders by 
the proteins, that accumulate within cells or in the extracellular space. Protein deposits 
within the affected tissues are a characteristic feature of many neurodegenerative diseases 
(Table 1–1). 
The causes of neurodegenerative disease can be genetic mutations (Bertram & Tanzi 2005); 
medical conditions like alcoholism (Nixon 2006; Morris et al. 2010), tumors (Wang et al. 
2013; Rice et al. 2003); viral infections (Zhou et al. 2013) like the infection of herpes simplex 
virus (Ito et al. 2000; Mégret et al. 2007) or influenza virus (White et al. 2014; Jang et al. 
2009; Mori & Kimura 2001; Sulkava et al. 1981). However, in many cases of Alzheimer’s and 
Parkinson’s disease patients, the cause remains unknown.  
1.2 Alzheimer’s disease 
AD is the most common fatal neurodegenerative disorder over 65 years of age (Glenner 
1983; LaFerla et al. 2007; Babusikova et al. 2011; Brookmeyer et al. 1998) and belongs to the 
top 10 leading causes of death in USA (Alzheimer’s Association 2015; National Center for 
Health Statistics 2015).  
AD was first described by the German psychiatrist and neuropathologist Alois Alzheimer. In 
1906, he reported a case of a 51 years old patient named Auguste Deter, who suffered from 
senile dementia and died five years later, at the age of 56 (Alzheimer 1907).  
The major characteristic symptoms of AD are cognitive failures, impairment of memory and 
dramatic changes in behavior, with  symptoms like loss of memory, problems with language, 
personality and mood changes (LaFerla et al. 2007; Babusikova et al. 2011). The 
understanding of cause and pathophysiology of AD is still very limited. An effective early 
diagnosis , therapy or prevention of AD are not available (Babusikova et al. 2011).  
1.2.1 Characteristic microscopic findings of AD 
Examining the preparations of the brain of the patient by using microscopy, Alzheimer found 
plaques that could be stained with Iodine (Figure 1–1) (Alzheimer 1907; Perl 2010). Emil 
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Kraepelin described this disease in his book ‘Psychiatrie’ and named it Alzheimer‘s disease 
(AD) (Alzheimer 1907). Structures that could be stained in such a way had been described by 
Rudolf  Virchow as ‘starch–like’ or amyloid (Virchow 1853). The modern biophysical 
definition of amyloid focuses on their unique protein folding structure, in which 
intermolecular β–pleated sheets form a twisted fibrillar superstructure that can be detected 
by X–ray diffraction (Dobson 2003; Dobson 2004).  
 
 
1.2.2 Amyloid and tau hypothesis 
The causes for most cases of AD are still unknown. However, 5–10% of AD patients with 
early–onset disease (< 65 years) suffer from familiar AD, caused by several mutations that 
were identified either in the amyloid precursor protein (APP), or inpresenilin 1 and presenilin 
2, which are involved in the processing of APP as discussed in 1.3 (Campion et al. 1995; Levy–
Lahad et al. 1995; Mullan et al. 1992; Rogaev et al. 1995; Babusikova et al. 2011).   
The devastating neuropathology of AD is tightly linked to two polypeptides: the Amyloid 
beta peptide (Aβ), which deposits extracellularly in the cortical plaques (G G Glenner & 
Wong 1984; George G. Glenner & Wong 1984), and the tau protein, which deposits 
intracellularly in neurofibrillary tangles (Lee et al. 1991; Grundke–Iqbal et al. 1986). 
Figure 1–1: Photomicrograph of the temporal cortex of a patient with Alzheimer's disease (AD). Two 
senile (neuritic) plaques (arrow A) with a neurofibrillary tangle (arrow B) between them are shown, 











1.3 APP processing and Aβ generation 
The amyloid precursor protein (APP) is a transmembrane glycoprotein (O’Brien & Wong 
2011). Its physiological function is still unclear (Babusikova et al. 2011). The amino–terminal 
(N–terminal) end of APP may be localized toward to the extracellular space or may be 
localized in the lumen of intracellular vesicles (Babusikova et al. 2011; Neve et al. 2000). The 
carboxy–terminal (C–terminal) end of APP is the cytoplasmic domain (Babusikova et al. 
2011).  
Aβ is generated at cholesterol–rich regions of neuronal membranes by proteolytic cleavage 
of the APP via groups of enzymes or enzyme complexes termed α–, β– and γ–secretases 
(Figure 1–2) (Jarrett et al. 1993; Shoji et al. 1992; Simons et al. 1998; LaFerla et al. 2007).  
Three enzymes of  the ADAM family with α–secretase activity have been identified: ADAM9, 
ADAM10 and ADAM17 (LaFerla et al. 2007; Allinson et al. 2003). The β–secretase, a type I 
integral membrane protein, is a β–site APP–cleaving enzyme 1 (BACE1) (Hussain et al. 1999; 
Sinha et al. 1999; Vassar et al. 1999; LaFerla et al. 2007). The γ–secretase is a enzymes 
complex, consisting of presenilin 1 and 2 (PS1 and PS2), nicastrin, anterior pharynx defective 
and presenilin enhancer 2 (Francis et al. 2002; Levitan et al. 2001; Steiner et al. 2002; Wolfe 
et al. 1999; Yu et al. 2000; LaFerla et al. 2007). 
There are two pathways of the cleavage and processing of APP: a non–amyloidogenic 
pathway and an amyloidogenic pathway (Figure 1–2) (LaFerla et al. 2007):  
- In the non–amyloidogenic pathway (Figure 1–2), APP is cleaved by the α–secretase at 
a position 83 amino acids from the C– terminus, producing a large N–terminal 
ectodomain (sAPPα), which is secreted into the extracellular medium (Kojro & 
Fahrenholz 2005; LaFerla et al. 2007). The product, a 83–amino–acid C–terminal 
fragment (C83), will still remain in the membrane (Haass et al. 1993; LaFerla et al. 
2007). In this pathway, the cleavage of APP by the α–secretase occurs within the Aβ 
region, which may prevent formation of full–length Aβ (LaFerla et al. 2007). C83 
fragment could also be cleavaged by the γ–secretase, a short peptide p3 and APP 
Intracellular Domain (AICD) would be then produces (Haass et al. 2012). 
- In the amyloidogenic pathway (Figure 1–2 and Figure 1–3 a) , Aβ peptide is produced 
by endoproteolysis of APP by β– and γ–secretases and is secreted into the 
extracellular space (LaFerla et al. 2007). APP is at first cleaved by the β–secretase at a 
position located 99 amino acids from the C terminus; and then the membrane 
domain, 99–amino–acid C–terminal (C99), with newly generated N terminus of Aβ is 
cleaved by γ–secretase into fragments of 43 –36 aa length with in the membrane 
(LaFerla et al. 2007), which is then processed further to yield peptides of 37–43 aa. 
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While Aβ release by γ–secretase cutting, AICD, the rest part of C99, is released into 




Most of the produced Aβ peptide is 40 residues in length (Aβ1–40), whereas a small 
proportion (approximately 10%) is the 42 residue variant (Aβ1–42, Figure 1–3 a and b) (LaFerla 
et al. 2007; Ahmed et al. 2010). Two additional hydrophobic residues, Ile–41 and Ala–42, at 
the C–terminus, let Aβ1–42 is more hydrophobic than Aβ1–40, that may lead Aβ1–42 more prone 
to form fibril (Jarrett et al. 1993). Under the same aggregation conditions, such as the 
concentration of Aβ peptide, the compositions of buff solution, temperature and the 
frequency of mechanic shaking, Aβ1–42 aggregates more quickly than Aβ1–40 in vitro 
(Hasegawa et al. 1999; Ball et al. 2013; Jarrett et al. 1993).  
Both types of Aβ form small soluble aggregates (Figure 1–3 c), insoluble fibrils (Figure 1–3 d) 
and plaques in the extracellular space of the brain in AD patients (Masters et al. 1985; 
George G. Glenner & Wong 1984). Aβ1–42 is the predominant isoform found in cerebral 
plaques (Younkin 1998; LaFerla et al. 2007), causes more extensive damage to cultured 
neuronal cells than Aβ1–40 (Iwatsubo et al. 1996; Suzuki et al. 1994; Gravina et al. 1995; 
Roher et al. 1993; Dahlgren et al. 2002; Ball et al. 2013). Those observations suggest that the 
addition of the two C–terminal residues has a significant effect on the physiological and 
biophysical behavior of the two type of Aβ isoforms (Ball et al. 2013). 
The experiments of present study will therefore largely focus on the Aβ1–42 behaviors of 
cultured cells and of model membrane systems. 
Figure 1–2: Two pathway of amyloid precursor protein (APP) proteolysis. Most APP is processed 
through the non–amyloidogenic pathway, which precludes Aβ formation. Figure adapted from LaFerla 









1.4 Formation of Aβ aggregates  
1.4.1 Protein folding and aggregation 
To perform their biological function, most proteins need to fold into three dimensional 
structures that determine their activities (Anfinsen 1973). The conformational stability of a 
protein is generally defined as the free energy change ( ΔG0 )of the equilibrium between the 
folded/native and the unfolded/denatured state (Mirsky & Pauling 1936). A schematic 
energy landscape for protein folding, i.e. the intramolecular interaction, and protein 
aggregation, i.e. the intermolecular interactions, is shown in Figure 1–4 (Hartl & Hayer–Hartl 
2009).  In amyloid–forming polypeptides, the natively folded protein is not the lowest energy 
state. It is only meta–stable with respect to the amyloid fibril conformation. A substantial 
energy barrier prevents easy interconversion between both states. 
Figure 1–3: Aβ peptide structures. (a) The γ–secretase cleaves membrane domain (APP–CTF) of APP 
into different peptide length. Figure adapted from George–Hyslop & Schmitt–Ulms (George–hyslop & 
Schmitt–ulms 2010). (b) Sequence of human Aβ1–40 and Aβ1–42. (c–d) Models of monomeric Aβ1–42 
structure based on solid–state and solution NMR spectroscopy. (c) Aβ1–42 monomer in small 
aggregates within lag–phase (ThT negative). (d) Aβ1–42 monomer within fibril contained a β–turn––β 




1.4.2 Aβ aggregation – polymerization model  
The aggregation of amyloid peptide has been hypothesized to follow a nucleated 
polymerization mechanism (Burke et al. 2013; Lomakin et al. 1996; Murphy 2002; Chiti & 
Dobson 2006). The formation of aggregates is assumed to occur in two phases, first the 
nucleation phase or lag phase, which is a thermodynamically unfavored event; and second 
the elongation phase or growth phase (Figure 1–5) (Kumar & Walter 2011).  
1.4.2.1 Lag phase 
The formation of amyloid aggregates is a sequential addition of the monomers to a growing 
multimer (Figure 1–5). The thermodynamics of this process depend on the size of the 
multimer. It is unfavourable for the formations of dimmers and small oligomers. The 
monomer may be incorporated more easily, in regard to the reaction energy, when the 
multimer is larger than a critical size. This critical size (n monomer units) defines the nucleus, 
which has highest–energy on the polymerization pathway (Bieschke et al. 2006; Frank 
Ferrone 1999; Goldstein & Stryer 1986; Powers & Powers 2008; Powers et al. 1986).  
Figure 1–4: Schematic energy landscape of protein folding and aggregation. The surface simulates 
the the energy landscape of folding of a small protein, and the energy levels of possible 
conformational states.  The unfolded state is the starting point for folding into a native structure, in 
order to minimize its free energy. The intermolecular protein (lilac) associations cause the energy 
minimum of those higher order species, such as fibril, deeper and sharper than native state (blue).  










In the Asakura and Oosawa model (Asakura & Oosawa 1954; Asakura & Oosawa 1958), 
reactions of a classical nucleated polymerization are characterized by: 
- a critical concentration (Kc), below which aggregates and/or fibrils cannot 
form; at peptide concentrations above Kc, aggregates grow until the 
monomer concentration decreases to Kc; 
- a lag phase before aggregates/fibrils form which can be eliminated by the 
addition of preformed aggregates (seeds or nuclei); 
- the rate limiting step is the formation of seeds/nuclei to promote aggregation, 
i.e. aggregate formation rate depend strongly on monomer concentration, 
which increases with the size of the nucleus.  
T50, a time at which the formation of aggregates/fibril approachs to 50% of steady state (the 
saturation phase), is used to present this concentration–dependent manner of Aβ 
aggregation kinetics. Common logarithm of t50 can be calculated as:          
  50
1log(t ) constant log
2 tot
n X   
 
         [1] 
Figure 1–5: Model of amyloid aggregation. The formation of amyloid aggregates/fibrils was 
hypothesized in a nucleation and an elongation phase. Typical kinetic of monomer aggregation is a 
sigmoidal curve with a slow lag phase and a rapid growth phase (green curve). Aggregation kinetic with 
preformed seeds (nucleus) display a very short lag phase (red curve). Figure adapted from Kumar and 
Walter (Kumar & Walter 2011). 
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where [X]tot is the total concentration of amyloid peptide, n is the number of subunits in the 
nucleus.  
Log–log plots of t50 versus [X]tot are often used in studies of amyloid fibril formation 
reactions to determine if the reaction follows the simple nucleation model (Arvintes et al. 
1993; Bieschke et al. 2006; Frankenfield et al. 2005; Hurshman et al. 2004; Powers & Powers 
2008; Serio et al. 2000; Sokolowski et al. 2003; Cohen et al. 2013). 
1.4.2.2 Elongation phase 
In the elongation phase, i.e. growth phase, the nuclei form speedily by adding of monomers, 
grow to reach the steady state. The larger polymers/fibrils will be then formed (Figure 1–5). 
In addition to the classical nucleated polymerization model, the formation of a higher order 
structure is suggested through a secondary nucleation pathway (Figure 1–6), that results 
from fibril fragmentation or it is a fibril surface catalyzed aggregation process (Meisl et al. 
2014; Cohen et al. 2013).   
 
 
Figure 1–6: Schematic representations of the microscopic steps in aggregation. (a) Overview of 
different aggregation processes, comparing their dependences on the concentration of monomers (m) 
and fibril, and their contribution to the number (P) and mass concentrations (M) of fibrils; with k+, the 
rate constants for elongation at fibril ends, kn, primary nucleation in solution of order nc. k2, secondary 
nucleation on the fibril surface of order n2, and k−, fibril fragmentation. (b) Reaction scheme for 
secondary nucleation. Monomers accumulate to an aggregate; monomers aggregate to an aggregate; 








1.4.3 Structural classification of Aβ aggregates 
Aβ aggregates accumulate extracellularly in specific regions of the brain of AD patients 
(Selkoe 2002). Because of the aggregation and the different preparation methods, Aβ has 
been observed in a variety of forms in vitro, such as disordered monomers, dimers, small 
oligomers, ring–like oligomers, protofibrils or twisted fibrils (Meinhardt & Fändrich 2009).  
The Aβ aggregates sizes range from dimers up to very large aggregates, for which molecular 
weights of more than a million Da have been reported in vitro (Morales–Penningston et al. 
2010; Glabe 2008; Harper et al. 1997; Walsh et al. 1999; Garzon–Rodriguez et al. 1997; 
Soreghan et al. 1994; Hilbich et al. 1991; Burdick et al. 1992).  
Oligomers of A were suggested to be the primary toxic species in AD (Glabe 2008; Lue et al. 
1999; McLean et al. 1999). These spherical particles of 3–10 nm are formed at an early phase  
of aggregation and  disappear as mature fibrils are formed (Anguiano et al. 2002; Lashuel et 
al. 2002; Glabe 2008; Harper et al. 1997). They are therefore intermediates in the pathway 
of fibril formation (Glabe 2008). However, there is no standard definition for “oligomer” with 
respect to size and structure. 
Under different conditions of preparation, soluble Aβ oligomers may show a rich variety in 
sizes, morphologies, such as amorphous aggregates, micelles, protofibrils, prefibrillar 
aggregates, globulomers, amylospheroids, toxic soluble Aβ, paranuclei and annular 
protofibrils, showing  different levels of cytotoxicity (Walsh et al. 1997; Burdick et al. 1992; 
Soreghan et al. 1994; Harper et al. 1997; Glabe 2008; Lashuel et al. 2002; Lomakin et al. 1997; 
Lambert et al. 1998; Bucciantini et al. 2002; Lesné et al. 2006; Barghorn et al. 2005; 
Yamamoto et al. 2007; Hoshi et al. 2003; Bitan et al. 2003). The size of the oligomers could 
be differentiated by sedimentation, size exclusion chromatography and gel electrophoresis 
(Glabe 2008).  
It is not easy to get a homogeneous Aβ oligomer preparaation with only one defined 
structure. The preparation is mostly heterogeneous, which may contain Aβ oligomers 
without β–sheets, with parallel β–sheets and/ or with antiparallel β–sheets (Glabe 2008; 
Ahmed et al. 2010). Small oligomers/aggregates are mobile and have a higher rate of 
diffusion (Glabe 2008), which may enable them to spread between cells. Due to their small 
size, the number of reaction ends for the monomer addition per unit mass of peptide is 
higher than for  large fibrils (Glabe 2008). If the growth of β–sheets is important for 







1.5 Interaction of Aβ and its aggregation on membrane 
surfaces 
Several studies have suggested that the interaction of misfolded proteins with liquid 
interfaces and surface plays a crucial role for protein–misfolding diseases, such as 
Alzheimer’s disease, Parkinson’s disease and Huntington’s disease (Burke et al. 2013). Lipid 
bilayer properties may modulate the protein conformations and influence their aggregation 
state (Burke et al. 2013).   
Based on its amphiphilic character, Aβ may have the ability to interact with membranes, and 
even insert into the lipid bilayer (Williams & Serpell 2011; Lansbury & Lashuel 2006; Burke et 
al. 2013). Additionally, Aβ is cleaved from APP and contains a part of the transmembrane 
domain of APP, suggesting that Aβ may be able to modulate the lipid bilayer function (Burke 
et al. 2013).  
Many observations indicate that the binding of Aβ to membrane could depend on the 
presence of specific lipid components, i.e, cholesterol (Burke et al. 2013; Yip et al. 2001; 
Reiss et al. 2004; Yu & Zheng 2012), sphingolipids (Burke et al. 2013; Van Echten–Deckert & 
Walter 2012), gangliosides (Burke et al. 2013; McLaurin & Chakrabartty 1996), and neutral or 
charged phospholipids (Burke et al. 2013; McLaurin & Chakrabartty 1997; Sabaté et al. 2005; 
Sabaté & Estelrich 2005; Sabaté et al. 2012).  
It has been hypothesized that aggregation of Aβ in or near membrane leads to disruption of 
membrane structure, change of the membrane curvature or creation of membrane pores 
(Figure 1–7) (McLaurin & Chakrabartty 1997; McLaurin & Chakrabartty 1996; Mirzabekov et 
al. 1996; Gorbenko & Kinnunen 2006; Burke et al. 2013). 
 
 
Figure 1–7: Schematic representations of potential mechanisms of amyloid/lipid association. (a) A 
schematic representation of the lipid bilayer. (b) Insertion of amyloid peptides into the lipid bilayer. (c) 
Lateral association of amphiphilic α–helices lipid–binding domains of amyloid peptide. (d) 









1.6 Internalization of Aβ 
The plaques in the brain of AD patients also contain numerous proteins other than Aβ1–42, 
which are normally only found in the intracellular space, such as lysosomal proteases or 
molecular chaperones (Friedrich et al. 2010). One hypothesis to explain this observation is 
that extracellular Aβ could be taken up by certain cells at low physiologically relevant 
concentrations of Aβ (Figure 1–8 a), and then concentrated into endosomes and lysosome 
(Hu et al. 2009). Concentrated Aβ in endocytic vesicles with low pH would find optimal 
conditions for a rapid aggregation (Hu et al. 2009).  
The intraneuronal accumulation of Aβ is also observed in transgenic mice model and human 
patients, suggesting that intracellular accumulation may contribute to disease progression 




Figure 1–8: Aβ1–42 cellular uptake and hypothetical pathway. (a) Cell uptake of FITC–Aβ1–42. SHSY5Y 
cells (a–A), primary murine cortical neurons (a–B) and HEK293 cells (a–C) were treated with 250 nM 
FITC–Aβ1–42 for 24 h, imaged by confocal/phase–contrast microscopy. Vesicular uptake of FITC–Aβ1–42 
was observed only in the neurons and SHSY5Y cells. No uptake could be observed in SHSY5Y cells by 
treating with 250 nM fluorescein (a–D) or FITC–scrambled–Aβ1–42 (a–E) for 24 h. A similar uptake as 
FITC–Aβ1–42 could be observed by treating with FITC–Aβ1–40 (a–F). Figures adapted from Hu et al (Hu et 
al. 2009). Scale bar, 10 µm. (b) Schematic representation of the mechanism of intracellular amyloid 
plaque formation. Pathway I, consistent with data by Friedrich et al, the formation of large 
intracellular aggregates is followed by the uptake of small and (white background). Hypothetical 
pathway II, the formation of large aggregates are extracellularly, they will be then taken up by the cells 
(gray background). Figure adapted from Friedrich et al (Friedrich et al. 2010). 
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Friedrich et al have speculated that, after association of soluble Aβ with the cells, the 
amyloid plaques would be formed intracellularly  (Friedrich et al. 2010). However, this is not 
the only possible pathway of Aβ internalization. In an alternative model, monomeric Aβ 
could aggregate extracellularly on the plasma membrane into oligomers, which are then 
endocytosed (Figure 1–8 b).  
The present study aims to answer the question, where the intracellular Aβ aggregates 
originate, and whether Aβ aggregation occurs in the extracellular space, on the membrane 
or in the endocytotic pathway. It will explore in detail the relation between Aβ aggregation, 
membrane interaction, endocytosis and toxicity.  
1.7 The plasma membrane  
The most basic function of biological membranes is to be a physically barrier, to separate the 
intracellular components from the extracellular matrix and to regulate exchange between 
the two spaces (Chan & Boxer 2007).  
Cellular membranes are formed by a large number of different lipid species and membrane 
proteins, including integral and peripheral membrane proteins, in various conformational 
states and topology, such as the number of transmembrane domains and their orientations 
in the membrane  (van Meer et al. 2008). Singer and Nicolson described a two dimensional 
cell membrane, called fluid mosaic model, which proteins molecules distributed among a 
large number of phospholipid molecules (Figure 1–9 a) (Singer & Nicolson 1972). Modern 
research found that multiple factors increase the complexity of the plasma membrane, such 
as the ratio between membrane proteins and lipid molecules, limited lateral diffusion or the 
function of channel proteins.  
 
        
Figure 1–9: General models for membrane 
structure. (a) The Singer–Nicholson “fluid 
mosaic model” (Singer & Nicolson 1972). (b) 
An amended and updated version based on 
original model by Singer and Nicholson. 









The fluidity of membrane is influenced by the lipid compositions of the membranes. Some 
lipids facilitate membrane deformations, such as budding, tubulation, fission and fusion, and 
allow aggregation of particular proteins in membranes (van Meer et al. 2008). Lipids can 
display rotational and lateral movements within the membrane (Mouritsen 2005). The lipid 
compositions as a percentage of the total phospholipid (PL) of different membranes in 
mammals cells and yeast are shown in Figure 1–10 (van Meer et al. 2008). Among them, 
phosphatidylcholine (PC) is always relatively dominant in all cell organelle membranes. 
 
 
Figure 1–10: Lipid synthesis and steady–state composition of cell membranes. The lipid composition 
of different membranes varies throughout the cell in mammals (blue) and yeast (light blue). In 
mammal cells, phosphatidylcholine (PC) is the major phospholipids of all the membranes, followed by 
phosphatidylethanolamine (PE) and sphingomyelin (SM) in plasma membrane, in membranes of late 




1.8 Model membrane systems 
To study particular lipid–lipid and protein–lipid interactions of complex natural membranes, 
different model systems have been developed (Chan & Boxer 2007; Stöckl & Herrmann 
2010). The simplified model membrane systems retain the bilayer structure, with defined 
individual lipid or protein components (Chan & Boxer 2007). The organization of these 
components and heir dynamics can be visualized (Chan & Boxer 2007). These systems can be 
grouped into two different classes by the topology of the membrane (Stöckl & Herrmann 
2010): 
- Planar model systems: the membrane forms planar structures in lipid 
monolayers or supported bilayers. 
- Vesicular model systems: the membrane forms a curved vesicular structure. 
Multilamellar vesicles are enveloped by more than one phospholipid bilayer, 
and unilamellar vesicles consist of a single bilayer.  
The unilamellar vesicles can be divided by their sizes in (Stöckl & Herrmann 2010): 
- Small unilamellar vesicles (SUVs) have diameters < 100 nm. 
- Lange unilamellar vesicles (LUVs) are around 100 nm – 200 nm. LUV may 
resemble intracellular vesicles like lysosomes or other trafficking vesicles. 
- Giant unilamellar vesicles (GUVs) have diameters up to several tens of 
micrometers. 
Due to their size, shape changes of GUVs can be directly visualized by optical microscopy 
(Staneva et al. 2004; Papadopulos et al. 2007; Farge & Devaux 1992; Stöckl & Herrmann 
2010). A direct observation of membrane permeabilization is possible as well (Ambroggio et 
al. 2005; Stöckl & Herrmann 2010).  
GUVs made from appropriate lipid mixtures show separation into liquid disordered (Ld) and 
liquid ordered (Lo) phases (Stöckl & Herrmann 2010). These domains can be visualized by 
labeling with fluorescent compounds that either partition into the different lipid phases or 
change physical properties like fluorescence lifetime or polarization depending on the 
different domains (Veatch & Keller 2003; Veatch & Keller 2005; Owen et al. 2006; 
Margineanu et al. 2007; Korlach et al. 1999; Dietrich et al. 2001; de Almeida et al. 2007; 
Baumgart, Hunt, et al. 2007; Bagatolli 2006; Stöckl & Herrmann 2010; Stöckl, Plazzo, et al. 








1.9 Giant plasma membrane vesicles 
Giant plasma membrane vesicle (GPMV), average diameter up to 10 nm, is type of vesicular 
model membrane system, that is isolated from the plasma membranes of cultured cells 
(Baumgart, Hammond, et al. 2007). The examinations of GPMVs shown, that GPMVs are 
purely plasma membrane vesicles without any intracellular organelles, assembled 
cytoskeleton or nuclear material (Scott et al. 1979; Sezgin, Kaiser, et al. 2012). The 
compositions of GPMVs, such as the pinning of plasma membrane domains by cytoskeleton, 
membrane–associated proteins or membrane rugosities induced by protein–protein 
interactions (Baumgart, Hammond, et al. 2007), could be characterized by electron 
microscopy (EM). Compared to GUVs (Table 1–2), their biological nature makes GPMVs 
more physiological membrane models.  
 
Table 1–2: Comparing properties of GUVs and GPMVs. The generalized polarization (GP) value is 
calculated from maximum emissions intensities at 440 nm and at 490 nm (Parasassi et al. 1990; Kaiser et 







 [2].  GUV standard raft mixture with dioleoylphosphatidylcholine 
(DOPC) :sphingomyelin (SSM) : cholesterol (chol) at 2:2:1. D: diffusion coefficient. Table adapted from 
Sezgin et al. (Sezgin, Kaiser, et al. 2012).  
Characteristic GUV GPMV 
Complexity Simple lipid composition; few, if 
any, proteins reconstituted. 
Physiological lipid complexity, 
contains native proteins. 
Order difference 
between phases 
Large ( >1.0 GP units) (Kaiser et 
al. 2009)  
Small (~0.2 GP units) (Kaiser et al. 
2009) 
Protein partitioning Most peptides/proteins enrich in 
disordered phase (Kahya et al. 
2005; Shogomori et al. 2005; 
Bacia, Schuette, et al. 2004). 
 
GPI–anchored and some 
palmitoylated proteins are raft phase 
preferring (Levental et al. 2010; 
Sengupta et al. 2008; Baumgart, 
Hammond, et al. 2007). 
Lipid analog 
partitioning 
Most lipid analogs are disordered 
phase preferring (Baumgart, 
Hunt, et al. 2007). 
Many lipid analogs retain 
partitioning characteristics of native 

















Up to 35–38°C (Veatch & Keller 
2003). 
Preparation–dependent; below 20°C 
(Levental et al. 2011). 
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In pharmaceutics, GPMVs have been used as models to study the interactions of 
pharmaceutical compound and biological membrane in vitro, to test membrane permeability 
or therapeutic effect. (Säälik et al. 2011; Dubavik et al. 2012; Sezgin, Kaiser, et al. 2012).  
In the 1970s, "clusters of lipids" in membranes were first described (Israelachvili et al. 1980; 
Karnovsky et al. 1982; Stier & Sackmann 1973). Those membrane microdomains with 
organized lipid mixtures were later named rafts. Recently, GPMVs becomes a popular tool to 
study lipid rafts and to observe the phase separation of membranes. This model membrane 
system carries its own complexity of protein and lipid composition from cellular plasma 
membrane. The biological nature of GPMVs might allow a relatively uniform small scale 
partitioning of the Ld phase into Lo phase, i.e. lipid rafts. Thus, in GPMVs the phase 
separations can only be observed in at low temperatures, that would not be simply like in 
GUVs (Baumgart et al. 2003; Baumgart, Hammond, et al. 2007).  
In the present study, GPMVs were isolated from the SH–EP cells, which were also used for 
study of Aβ cellular uptake. 
1.10 Endocytosis 
The formation and inward movement of plasma membrane vesicles is called endocytosis 
(Vassilieva & Nusrat 2008; Marsh & McMahon 1999; Higgins & McMahon 2002). Endocytosis 
plays a decisive role in the cell survival and stimulates numerous cell functions, including 
antigen presentation, nutrient acquisition, clearance of apoptotic cells, pathogen entry, 
receptor regulation, hypertension, and synaptic transmission (Marsh & McMahon 1999).  
Extracellular materials can be absorbed via different pathways into the cells (Figure 1–11) 
(Mayor & Pagano 2007).  
There are three main endocytic pathways: phagocytosis for solid particles, macropinocytosis 
for fluid and the clathrin or caveolin mediated endocytosis for small entities, such as 
proteins. Small molecules and proteins, can be internalized by receptor mediated 
endocytosis via several mechanisms, which occur on the membranes of the whole cell body 
(Marsh & McMahon 1999).  
Formation of membrane vesicles is a complex process that is dependent on the nature of the 
vesicle protein coat and the cargo (Vassilieva & Nusrat 2008). The complexities of 
endocytosis require many intermediate steps. After the formation of endocytic vesicle on 
the plasma membrane, lots of cellular compartments are involved in followed fusion process 










The receptor mediated endocytosis can be categorized as clathrin–dependent or 
clathrinindependent (Vassilieva & Nusrat 2008). Their endocytotic mechanisms are 
presented below. 
1.10.1 Clathrin–mediated endocytosis 
Clathrin–mediated endocytosis is described a formation invagination, namely clathrin–
coated vesicles (CCVs), by the plasma membrane to absorb the molecules from extracellular 
milieu  (Vassilieva & Nusrat 2008; Marsh & McMahon 1999). Figure 1–12 shows a schematic 
of clathrin assembly and release, and clathrin coated pit formation (Higgins & McMahon 
2002). 
Studies showed that, the assembly of a CCV may take about 1 min in cultured cells, and up to 
thousands those CCV can form per minute (Gaidarov et al. 1999; Marsh & Helenius 1980; 
Marsh & McMahon 1999). This pathway usually mediates by membrane receptors, such as 
transferrin receptors, epidermal growth factor (EGFR), and low–density lipoproteins (LDLR) 
(Vassilieva & Nusrat 2008).  
 
Figure 1–11: Pathways of entry into cells. Large and solid particles via phagocytosis; extracellular fluid 
via macropinocytosis; and the receptor–mediated endocytosis, such as clathrin or caveolin dependent 
endocytosis. CLIC, clathrin– and dynaminindependent carriers; GEEC, glycosyl phosphatidylinositol–
anchored protein enriched early endosomal compartments. Figure adapted from Mayor and Pagano 
(Mayor & Pagano 2007). 
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1.10.2 Caveolar–mediated endocytosis 
Caveolar–mediated endocytosis, also called clathrin–independent endocytosis, is raft–
dependent plasma membrane invagination process. Cholesterol, sphingolipids and 
cholesterol–binding proteins accumulate in those invaginations (Figure 1–11) (Parton 2003; 
Parton & Simons 2007; Cohen et al. 2004; Hommelgaard et al. 2005; Parton & del Pozo 2013; 
Vassilieva & Nusrat 2008). Particles are internalized by caveolar–mediated endocytosis into 
an endosomal compartment called a caveosome (Pelkmans et al. 2001; Vassilieva & Nusrat 
2008). Caveosomes contain caveolins but they do not accumulate transferrin, EEA1 or other 
markers of clathrin–mediated endocytosis and have neutral pH (Stan 2005; Vassilieva & 
Nusrat 2008). Comparing with the clathrin cycle, such as in the synapse, caveolar–mediated 
endocytosis may slower and be not tightly regulated (Marks & McMahon 1998; De Camilli 
1995; Cremona & De Camilli 1997; Marsh & McMahon 1999). 
For both clathrin–dependent and –independent endocytosis, dynamin, is involved in the 
scission of invaginations from plasma membrane (Vassilieva & Nusrat 2008; Mayor & Pagano 
Figure 1–12: Clathrin–mediated endocytosis. (1) 
Clathrin (blue), AP180(red) (Ford et al. 2001) and AP2 
adaptor complex (green) assemble on the surface of the 
cytoplasmic side of membrane. (2) Pits formation. (3) 
Formation of pits neck (Stowell et al. 1999) through 
endophilin (Farsad et al. 2001), amphiphysin (Takei et al. 
1999) and dynamin (Sweitzer & Hinshaw 1998). (4) GTP–
dependent scission caused by dynamin and amphiphysin 
leading to (5) Vesicle release (Marks et al. 2001; Sweitzer 
& Hinshaw 1998; Stowell et al. 1999). (6) Release of 
clathrin lattice with the participation of synaptojanin 
(Cremona et al. 1999) and auxilin (Greener et al. 2001). 
The uncoated vesicle will fuse with an acceptor 
membrane and releases its cargo. Figures adapted from 








2007). Dynamin is a fission guanosine triphosphatase (GTPase) (Mayor & Pagano 2007). It 
self–assembles around liposomes which can disperse the liposomes into small vesicles 
(Hinshaw 2000; Vassilieva & Nusrat 2008). The regulation of fission of plasma membrane 
vesicles through dynamin activity was observed in living cells (Vassilieva & Nusrat 2008).            
1.10.3 Macropinocytosis 
Macropinocytosis (Figure 1–11) was observed and first filmed by Warren Lewis (Warren H. 
Lewis 1936). He described a non–specific process to internalize the fluid and membrane into 
macropinosomes. This endocytotic process is growth factor–induced and actin–dependent 
(Mercer & Helenius 2009; Lim & Gleeson 2011). Macropinocytosis plays an important role in 
cell motility and antigen presentation, and can be modified by infectious pathogens, such as 
protozoa, bacteria, viruses and prions, while entering the host cells (Mercer & Helenius 2009; 
Lim & Gleeson 2011).  
Macropinocytosis of tau protein was reported by Holmes et al. The authors suggested that it 
may be a key step in aggregate propagation in tauopathies and synucleinopathies (Holmes et 
al. 2013; Holmes et al. 2014).   
1.10.4 Receptor–mediated endocytosis of transferrin 
Transferrin is an iron–binding plasma glycoprotein  (Crichton & Charloteaux–Wauters 1987). 
When loaded with iron, transferrin protein can bind to a transferrin receptor (TfR)  at neural 
pH (~ 7.2), and can be internalized by receptor–mediated endocytosis through clathrin–
coated pits (Frazier et al. 1982; Karin & Mintz 1981; Nunez et al. 1977; van Bockxmeer & 
Morgan 1979; Ward et al. 1982). A decrease of the endosomal pH (~ 5.5) induces the release 
of iron from transferrin–TfR complex. Once iron is released, TfR and ligand will return to the 
cell surface (Figure 1–13) (Harding et al. 1983; Maxfield & McGraw 2004; Hsu et al. 2012). 
Therefore, fluorescent transferrin conjugates and TfR are broadly used as marker for 
tracking endocytic pathways (Iacopetta et al. 1983; Harding et al. 1983; Jandl & Katz 1963; 
Laurell & Ingelman 1947) 
The uptake of transferrin depends on both temperature and energy (Sullivan et al. 1976; 
Harding et al. 1983). Low temperature and/or ATP depletion can inhibit transferrin uptake. 
Transferrin has been oberserved that only bind to the plasma membrane at 4°C, but would 
not be taken up at this temperature. By a further incubating the cells at 37°C, transferrin is 
then taken up  into a trypsin–resistant space (Harding et al. 1983). However, their binding 
and uptake are substantially less (2.5 fold)  and slower than under the normal condition, i.e. 
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constant at 37°C (Harding et al. 1983). The possible reason could be that the structure of TfR 
is disrupted by attacking of trypsin at 4°C. Although TfR regenerate with subsequent 
incubation at 37°C, the number of TfRs and their uptake are reduced (Harding et al. 1983).  
 
 
1.11 Thioflavin dyes 
Thioflavin dyes, thioflavin T (ThT, Figure 1–14) and thioflavin S (ThS), are benzothiazole dyes. 
They are widely used to visualize β–sheet–rich amyloid structures under pathophysiological 
conditions both in vitro and in vivo (Kelényi 1967; Vassar & Culling 1959; LeVine 1993). In 
very recently study, the cationic ThT was also used to study the oscillations in membrane 
potential (Prindle et al. 2015).  
 
            
 
ThT is positively charged in a solution with pH 5–9 (LeVine 1993; Prindle et al. 2015), binds 
rapidly to β–sheet structures of amyloid aggregates, which results a red shift in both 
excitation maximum (Ex. max) to 450 nm and emission maximum (Em. max) to 482 nm, 
compared to the free dye with Ex. max at 385 nm and Em. max at 445 nm (LeVine 1993).  
There are two main hypotheses for the binding mechanism between ThT and amyloid. The 
channel model suggests that ThT recognizes the surfaces of cross–β structures (Biancalana & 
Figure 1–14: Structure of thioflavin T (ThT). 
Figure adapted from LeVine. (LeVine 1993). 
Figure 1–13: Schema of endocytic recycling pathways of transferrin. Iron loaded transferrin binds to 
transferrin receptor (TfR) at the cell surface at neutral pH. Iron and transferring–TfR complex is 
endocytosed via clathrin–coated pits. After releasing the iron (early endosome, pH about 5.5), 








Koide 2010); and the self–association models suggests that ThT molecules forms micelles in 
aqueous solutions resulting in hydrophobic interactions between ThT micelles and amyloid 
(Biancalana & Koide 2010; Khurana et al. 2005). ThT expresses stable fluorescence in 
solution with neutral pH or above 7 (LeVine 1993). The intensity and stability of fluorescence 
are reduced by lowering pH (Khurana et al. 2005; LeVine 1993). Khurana et al. suggested 
that the formation of ThT micelles depends on the concentration and charge of ThT and the 
disruption of ThT micelles at low pH leads to the reduction of the binding to amyloid and ThT 
fluorescence (Khurana et al. 2005). 
Unlike ThT, ThS is negatively charged at solution pH 5–9 (LeVine 1993), is a mixture of at 
least 6 sulfonated compounds (LeVine 1993; Wei et al. 2005), displays an enhanced Em.max 
with red shift at 482 nm and unchanged Ex. max at 385 nm occurring β–sheet binding 
(LeVine 1993). Its binding and fluorescence are less sensitive to pH (LeVine 1993). Thus ThS is 
more suitable for staining inside the endocytic vesicles or under acidic conditions. 
Additionally, in the praxis, I observed that ThS seems to be better at passing through the 
membranes without accumulating on the membrane and binding selectively to Aβ aggregate 
with high affinity, but not to Aβ monomers. 
Based on their different binding characteristics, ThT was used for the aggregation assay in 
vitro and ThS for the microscopy of cultured cells in the present study. 
1.12 MTT assay 
3–(4,5–Dimethylthiazol–2–yl)–2,5–diphenyltetrazolium bromide (MTT) is a tetrazolium dye. 
MTT  is reduced from a yellow tetrazole to purple formazan by NAD(P)H–dependent 
oxidoreductase enzymes (Berridge et al. 2005; Mosmann 1983). Therefore, the MTT assay is 
broadly used to measure the activity of cellular metabolism, cytotoxicity, cell viability and 
cytostatic activity (Mosmann 1983). The most part of NAD(P)H metabolismdepends on 
oxidoreductase enzymes, so that the reduction of MTT is an adequate marker of the cellular 
metabolic activity due to NAD(P)H flux (Berridge & Tan 1993; Berridge et al. 2005). The 
insoluble purple formazan product can be dissolved by adding a solubilization solution, and 
then the absorbance of the colored solution can be measured at 500–600 nm wavelengths 




1.13  Förster resonance energy transfer 
Fluorescence involves the absorption of light energy by a fluorophore molecule and emission 
of that energy at a longer (lower energy) wavelength (Remedios 2001). Förster resonance 
energy transfer (FRET) is a physical process by which energy is transferred nonradiatively 
from an excited molecular fluorophore (the donor) to another fluorophore (the acceptor) by 
means of intermolecular long–range dipole–dipole coupling (Förster 1948).  
FRET becomes a powerful and sensitive tool, to visualize spatial distribution of single 
molecule in vitro and inside the cells (Swift & Trinkle–Mulcahy 2004) and to investigate the 
proximity of two molecules as well as related biological phenomena (dos Remedios et al., 
1987).  
Besides the fluorescence emission, there are many other competing pathways can decrease 
the energy level of an excited fluorophore, FRET is one of them. Their rate constants include 
(Remedios 2001): 
- the fundamental photon emissive rate (κF) of fluorescence;  
- the rate of loss as heat by internal conversion (κIC);  
- the rate of transfer to a quencher (κQ);  
- the rate of photodestruction or photobleaching (κPB);  
- the rate of triplet state formation through intersystem crossing (κISC);   
- the rate of resonance energy transfer (κFRET). 
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Figure 1–15: A microtiter plate after an MTT assay. Increasing amounts of cells resulted in increased 








where κOP is the rate constant for all other processes (Remedios 2001). From this 
relationship, an increase in κFRET will decrease the donor lifetime (τ) (Remedios 2001). κOP 
describe the total energy loss occurred a parallel processes beside the resonance energy 
transfer that should be considered and introduced into the calculation of the donor 
fluorescence lifetime (Remedios 2001). Only under very ideal circumstances, the acceptor of 
a donor–acceptor pair can gain all the energy loss of the donor (Remedios 2001).   
The relationship between vibrational energy states, the fluorescent state and resonance 
energy transfer can be demonstrated in the Jablonski diagram (Figure 1–16)  (Lakowicz 2006; 
Remedios 2001).  
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FRET is a physically energy transfer process, which depends on distances between donor and 
acceptor molecules. A typically theoretically distances for highly efficient FRET is within the 
Förster radius, which is defined as the distance at which half the excitation energy of the 
donor is transferred to the acceptor (typically 3–6 nm), and measures approximately 10–100 
Å (Sekar & Periasamy 2003).  
 
Figure 1–16: Modified Jablonski 
diagram indicating the donor energy 
levels at ground state (S0) and in the 
excited state (S1–4). A radiationless 
transfer of energy from the donor to 
an acceptor will reduce the intensity 
of the donor fluorescence. κFRET: Rate 
of resonance energy transfer; κOP: 
rate constant. Diagram adapted from 
Remedios (Remedios 2001). 
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2 Aim of the thesis 
One of the pathological hallmarks of Alzheimer’s disease (AD) is deposits of the protein 
fragment β–amyloid in the form extracellular plaques (George G. Glenner & Wong 1984). 
Amyloid–beta peptides (Aβ) between 38–43 amino acids in length are formed by proteolytic 
cleavage of a membrane protein, the amyloid precursor protein (APP). Aβ is released as a 
monomer and tends to form aggregates spontaneously. The oligomeric species of Aβ1–42 are 
tightly linked to AD pathogenesis and are presumed to be the cause of neuronal 
damage(Walsh et al. 2002). Many studies have suggested that the reuptake of extracellular 
Aβ1–42 and subsequent formation of intracellular aggregates might be one pathway that 
leads to neuronal damage and neurotoxicity (Friedrich et al. 2010; Hu et al. 2009). However, 
questions remain as to where aggregates form, how the state of aggregation of Aβ1–42 
relates to its internalization, and why oligomeric species are far more toxic than monomers 
and large fibrils. Clearly the aggregation and internalization of Aβ1–42 and the connections 
between these processes may be vital in understanding the ultimate toxic effects of this 
peptide.  
My thesis project aims to understand the structural and mechanistic details of Aβ1–42 
internalization. We examined the relationship between the aggregation state of extracellular 
Aβ1–42 and the efficiency of its internalization, to determine whether the formation of 
aggregates is a prerequisite to or the consequence of its neuronal uptake; used fluorescently 
labeled Aβ1–42 to visualize the aggregation state of peptides and track their neuronal uptake 
in a human neuroblastoma (SH–EP) cell model. 
The second aim of my thesis is to characterize Aβ – membrane interaction in detail. One of 
the key reactions in these processes is the binding and aggregation of Aβ1–42 on the plasma 
membrane. Therefore, we observed interactions of Aβ1–42 with lipid bilayers by using 
different types of giant unilamellar vesicles (GUVs) as simplified model system and the giant 
plasma membrane vesicles (GPMVs) isolating from the plasma membrane of neuroblastoma 
cells by confocal microscopy. By using two species of Aβ1–42 monomers that were each 
labeled with a different fluorophore, we could track Aβ self–association by Förster 
resonance energy transfer (FRET).  
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Primary hippocampal neuron AG Jochen Meier, MDC–Berlin, Germany 
SH–EP cells line 
R. König, F Westermann and M. Schwab, German Cancer Research 




Amyloid beta 1–40 peptide R. Volkmer, Institute for Medical 
Immunology, Charité, Berlin, 
Germany. 
Amyloid beta 1–42 peptide 
Amyloid beta 1–42 peptide with a single N–terminal cysteine residue 




Dioleoyl–phosphatidylserine (DOPS) Avanti Polar Lipids Inc., 840035 
1,2–dioleoyl–sn–glycero–3–phosphocholine (DOPC) Avanti Polar Lipids Inc., 850375 
1–palmitoyl–2–[6–[(7–nitro–2–1,3–benzoxadiazol–4–
yl)amino]hexanoyl]–sn–glycero–3–phosphocholine (C6–NBD–PC) 
Avanti Polar Lipids Inc., 810130 
1,2–dioleoyl–sn–glycero–3–phosphoethanolamine (DOPE) Avanti Polar Lipids Inc., 850725 
N–stearoyl–D–erythro–sphingosylphosphorylcholine (SSM) Avanti Polar Lipids Inc., 860586 




Anti–58K Golgi protein antibody Abcam, ab27043 
Anti–caveolin–1 antibody Santa Cruz, sc–894 
Anti–clathrin heavy chain antibody Abcam, ab21679 
Anti–EEA1 (C45B10) antibody  Cell Signaling, 3288 
Anti–LAMP2 antibody Abcam, ab13524 
Anti–mouse IgG Peroxidase antibody Sigma–Aldrich, A9044 









Hoechst 33342 Invitrogen, 639181 
 
Dyes 
Calcein Sigma–Aldrich, C0875 
ChemiGlow Alpha Innotech Corporation 
Merocyanine 540 Sigma–Aldrich, 323756 
Thioflavin S Sigma–Aldrich, T1892 
Thioflavin T  Merck, 49005 
 
Protein Conjugates 
Transferrin From Human Serum, Alexa Fluor® 488 Conjugate Invitrogen, T–13342 
Transferrin From Human Serum, Alexa Fluor® 647 Conjugate Invitrogen, T–23366 
Anti–mouse lgG antibody, cy5 Abcam, ab6563 
Anti–rabbit lgG antibody, cy5 Abcam, ab6564 
 
Reactive Fluorophores 
Alexa Fluor 488 C5 maleimide Life Technologies, A–10254 
Alexa Fluor 488 NHS Ester Life Technologies, A–20000 
Alexa Fluor 633 C5 maleimide Life Technologies, A–20234 
Alexa Fluor 633 NHS Ester Life Technologies, A–20005 
Alexa Fluor 647 C2 maleimide Life Technologies, A–20347 
Atto 488 maleimide Atto tec, AD 488–41 
Atto 565 maleimide Atto tec, AD 565–41 
Atto 633 maleimide Atto tec, AD 633–41 
Atto–488 NHS–Ester Atto tec, AD 488–31 
Atto–565 NHS–Ester Atto tec, AD 565–31 
Atto–633 NHS–Ester Atto tec, AD 633–31 
Cy5 maleimide GE, PA15131 
 
Chemicals and kits 
 
1,1,1,3,3,3–hexafluoro–2–propanol (HFIP) Fluka, 1441290V 
Bovine serum albumin (BSA) Sigma, A8531 
Dimethyl sulfoxide (DMSO) Sigma, 078K06961 
Dithiothreitol Sigma, D0632 
Dulbecco's Modified Eagle Medium (DMEM) ThermoFisher, 11880–028 
Ethanol Roth, 5054.4 
Fetal Bovine Serum (FBS)                       Invitrogen, 10099133 
Formaldehyde solution Sigma, F8775 
Glucose Sigma, G8270 
L–Glutamine Invitrogen, 25030 
Penicillin–Streptomycin, Liquid, 10000 units / ml of Pen, 10000 µg / ml of 
Strep ThermoFisher, 015140 
Tris(2–carboxyethyl)phosphine hydrochloride (TCEP) Sigma, 75259–1G 
Trypsin 0.05 %/EDTA 0.02 % in PBS without Ca2+ and Mg2+ Pan–biotech, P10–023100 
Tween–20 Serva, 100260 
CellTiter 96® Non–Radioactive Cell Proliferation Assay [3–(4,5–
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96–well black tissue culture treated BD Falcon, 353219 
Cell culture dish 35mm, poly–lysine–coated glass bottom MatTek Corporation, P35GC–1.5–14–C 
Cell culture flask  BD Falcon 
FESP cantilevers for AFM, 75 kHz Bruker, A079/19 
Gel filtration, Superdex 75 PC 3.2/30 GE, 17–0771–01 
Membrane filter, 0.22 μm Millipore, UFC30GV00 
Membrane filter, 200 nm polycarbonate  Nuclepore, Whatman Schleicher & Schuell 
Membrane filter, 30 kD Millipore, UFC503024 
Mica Ted Pella 
 
Atomic Force Microscopy, Nano wizard II JPK, Berlin 
CD spectrometer, Model J–720 Jasco 
Centrifuge  Eppendorf 
Gel Filtration, SMART System GE 
Image reader LAS–3000 Fujifilm 
Lyophyllization Savant Speed Vac 
NanoDrop 8000 Photometer Peqlab,  
Plate reader, Infinit E M200 Tecan, Austria 
Sonication (water bath) Bandelin Sonorex TK 52 
Thermomixer shaker Eppendorf 
 
Confocal microscope, FV–1000MPE Olympus 
Confocal microscope, Olympus IX83 microscope with 
Yokogawa CSU–W1 Confocal Spinning Disc unit 
Olympus 
Confocal microscope TSC SP2 & SP5, with Leica HyD hybrid 
detector for SP5 Leica 
Evolve 512 EMCCD Camera for Spinning Disc Photometrics 




Mediums and buffers 
 
Blocking buffer 3 % (w/v) BSA in PBS 
Cell culture medium 
DMEM, 10 % (v/v) fetal bovine serum, 4 mM L–Glutamine, 110 mg/L sodium 
pyruvate, 100 units/ml penicillin, 100 units/ml streptomycin, 4.5 g/L  D–glucose 
Dulbecco's phosphate–
buffered (PBS) 
ThermoFisher, Gibco, 14190. 200 mg/L KCl, 200 mg/L KH2PO4, 8 g/L NaCl, 2.16 
g/L Na2HPO4–7H2O  
Freezing medium 10 % DMSO, 90 % fetal bovine serum     
Glucose buffer / GUVs 
microscopy buffer 
280 mM glucose, 5.8 mM NaH2PO4, 5.8 mM Na2HPO4, osmolality 300 
mOsm/kg, pH 7.2 
GPMV buffer / 
vesiculation chemicals 10 mM hepes, 150 mM NaCl, 2 mM CaCl2, pH 7.4 
Sucrose buffer  250 mM sucrose, 15 mM NaN3, Osmolarity 280 mOsm/kg, pH 7.2 
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3.2 Methods 
3.2.1 Preparation and fluorescent labeling of Amyloid beta peptide 
3.2.1.1 Aβ peptide peptide stock solutions 
Synthetic human Amyloid beta 1–40 peptide (Aβ1–40), Amyloid beta 1–42 peptide (Aβ1–42) 
and   Aβ1–42 with a single N–terminal cysteine residue (Institute for Medical Immunology, 
Charité, Berlin, Germany) were dissolved in hexafluoro–2–propanol (HFIP) to a final 
concentration of 5 mg/ml, were sonicated in a water bath for 15 min, and were incubated at 
room temperature (RT) overnight. Aliquots of 100 µl were flash frozen by liquid nitrogen, 
HFIP was removed by lyophilization (Savant SpeedVac, Thermo), and the aliquots of peptides 
were stored at –20 °C until use. 
3.2.1.2  Monomerization of unlabeled Aβ peptide 
To prepare unlabeled monomer, lyophilized Aβ1–42 was dissolved in 10 mM Sodium 
hydroxide (NaOH, pH 12), sonicated for 30 min in ice–cold water bath, passed through a 0.22 
µm and a 30 kD filter (Millipore). The monomers was kept on ice and used immediately or 
within 1 h.   
The concentration of labeled Aβ1–42 monomers were calculated by Beer–Lambert law at 280 
nm using an extinction coefficient of 1280 M-1cm-1. 
3.2.1.3  Fluorescence labeling and purification 
The fluorescent dyes were dissolved in dimethyl sulfoxide (DMSO) of 10 mg/ ml, and stored 
at –20 °C until use.  
Aβ1–42 (200 µM) with a single N–terminal cysteine residue was labeled by Atto 488 maleimide 
(Aβ1–42
488), Atto 565 maleimide (Aβ1–42
565) or Atto 633 maleimide (Aβ1–42
633, Atto–tec) at a 
1:1.5 molar ratio in NaOH (10 mM, pH 12) containing 0.05 mM tris(2–
carboxyethyl)phosphine hydrochloride (TCEP). The mixture has pH at 7.5, and would be 
incubated at 4 °C overnight.  
Aβ1–42
565 and free Atto565 maleimide were separated by size–exclusion chromatography 
(SEC, SMART gel filtration system, GE) using Superdex 75 PC 3.2/30 column (GE). Superdex 
75 PC 3.2/30, a prepacked Precision Column (2.4 ml), has a separation range for molecules 
with molecular weights between 3 000 and 70 000 and pH stability working range of 3–12. 
Sample of 50 µl was loaded, run in 10 mM NaOH buffer (pH 12) with a flow rate at 40 µl/min 
at RT. The eluents were collected in 100 µl fraction, were examined by ultraviolet (UV) 
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absorption to determine the concentration of eluted Aβ, protein at 214 nm and 280 nm, 
Atto 488 at 488 nm, Atto 565 at 565 nm and Atto 633 at 600 nm. 
For the preparation of Atto 565 labeled scrambled–Aβ1–42 (sc–Aβ1–42
565, Millipore), sc–Aβ1–42 
was dissolved in 10 mM NaOH and labeled with Atto 565–NHS. The labeling process and the 
separation of sc–Aβ1–42
565 and free dyes were the same as described above.  
Degree of labeling was determined from absorption at 280 nm and at the excitation 
maximum of the fluorophores, and correcting for absorbance of the fluorophores at 280 nm,        
maxmax max
280 max 280 max
//









         [6] 
where A is absorption; εmax is the extinction coefficient at absorption maximum of 
fluorescent dye; εprot is the extinction coefficient at max of labeled protein; CF280 is 
correction factor, which is given by the product description. 
The concentrations of labeled Aβ1–42 monomers and protofibrils were calculated through 
area ratio of SEC at 565 nm by integration.   
3.2.2 Preparation and labeling of lipid membrane vesicles 
3.2.2.1 Preparation of large unilamellar vesicles (LUVs) 
Large unilamellar vesicles (LUVs) were preparted from multilamellar vesicles (MLVs). To 
develop the MLVs, lipids were dissolved in chloroform with or without 1 mol% of the 
fluorescent lipid analogue, and were dried under nitrogen in a glass tube to form a thin lipid 
film. The lipid film was dissolved in 1 ml PBS to a final lipid concentration of 1 mM, and was 
vortexed well to generate MLVs. Following five freeze–thaw cycles, MLVs were extruded ten 
times through a 200 nm polycarbonate membrane filter (Nuclepore, Whatman Schleicher & 
Schuell, Dassel, Germany). Large unilamellar vesicles (LUVs) were stored at 4°C and used 
within one week after preparation. 
 
3.2.2.2  Preparation of giant unilamellar vesicles (GUVs) 
Giant unilamellar vesicles (GUVs) were prepared using the electroformation method as 
described by Stöckl et al (Stöckl et al. 2010). In brief, lipids with or without 1 % of lipid 
analogue were dissolved in 50 µl chloroform to a total lipid concentration of 100 nM. The 
titanium chambers (Figure 3–1) were preheated to 50 – 60°C by hotplate. Lipid solution was 
spotted onto two slides. The slides were further heated on the hotplate to evaporate the 
chloroform, and to keep a homogenous distributed lipid films on the slides. Chambers were 
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assembled with parafilm (Figure 3–1), and were placed under vacuum (< 10 mbar) for 1 h, to 
remove the rest of the chloroform. Lipid coated titanium chambers were filled with 1 ml 
sucrose buffer (osmolality of 280 mOsm/kg), were supplied an alternating electric field of 10 
Hz rising from 0.02 – 1.1 V in the first 48 min and hold for 3 h, then increased the voltage of 
1.3 V frequency of 4 Hz for 30 min to detach GUVs. GUVs were stored at RT, were used 
within one week. 
 
 
3.2.2.3 Preparation of giant plasma membrane vesicles (GPMVs) 
Cell–free giant plasma membrane vesicles (GPMVs) formation and isolation followed a 
procedure modified from the protocol by Sezgin et al ( Figure 3–2a) (E Sezgin et al. 2012).  
SH–EP cells were grown in a 75–cm2 cell culture flask to 90 – 100% confluency. Cells were 
washed twice with GPMV buffer (10 mM Hepes; 0.15 M NaCl; 2 mM CaCl2; pH 7.4), and then 
added 1.5 ml of GPMV buffer containing vesiculation agents (25 mM Paraformaldehyde 
(PFA); 2 mM Dithiothreitol (DTT)). The cells were then incubated at 37°C for 1 h. The GPMVs 
rich supernatant was removed from 75–cm2 cell culture flask into an Eppendorf tube, and 
was stored at 4 °C for 2 h to concentrate the GPMVs via gravity. If necessary, GPMVs could 
be labeled by fluorescent dye. GPMVs were incubated with fluorescent dye, such as 
merocyanine 540 (0.02 mg/ml), at 4°C for 1h, before they were imaged by microscopy 
(Figure 3–2 b). GPMVs were stored at 4 °C and were measured within two days. 
Figure 3–1: Schema of titanium chamber slides for giant unilamellar vesicles preparation. Figure 
adapted from Stöckl et al. (Stöckl et al. 2010).  
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3.2.3 Monitor aggregation kinetics of Aβ1–42 by thioflavin T 
Aβ1–42 monomer aggregation assay was performed in PBS containing 20 µM thioflavin T (ThT) 
in a plate reader (Infinit E M200, Tecan) at 25°C or 37 °C. ThT fluorescence (excitation 
wavelength of 440 nm and emission wavelength of 485 nm) was measured through the 
bottom of the 96–well plate every 5 min after 5 s shaking. Every experiment was carried out 
in separated 3 wells of each concentration. The results are presented as mean values. 
3.2.4 Circular dichroism spectroscopy 
Aβ1–42 samples of 15 µM in PBS were measured in a 1–mm path length cuvette. Circular 
dichroism (CD) spectra were recorded between 200 – 260 nm with a step size of 1 nm by 
using a CD spectrometer (Model J–720, Jasco).  
Figure 3–2: Preparation of giant plasma membrane vesicles (GPMVs) (a) Flow of isolation of GPMVs 
from the cells. GPMVs form and separate from the plasma membrane after incubating the cells with 
vesiculation chemicals. Isolated GPMVs can be then labeled: green circles represent fluorescently 
labeled vesicles; red and green areas represent phase–separated GPMVs. Figure adapted from Sezgin 
et al. (Sezgin, Kaiser, et al. 2012). (b) DIC image of our GPMVs harvesting, were recorded by confocal 
microscopy. Scale bar 10 µm. 
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3.2.5 Atomic Force Microscopy 
Mica was glued on a glass slide with superglue. The surface layer of mica was removed by 
adhesive tape. Samples of 10 μl were loaded onto the freshly cleaved mica disk for 5 min, 
washed three times with freshly filtered deionized water (3 x 100 µl) and dried overnight. All 
the images were taken using intermittent contact mode on a Nanowizard II/Zeiss Axiovert 
setup (JPK) and FESP tips (Bruker). 
3.2.6 Cell culture 
SH–EP (German Cancer Research Center, Heidelberg) cells were maintained in culture 
medium in 75 cm2 cell culture flasks at 37 °C and 5% CO2. Before monolayers reached 80 – 
90 % confluency, the cells were subcultured: washed twice with PBS; incubated with 1 ml 
trypsin solution at 37 °C for 5 min; added 9 ml culture medium to stop the trypsinization; 
and ca. 105 cells were seeded into a new 75 cm2 cell culture flasks. For the different 
experiments, cells were seeded into 96–well plates or 35 mm cell culture dishes.  
For storage, the cells were detached from culture flask, were pelleted for 3 min at 2500 g, 
were resuspended in freezing medium, kept at –80 °C for 1 d and stored in liquid nitrogen.  
For thawing cells, cryotube of frozen cells from liquid nitrogen were incubated in water bath 
at 37 °C. The cells suspension (1 ml) were added into 5 ml culture medium, were pelleted for 
1 min at 2500 g, were resuspended in culture medium, were transferred into a cell culture 
flask, and were incubated in the incubator (37 °C, 5% CO2)as usual. 
Primary hippocampal neurons from rat embryos were a gift of J. Meier, MDC Berlin and were 
prepared and cultured as previously described (Winkelmann et al. 2015).  
3.2.7 Cellular uptake of Aβ1–42 
The cells were cultured in 96–well black tissue culture treated plates (BD Falcon) or 35 mm 
poly–lysine–coated glass bottom dishes (MatTek Corporation) to reach ca. 80% confluency. 
After washing twice with PBS (100 µl / well for 96–well plate or 1.5 ml for dish), the cells 
were treated by Aβ1–42 or labeled Aβ1–42 at various concentrations, temperatures and times, 
as indicated in each experiment. The cells were then washed twice with PBS, were further 
incubated in culture medium for live cell imaging, or were fixed with 3.7% PFA in PBS for 10 
min. The fixed cells were incubated in PBS for microscopy.  
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3.2.8 MTT assay 
The cells were cultured in 96–well plates, grown up to about 80% confluency and treated 
with different aggregates species of Aβ at various concentrations as indicated in each 
experiment. Each experiment was carried out in 2 separate 96–well plates. One plate was 
prepared for determination of cell number by high–content screening (HCS) microscopic. 
The second plate was used for 3–(4,5–dimethylthiazol–2–yl)–2,5–diphenyltetrazolium 
bromide (MTT) assay (Promega Cell Proliferation Assay kit). Each concentration of Aβ was 
repeated in 12 separate wells per plate. After treatment with Aβ, the cells were washed 
twice with PBS, were incubated with 15 µl MTT solution (12 mM) in 100 µl fresh culture 
medium per well at 37 °C for 4 h. The reaction was stopped by adding solubilization solution 
(100 µl / well, Bio-Rad). The cells were further incubated at 37 °C for 2 h. The absorbance of 
MTT was recorded at 570 nm by using a plate reader.  
3.2.9 Thioflavin S staining 
Thioflavin S (ThS) was dissolved in 50% ethanol to 1 mg/ml, was stored at 4°C.  
Fixed or live cells were washed twice with PBS, were incubated with Thioflavin S (ThS) of 10 
µg / ml in PBS or cell culture medium, at RT or living cells required temperatures, 4°C or 37°C, 
for 10 min. After that the cells were washed with PBS 2–5 times, were incubated in PBS for 
fixed cells or in cell culture medium for live cells until microscopy.  
3.2.10 Secondary immunofluorescence staining (IF) 
To examine if the dye fluorescence of Aβ1–42
565 accurately reports the formation of 
intracellular Aβ1–42 aggregates and their cellular locations, the cells were costained with anti–
β–amyloid mouse monoclonal antibody (6E10, Covance) or endocytic markersby 
immunofluorescence staining after treatment with Aβ1–42
565 aggregate. 
The fixed cells were permeabilized with 0.5 % Triton X–100 at RT for 5 min, washed twice 
with PBS. Then cells were incubated with blocking buffer (3 % BSA in PBS) at RT for 1 h, then 
with primary and secondary antibody in blocking buffer in the dark at RT for 1 h, respectively. 
The cells were washed with PBS twice between each step. Cell nuclei were stained with 
Hoechst 33342 or DAPI. The dishes were stored in the dark until being viewed by using a 
confocal microscopy.  
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The primary antibodies and their dilutions used for presented project are listed in Table 3–1. 
Cy5–labeled anti–mouse and –rabbit antibodies were used as secondary antibodies, were 
diluted at 1:2000 in blocking buffer.  
 
Table 3–1: Primary antibodies for IF. 
 Antibodies Working dilution 
Aβ 
Anti–β–amyloid mouse monoclonal 
antibody 6E10 
1:1000 
Caveolin marker Anti–caveolin–1 antibody 1:500 
Clatherin Anti–clathrin heavy chain antibody 1:500 
Early endosome marker Anti–EEA1 (C45B10) antibody 1:500 
Golgi marker Anti–58K Golgi protein antibody 1:1000 
Lysosome marker, LAMP2 Anti–LAMP2 antibody 1:500 
 
3.2.11 Fluorescence microscopy 
3.2.11.1 Confocal microscopy 
All confocal microscopic experiments were performed in 35 mm culture dishes. The images 
were recorded by confocal laser scanning microscopy (Leica TSC SP2 and SP5, SP5 with Leica 
HyD hybrid detector; Olympus FV–1000MPE) with 60x or 63x/ 1.4–0.6 oil–immersion 
objective, 40x/1.35 or 60x/1.2 water immersion objective, or spinning disc confocal 
microscopy (Olympus IX83 microscope with Yokogawa CSU–W1 Confocal Spinning Disc unit 
and Evolve 512 EMCCD Camera) with 60x/1.2 water objective. The climate chamber for 
microscopy was set to 25 °C for fixed cells and 37 °C for living cells. Confocal fluorescence 
images were obtained by sequential excitation, if more than two fluorophores were 
monitored. Wavelength settings are given as Table 3–2. Additionally, differential 
interference contrast (DIC) pictures were recorded simultaneously in each case.  
The visualization of GUVs was followed by the protocol by Stöckl et al (Stöckl et al. 2010). 
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Table 3–2: Wavelength settings. 
Fluorophores Excitation / nm Emission / nm or filters 
Alexa488 488 490 – 540 
Alexa647 633 or 640 650 – 700; ET 700/75 nm 
Atto488 488 500 – 550; ET 525/50 nm 
Atto565 543 or 561 550 or 580 – 610; ET600/50 nm 
Atto633 633 or 640 650 – 700; ET 700/75 nm 
Calcein 488 490 – 540; ET470/25 nm 
Cy5 633 or 640 650 – 700 
DAPI 405 440 – 470 
Hoechst 33342 405 440 – 470; ET460/50 nm 
Merocyanine 540 543 560 – 600; U–MWG2 
NBD 488 500 – 550 
Thioflavin S 405 420 – 470; ET460/50 nm 
 
3.2.11.2 Live cell microscopy  
Experiments of live cell imaging were performed in 35 mm dishes by using confocal / 
spinning disc confocal microscopy. The temperature of incubation chamber on microscope 
was set on 37°C, and 5% CO2 was filled into the incubation chamber.  
3.2.11.3 High–content screening and analysis 
For HCS microscopy experiments, the cells were cultured in 96–well plates. The fixed cells 
were incubated with Hoechst 33342 (1 µg/ml in PBS) at RT for 10 min to visualize the nuclei.  
The images were acquired automatically on ArrayScan VTI HCS Reader (Thermo Scientific) 
with a 10x objective. Autofocus was set on Hoechst 33342 channel. For the compartmental 
analysis, ArrayScan VTI software was used to identify nuclei by Hoechst 33342 fluorescence, 
to fit cell dimensions and to identify Aβ1–42 aggregates through Atto 565 fluorescence. Nine 
images were recorded per well for each channel. Readout measurements included nuclear 
number area and intensity; aggregates intensity, number and size; and sizes of the cells. 
Total intensity of spots and mean intensity/count/area of spots per well were calculated 
from nine images, and were normalized to cell numbers.  
Figure 3–3 shows one of the compartmental analysis, identified nuclei by Hoechst 33342 
fluorescence (white) were used to fit cell dimensions, blue line of nuclei and red line of cell, 
and identify Aβ1–42 aggregates by labeling fluorescence (yellow spot).  
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3.2.12 Förster resonance energy transfer (FRET) 
Spectroscopy–Based Förster resonance energy transfer (FRET) measurement was performed 
in 96–well plate, was recorded through the bottom of the 96–well plate in a plate reader 
(Infinit E M200, Tecan) at 25°C.  
 






           [7] 
where 𝐼𝐷
′  and 𝐼𝐷  are the donor fluorescence intensities with and without acceptor, 
respectively.  
The images for sensitized emission FRET analysis were recorded by confocal microscopy 
described as above. Corrected FRET images were calculated from FRET, donor, and acceptor 
pixel intensities using the Fiji distribution and the PixFRET plugin (Feige et al. 2005).  
Briefly, for FRET analysis three group cells were prepared: sample contained only donor; 
sample contained only acceptor; sample contained donor and acceptor. Each sample was 
imaged with following settings: the first one excitation of the donor and detection of the 
Figure 3–3: High–content screening (HCS) microscopic images of SH–EP cells with Aβ1–42
565 
aggregates. Left: cell nuclei were stained with Hoechst 33342 (white), identified by the image analysis 
software (blue contour lines). Right: the software identification of Aβ1–42 aggregates (yellow), nuclei 
(blue contour lines) and the cell bodies (red contour lines). Scale bar 100 µm. 
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donor; the second one excitation of the acceptor and detection of the acceptor; the third 
one excitation of the donor and detection of the acceptor. 
For the Atto 488 – Atto 633 FRET pair, the fluorescence was measured with excitation 
wavelengths of 488 nm for Atto 488 (donor only sample), 633 nm for Atto 633 (acceptor only 
sample)  and 488 nm  for Aβ1–42
488 – to – Aβ1–42
633 FRET (FRET sample), and emission 
wavelengths 500–600 nm (donor only sample), 650–800 nm (acceptor only sample) and  
650–800 nm (FRET sample), respectively. 
Bleed–Through (BT) values were calculated from the images of the donor or acceptor only 
sample by using Donor or Acceptor Model of PixFRET program. Intensity–independent donor 














         [9] 
which were fitted with a linear model. 
The corrected FRET intensity for each pixel is given by:  
0
FRET FRET donor donor acceptor acceptorI I BT I BT I           [10] 
where IFRET is the raw fluorescence intensity of the FRET channel, Idonor and  Iacceptor are the 
fluorescence intensities of the donor and accepto, respectively. IFRET is normalized (nFRET) as 







         [11] 
3.2.13 Fluorescence recovery after photobleaching  
Fluorescence recovery after photobleaching (FRAP) measurements were carried out on a 
Olympus microscope using the built–in setting for photobleaching. The experiments were 
performed in 35 mm dishes as described above.  
For FRAP of calcein, laser intensity at 488 nm was increased until calcein fluorescence had 
been completely bleached. FRAP was then performed in the focus plane of GUV membrane 
area of about 7 μm × 1 μm. After the photobleaching, the microscope programm was switch 
back to normal setting for observing the recovery of fluorescence. The bleached area was 




4 Results  
4.1 Membrane interaction of non–toxic Aβ1–42 benefits the 
conversion of cytotoxic aggregate 
One of the pathological hallmarks of Alzheimer’s disease (AD) is the presence of extracellular 
plaques composed mainly of 42aa Amyloid beta peptide (Aβ1–42) (George G. Glenner & Wong 
1984). The small hydrophobic Aβ1–42 peptide, which is generated by proteolytic cleavage of 
the amyloid precursor protein (APP), is released as a monomer from the plasma membrane 
into extracellular space, and tends to aggregate spontaneously into oligomeric, protofibrillar 
and fibrillar assemblies (Simons et al. 1998; Shoji et al. 1992; Jarrett et al. 1993). Oligomeric 
species of Aβ1–42 are tightly linked to AD pathogenesis and are presumed to be the cause of 
neuronal damage (Walsh et al. 2002). Several studies have suggested that the reuptake of 
extracellular Aβ1–42 into neurons may lead to the formation of intracellular aggregates, 
resulting in neuronal damage and neurotoxicity (Ida et al. 1996; Hu et al. 2009; Friedrich et al. 
2010). Endocytosis of misfolded proteins has also been observed in cell models of the tau 
protein, α–synuclein and huntingtin (Frost et al. 2009; Brundin et al. 2010), and recent 
evidence suggests that it may be the initial step in the replication of the misfolded protein by 
prion mechanisms (Brundin et al. 2010; Sanders et al. 2014; Prusiner 1998; Bieschke et al. 
2004; Frost & Diamond 2010). Several possible endocytotic pathways, such as 
macropinocytosis and receptor mediated endocytosis, have been discussed for Aβ and other 
misfolded protein aggregates (Yu et al. 2014; Lai & McLaurin 2010; Holmes et al. 2013; 
Treusch et al. 2011; Kanekiyo et al. 2013). However, our understanding of the connection 
between aggregation and cytotoxicity is still limited. It has not been conclusively determined 
how and when the Aβ1–42 peptide becomes toxic, whether Aβ aggregates prior to 
internalization or during the internalization process and, if so, in which intracellular 
compartments the aggregates form. Elucidating the connection between aggregation and 
internalization of Aβ1–42 peptide may be thus vital in understanding its toxicity. 
Here, we examine the relationship between the aggregation state of extracellular Aβ1–42 and 
the efficiency of its internalization. We aimed to determine whether the formation of 
aggregates and particularlyβ–sheet–rich structures , as reported by thioflavin dyes (LeVine 








4.1.1 Preparation and characterization of fluorescently labeled Aβ1–42 
In order to track the peptide and to observe aggregation of monomeric Aβ1–42 in the cultured 
cells, fluorescently labeled Aβ1–42 peptides were generated. Aβ1–42 with a single N–terminal 
cysteine residue is linked thiol–reactive fluorophores (maleimide–activated derivative), such 
as Atto565–maleimide (Aβ1–42
565), Alexa488–maleimide (Aβ1–42
488), or Alexa633–maleimide        
(Aβ1–42
633), via sulfhydryl–reactive crosslinking (as described in method section 3.2.1.3).  
Labeled Aβ1–42 and free dyes were separated by size exclusion chromatography (SEC). Aβ1–42 
eluted in two populations, which were identified as monomers (at 1.39 ml) and protofibrils 
(at 0.86 ml), respectively (Figure 4–1 a). Unlabeled monomeric Aβ1–42 and aggregation–
incompetent labeled scrambled–Aβ1–42
565 (sc–Aβ1–42
565) were used as controls for the peak 
location of monomers on SEC. Unlabeled monomeric Aβ1–42
565 was located from 1.3 ml to 1.5 
ml and has a peak at 1.31 ml (Figure 4–1 b);sc–Aβ1–42 was from 1.3 ml to 1.5 ml, peak at 1.38 
ml (Figure 4–1 c), both of which eluted similar to Aβ1–42




Figure 4–1: Separation of Aβ1–42 by size–exclusion chromatography (SEC) and detection by atomic 
force microscopy (AFM). (a–c) Peptides and labels were detected by absorption at 280 nM and 565 
nm, respectively. (a) Atto565 labeled Aβ1–42 (Aβ1–42
565) eluted in a two populations, protofibril at 0.86 
ml and monomer at 1.39 ml.  Unlabeled monomeric Aβ1–42 (b) and Atto565 labeled scrambled–Aβ1–42 
(sc– Aβ1–42, c), have very similar SEC elution profiles as Aβ1–42
565 monomer. (d) No monomers or 
aggregates were detected by AFM in the Aβ1–42
565 monomer fraction collected from SEC (1.39 ml). (e) 
Aβ1–42
565 protofibrils with an average height of about 4 nm could be detected in the high molecular 
weight fraction of SEC (0.86 ml) by AFM. Scale bars, 1 μm.  
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Those monomers could not be detected by atomic force microscopy (AFM, Figure 4–1 d). In 
contrast, AFM identified the PF fraction of Aβ1–42
565 to be protofibrils, which had an average 
height in 4 nm (Figure 4–1 e). 
The concentration of labeled Aβ1–42 monomers and protofibrils, i.e. the productions from SEC, 
were calculated through area ratio of SEC at 565 nm by integration.  The concentrations of 
unlabeled Aβ1–42 monomers were calculated by Beer–Lambert law at 280 nm. 
When incubated with thioflavin T (ThT), the protofibrils (35 µM monomer equivalent) bound 
the dye immediately and ThT fluorescence changed little over the course of an hour, while 
ThT fluorescence of the monomeric Aβ (35 µM) displayed sigmoid kinetics typical of 
nucleated polymerization (Figure 4–2). To avoid the influence of label to ThT fluorescence, 
unlabeled protofibrils were used in this experiment. Those unlabeled protofibrils were 
prepared by following the same protocol as for labeled Aβ1–42. When preparing unlabeled 
protofibrils, the same volume DMSO, in which the fluorophores were dissolved, was added 




To examine whether the fluorescence label influences Aβ1–42 monomer aggregation kinetics, 
we compared fibril formation kinetics and fibril morphologies of labeled and unlabeled    
Aβ1–42. Unlabeled monomeric Aβ1–42 was mixed with 10% Aβ1–42
565 (total Aβ1–42
 
concentration of 15 µM) and incubated in PBS at 25 °C. Aggregation kinetics were monitored 
by binding of ThT in vitro (Figure 4–3 a) (LeVine 1999). ThT aggregation curves were 
normalized to the maximum intensity of ThT fluorescence of plateaus. The addition of 10 % 
Aβ1–42
565 monomer slowed the formation of the higher orderedβ–sheet–rich structures only 
slightly.   
After 2 d further incubation, fibrils from both samples have twisted structures and in heights 
of about 5 nm, as observed by AFM (Figure 4–3 b and c). However, the amount of small 
Figure 4–2: Thioflavin T (ThT) binding assay of Aβ1–42 elutions from SEC. Unlabeled monomeric Aβ1–42 
(35 μM, Mono.), Aβ1–42 protofibrils (35 μM monomer equivalent, Proto-F.) and an elution fraction at 
0.5 ml on SEC (20 μl) were incubated in PBS in presence of ThT (20 μM). ThT fluorescence of 









globular aggregates in mixed sample (c c), which do not have fibril structures, is more than 
those in the sample of pure unlabeled Aβ1–42 (Figure 4–3 b). The mixing of Aβ1–42
565 seems to 
cause a delay of aggregation rate in the conversion of globular aggregates to well formed 





To test whether labeled Aβ1–42 co–aggregate with unlabeled Aβ1–42, two types of labeled  
Aβ1–42, Aβ1–42
565 and Aβ1–42
633, were used. Monomeric Aβ1–42
565 (1 µM), monomeric Aβ1–42
633 
(4 µM) and unlabeled Aβ1–42 monomer of different concentrations (0 to 20 µM) were 
incubated in PBS at pH 7 at 25 °C for 3d. Additionally, donor only sample contained Aβ1–42
565 
(1 µM) and Aβ1–42 (4 µM), and acceptor only sample contained Aβ1–42 (1 µM) and Aβ1–42
633
 (4 
µM), were prepared under the same conditions as controls. Aβ1–42
565–to– Aβ1–42
633 FRET was 
Figure 4–3: Aggregates formation of Aβ1–42 monomers with labeling. (a) Monomeric Aβ1–42 was mixed 
with 10 % Aβ1–42
565 monomers (total Aβ1–42
 concentration of 15 µM)  and incubated in PBS with 
intermittent shaking (5s every 5 min). Aggregation was monitored by ThT fluorescence. The curves 
were normalized to the maximum intensity of fluorescence of plateaus. All results are represented as 
mean values of 3 replicate wells. (b & c) Unlabeled monomeric  Aβ1–42 was mixed without (b) or with 
10% Aβ1–42
565 (c), incubated in PBS for 2 d. Similar fibril structures with twisted structures and height of 
about 5 nm were detected in both samples by AFM. Scale bars, 1 μm. Figure b and c adapted from Sha 
Jin, Master Thesis “Cellular uptake of amyloid–ß aggregates”. 
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then measured by a fluorescence plate reader at excitation at 520 nm. Fluorescence 
emission spectrum was detected from 550 to 700 nm. 
Comparing with the samples containing only donor (Aβ1–42
565, red curve) or acceptor       
(Aβ1–42
633, dark blue curve) fluorophores, FRET samples, which contain both donor and 
acceptor fluorophores, have a decreased fluorescence intensity of emission maximum (Em. 




The degrees of fluorescence intensities decreasing at Em. max show a strong dependence on 
the concentrations of mixed unlabeled Aβ1–42 monomers, the higher the concentration of 
unlabeled Aβ1–42, the less the decrease of the donor fluorescence intensities.       






     [12] 
Figure 4–4: Co–aggregation of unlabeled and labeled Aβ1–42 monomers. (a) To prepare co–aggregates 
from labeled and unlabel monomers, monomeric Aβ1–42
565 (1 µM), monomeric Aβ1–42
633 (4 µM) and 
unlabeled Aβ1–42 monomer of different concentrations (0 to 20 µM) were incubated in PBS at pH 7 at 
25 °C for 3d. Donor only sample (Aβ1–42
565 of 1 µM and Aβ1–42 of 4 µM), and acceptor only sample  
(Aβ1–42 of 1 µM and Aβ1–42
633
 of 4 µM) were as controls. Aβ1–42
565–to– Aβ1–42
565 FRET was measured by 
a fluorescence plate reader at excitation at 520 nm.  (b) FRET efficiency, which is strongly influenced 
by concentration of added unlabeled Aβ1–42, was gived by 1 /D DE I I  .  𝐼𝐷
′  and 𝐼𝐷  are the donor          
(Aβ1–42










′  and 𝐼𝐷  are the donor (Aβ1–42
565) fluorescence intensities at 592 nm with and 
without acceptor (Aβ1–42
633), respectively. The decreased FRET efficiencies by increasing the 
concentration of unlabeled Aβ1–42 indicate there are coaggregation and no segregation 
between labeled and unlabeled Aβ1–42 (Figure 4–4 b).  
To be noted, the acceptor fluorophore (atto633) alone has a very strong emission at 655 
(±10) nm when exciting at 520 nm, it may the cause that fluorescence intensity of the 
acceptor showed only weak changes at this spectrum area (655 nm) when mixing with 
unlabeled Aβ1–42. 
Nevertheless, this FRET experiment demonstrated that labeled and unlabeled Aβ1–42 form 
co–aggregates. Aβ1–42
565 and Aβ1–42
633 forms co–aggregates, resulting in a reduction of donor 
fluorescence. Adding excess unlabeled Aβ1–42 results in a rescue of the donor fluorescence 
signal, indicating that FRET between the two labeled species is reduced.   
In the present study, labeled Aβ1–42
 preparations were used in cellular uptake experiments. 
To determine whether Aβ1–42 monomers can be take up by the cells and to investigate 
whether the state of aggregation influences cellular uptake, protofibrils (Figure 4–1 e) and 
well–formed mature fibrils (Figure 4–3 c) were used to compare their respective cellular 
uptake with that of monomers.  
For kinetic analysis, based on the aggregation kinetic in vitro and AFM data, the mixtures of 
90% unlabeled Aβ1–42 and 10% Aβ1–42
565 was used, so that the internalized Aβ1–42 can be 
detected via fluorescence, and at the same time their aggregation kinetics are not too much 
affected by the fluorescent tag (Figure 4–3 a). 
Internalized Aβ1–42 in cultured human neuroblastoma (SH–EP) cells was imaged by confocal 
microscopy, or quantified using high–content screening microscopy (HCS).  
4.1.2 Cellular uptake of Aβ1–42 depends on its aggregation state 
First, we examined which form and under which conditions Aβ1–42 can be taken up by the 
cells. SH–EP cells were incubated with monomeric Aβ1–42
565 or aggregates, which were the 
protofibrils in this case, contained β–sheet–rich structures at 37 °C for 24 h.  The monomer 
and protofibril fractions, which were isolated by SEC after the labeling process (Figure 4–1 a), 
were used. A fluorescently labeled aggregation–incompetent scrambled peptide,                 
sc–Aβ1–42
565, was used as control. A soluble membrane–impermeable fluorescent dye, 
calcein (20 µM), was added to the extracellular medium, to mark the uptake of extracellular 
medium during vesicular trafficking from the plasma membrane into the cells in endocytic 






565 aggregates could be detected after treatment with aggregates (150 
nM, monomer equivalent, concentration in medium, Figure 4–5 a) or with monomers at a 
higher concentration (500 nM, concentration in medium, Figure 4–5 b). Treatment with low 
Figure 4–5: Internalization of Aβ1–42 depends on aggregation states. (a–d) Human neuroblastoma 
(SH–EP) cells were incubated with purified monomer or aggregates (protofibrils) of Aβ1–42
565 (red) at 
37 °C for 24 h, were imaged by confocal microscopy. Calcein (20 µM, green) was added to indicate the 
trafficking vesikels. (a) Aβ1–42
565 aggregates (Agg.) of 150nM, (b) monomeric Aβ1–42
565 (mono.) of 
500nM, (c) monomeric Aβ1–42 of 150 nM, (d) scrambled–Aβ1–42
565 (sc–Aβ)of 500 nM and (e) negative 
control (n.c.). Cellular uptake of Aβ1–42
565 was only observed by treating with aggregates or with 
monomers at 500 nM. Co–localization of internalized Aβ1–42
565 with calcein suggested that internalized 
Aβ1–42








concentrations of monomeric Aβ1–42
565 (150 nM, concentration in medium, Figure 4–5 c) or 
with aggregation–incompetent sc–Aβ1–42
565 at higher concentration (500 nM, concentration 
in medium, Figure 4–5 d), did not lead to detectable Aβ1–42
565 inclusions inside the cells, and 
showed background signals in Atto 565 channel similar to untreated cells (Figure 4–5 d). 
These observations suggest that Aβ1–42 uptake may depend on a particular state of 
aggregation, and that an effective uptake of monomer may require forming an ordered 
structure, i.e. in an aggregated state. Colocalization of internalized Aβ1–42
565 with calcein 
suggested that internalized Aβ1–42
565 was located in endocytic vesicle. 
Compared with the uptake of monomeric Aβ1–42
565 and of aggregation–incompetent           
sc–Aβ1–42
565 at relatively high peptide concentration (500 nM), Aβ1–42
565 monomer could be 
observed (Figure 4–5 b) and there is no detectable sc–Aβ1–42
565 in the cells (Figure 4–5 d). 
The lack of uptake of sc–Aβ1–42
565 verified that internalization was specific for the Aβ 
sequence and not a result of the fluorescent label.  
Intensities of the 565 nm channel from Figure 4–5 a–e were analyzed. Average fluorescence 
intensities per pixel were calculated from the endocytic vesicles marked by calcein, areas in 





Figure 4–6: Quantitative analysis of Aβ1–42
565 fluorescence. Average fluorescence intensities per pixel 
inside endocytotic vesicles, in the cytosol and in the extracellular space were calculated from the 565 
nm channel of confocal images in Figs. 2A–E. Bar graphs represent average values of ± standard 
deviations (SD) from image areas corresponding to endocytotic vesicles marked by calcein (n=10), or 
from areas in the cytosol without vesicles (n=3) or in the extracellular space (n=3), respectively. Only 
cells treated with aggregated Aβ1–42
565 (150 nM; A.150) or monomeric Aβ1–42
565 (500 nM; M. 500) 
displayed fluorescence above the background of untreated cells (n.c.), whereas those treated with 
Aβ1–42
565 monomers at 150 nM (M. 150) and scrambled Aβ1–42
565 (500 nM; sc. 500) did not. Inset: Cells 
treated under conditions that resulted in uptake of Aβ1–42
565 aggregates displayed a threefold increase 
in cytosolic Aβ1–42
565 signal compared to the extracellular space. Aβ1–42
565 fluorescence in the cytosol is 
~ 30–fold lower than inside the vesicles.  
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Quantitative analysis of Aβ1–42
565 fluorescence intensities  in the endocytic vesicles and in the 
cytosol revealed that a low level cytosolic Aβ1–42
565 signal could be detected after treatment 
with aggregates (150 nM) or high concentration (500 nM) monomeric Aβ1–42 but not at low 
monomer concentrations (150 nM). The Aβ1–42
565 signal in the surrounding cytosol was 
about 30–fold lower than in the vesicles. 
Additionally, to test whether Aβ1–42 is equally internalized into primary neurons, primary rat 
hippocampal neurons were treated with Aβ1–42
565. The phagocytic active glial cells were 
eliminated during preparation process. Primary neurons were incubated with Aβ1–42
565 
monomer of 150 nM or of 500 nM at 37°C. Calcein (20 µM) was added to show the endocytic 
vesicles. The cells were fixed after 24 h incubating with Aβ1–42
565 and were imaged by 
confocal microscopy. The uptake of Aβ1–42
565 by primary hippocampal neurons was observed 
when monomeric Aβ1–42
565 at 500 nM (Figure 4–7 a), but not at 150 nM (Figure 4–7 b), which 
were very similar as observed in the cultured SH–EP cells. The colocalizations with calcein 
indicate internalized Aβ1–42




These results suggest that Aβ1–42 uptake depends on a particular state of aggregation, and 
that the monomeric Aβ1–42 concentration in the cell culture medium has to reach a critical 
concentration for a successful uptake. A possible explanation may be that the threshold 
concentration of monomeric Aβ1–42 uptake would correspond to the critical concentration 
for Aβ1–42 aggregation. The freshly formed aggregate would be then taken up. This 
hypothesis will be discussed in section 4.1.5. 
Figure 4–7: Internalization of Aβ1–42 primary hippocampal neurons. Primary hippocampal neurons 
were treated with Aβ1–42
565 monomer at 500 nM (a) or 150 nM (b) and calcein (20 µM) at 37 °C for 24 








4.1.3 Calcein as fluid–phase marker for Aβ1–42 endocytosis 
Calcein is a soluble membrane–impermeable fluorescent dye. A colocalization of internalized 
Aβ1–42
565 with calcein (Figure 4–5 a and b) suggests Aβ1–42
565 would be endocytosed via a 
vesicular trafficking into endocytic vesicles. To test whether calcein indeed distinguishd the 
locations of Aβ1–42 inside the cells, i.e. in the endocytic vesicles, or on the cell surface. SH–EP 
cells were treated with calcein (20 µM) and Aβ1–42 mixture (500 nM, equivalent monomer 
concentration), which contained small aggregates and well–formed mature fibrils as 
described in Figure 4–3 c. After incubation at 37°C for 24 h, fixed cells were imaged by 
confocal microscopy (Figure 4–8).  
Two different morphology patterns of Aβ1–42
565 staining were observed. The point–like     
Aβ1–42
565 was close to nuclei and colocalized with calcein, suggesting they are in endocytic 
vesicles inside the cells. The second group of Aβ1–42
565 aggregates show relatively large size 
and irregular form, which located probably on the cell surface, did no show colocalization 




Figure 4–8: Internalization of Aβ1–42 small aggregates vs. large fibrils. SH–EP cells were incubated with 
a mixture of small aggregates and well–formed fibrillar Aβ1–42 (500 nM, equivalent monomer 
concentration), containing 10% Aβ1–42
565, at 37 °C for 24 h, were imaged by confocal microscopy. 
Calcein (20 µM) were added together with Aβ1–42 to the cells, to distinguish internalized Aβ1–42 




4.1.4 Costaining of the internalized Aβ1–42 with anti–β–amyloid 
antibody. 
To validate that the intracellular Atto 565 fluorescence indeed corresponds to internalized 
Aβ1–42, SH–EP cells were incubated with Aβ1–42 aggregates (identical experiment as shown in 
Figure 4–8, total Aβ1–42
 concentration at 500 µM, equivalent monomer concentration) or 
with Atto 565 dye only (500 nM) at 37 °C for 24 h. The fixed cells were then costained with 
anti–β–amyloid mouse antibody 6E10 by immunofluorescence staining (IF) and were 
visualized by cy5 conjugated anti–mouse secondary antibody.  
The colocalization between fluorescence and 6E10/cy5 confirmed the presence of the Aβ 
peptide (Figure 4–9 a), i.e. Atto 565fluorescence of labeled Aβ1–42
565 represents Aβ1–42.  This 
demonstrated that the fluorescent labels of Aβ1–42 can be used to track Aβ1–42 uptake and 
aggregates formation.   
Lack of the primary antibody, 6E10, to against Aβ1–42
565, no the fluorescence signal of Cy5 
conjugated secondary antibody could be detected (Figure 4–9 b), indicating no binding of 
Cy5 conjugated secondary antibody to Atto 565 dye or to Aβ1–42
565 molecules. 6E10/Cy5 
recognized specifically Aβ1–42




Figure 4–9: Costaining of the internalized Aβ1–42 with anti–β–amyloid antibody. SH–EP cells were 
incubated with Aβ1–42
565 aggregates (500 nM, equivalent monomer concentration) (a and b), or Atto 
565 dye (c) at 37 °C for 24 h. (a) Fixed cells were stained by anti–Aβ antibody (6E10) using 
immunofluorescence staining (IF), visualized by cy5 conjugated secondary antibody (cyan), and imaged 
by confocal microscopy. Cell nuclei were stained with Hoechst 33342 (blue). Internalized Aβ1–42
565 were 
costained and co–localized with 6E10/cy5. (b) No secondary antibody binding observed without 
primary antibody (6E10) to Aβ1–42








By incubating SH–EP cells only with Atto 565 dye and staining with 6E10/Cy5, no Atto 565 
fluorescence could be detected, indicating that Atto 565 dye alone could not be taken up by 
SH–EP cells. Uniformly distributed Cy5 fluorescence in very small dots–form, which was from 
IF staining, was observed, that correspond probably to the endogenous amyloid precursor 
protein APP (Figure 4–10). However, internalized Aβ1–42
565 can be distinguished from those 
background signals through their distribution and morphology.  
These control experiments confirmed that Aβ1–42 could be represented by using fluorescence 
label and be tracked via fluorescence in the cultured cells. 
 
 
4.1.5 Uptake of monomer requires a minimum concentration 
In the case of monomeric Aβ1–42 uptake, the intracellular Aβ1–42 would only be detected by 
treating the cells with Aβ1–42 monomer at 500 nM (Figure 4–5 b), but not at 150 nM (Figure 
4–5 c). An effective uptake of monomers seems to depend on concentration of Aβ1–42.  
To test this hypothesis we titrated the cells either with Aβ1–42 monomer or small aggregates 
at varying concentrations and quantified intracellular Aβ1–42 aggregates as a function of    
Aβ1–42 concentration by fluorescence of labeled Aβ1–42 using HCS microscopy.  
First, we tracked the amount of internalized Aβ aggregates as a function of time and found 
maximal intracellular Aβ1–42 signal after treatment with Aβ1–42 for about 1d (Figure 4–11). 
SH–EP cells were incubated with purified Aβ1–42
488 monomers of 200 nM at 37 °C from 1 h to 
49 h.  Intracellular Aβ1–42
565 in fixed cells was analyzed by HCS microscopy. Maximal 
intracellular Aβ1–42 fluorescence was reached after 27 h. We thus used 1d incubation for 
subsequent uptake experiments. 
 
Figure 4–10: Uptake of Atto 565 dye as control experiment. SH–EP cells were Atto 565 dye (500 nM) 
at 37 °C for 24 h. Uptake of Atto 565 dye cannot be observed by SH–EP cells, 6E10/cy5 could not 





SH–EP cells were then treated with Aβ1–42 monomers and aggregates, protofibrils from SEC 
(Figure 4–1 e) were used as aggregates, at 15 – 1500 nM (equivalent monomer 
concentration) incubated at 37°C for 24 h. For monomeric Aβ1–42, the total amount of 
intracellular aggregated Aβ1–42 as well as the number of aggregates and their total areas 
were proportional to Aβ1–42 monomer concentrations in the medium. No intracellular Aβ1–42 
aggregates were observed below a threshold concentration of about 300 nM (Figure 4–12 a 
and b). In contrast, no such threshold concentration existed for the internalization of 
preformed Aβ1–42
565 aggregates (Figure 4–12 c and d). Neither form of Aβ1–42, monomer or 
small aggregates, has significant effect on the number of cells (Figure 4–12 a and c).  
In all experiments, the concentrations of aggregates are reported as the equivalent 
concentration of the Aβ1–42 monomer. It means the total number of aggregates in the 
medium is much smaller than the number of monomers. However, the amount of 
internalized Aβ1–42
565 in the cells that were treated by aggregates is 3–5 times higher than in 
monomer treated cells. One possible explanation of the low number of cellular aggregates 
after monomer uptake could be detection bias of our method. The weak signal of a single 
fluorophore is not easy to detect by HCS microscopy and the aggregate detection algorithm 
requires a certain fluorescence threshold, which biases against the detection of monomers 
and very small aggregates. Nevertheless, it would be also very probable that uptake of 
performed Aβ1–42 aggregates is much more efficient than monomer. They can already be 
taken up by cells at very low concentration, based on their well–formed structures. 
 The observed threshold concentration for monomer uptake is similar to the critical 
concentration (Usui et al. 2009) that was reported for the aggregation of Aβ1–42 monomers, 
which suggests that aggregation may be a prerequisite for uptake. If so, it would be 
important to determine the location of aggregates formation and which type of aggregate 
species is efficiently taken up by the cells. In the next chapters will compare the cellular 
uptake of Aβ1–42 at different stages of its aggregation process.  
Figure 4–11: The time–dependence manner of internalized Aβ1–42. SH–EP cells were incubated with 
purified Aβ1–42
488 monomer (200 nM) at 37 °C from 1 h to 49 h.  Intracellular Aβ1–42
488 in fixed cells was 
analyzed by high–content screening (HCS) microscopy. Maximal intracellular Aβ1–42 was reached after 









4.1.6 Aggregation on plasma membrane precedes uptake of Aβ1–42 by a 
clathrin independent pathway  
To investigate the location at which the aggregates form that are the requested for uptake 
and to better track the dynamics of monomer uptake, we repeated the uptake experiment 
under conditions that allowed us to temporarily separate Aβ membrane interaction from its 
uptake into the cell.  
The cells were cooled to 4°C, which slows down both Aβ1–42 aggregation and cell metabolism. 
By lowering the temperature, Aβ aggregation kinetic is slower than at room temperature (RT) 
or at 37°C, the fluidity of membrane is decreased and the cell metabolisms is slowed (Alberts 
2008; Lodish et al. 2008; Uzman et al. 2000). Additionally, clathrin–mediated endocytosis is 
inhibited at 4°C as indicated by blocking the uptake of transferrin (Harding et al. 1983), 
which provides also an opportunity to investigate the pathway of Aβ cellular uptake.  
The general experimental process is shown in Figure 4–13. The cells were cooled to 4°C for 
15 min, and then were treated with Aβ at 4°C for 45 min. In this step, Aβ would be loaded to 
the cells. The cells were then washed with ice–cold PBS to remove unbound Aβ1–42. 
Depending on the goal of experiments, the cells were imaged directly, or were further 
Figure 4–12: The concentration–dependence manner of Aβ1–42 uptake. SH–EP cells were incubated 
with purified Aβ1–42
565 monomer (a & b) or aggregates (c & d) at 37 °C for 24 h. Intracellular Aβ1–42
565 in 
fixed cells was analyzed by HCS microscopy. Total fluorescence intensities of Aβ1–42
565, cell counts per 
well, the counts of Aβ1–42
565 aggregates per cell and their total area were plotted as a function of     
Aβ1–42
565 concentration in the cell culture medium. All results are represented as mean values ± SD of 6 
replicate wells. Figure adapted from Sha Jin, Master Thesis “Cellular uptake of amyloid–ß aggregates”. 
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restored at 37°C in fresh media for the uptake of Aβ1–42. The uptake of labeled Aβ1–42 was 




4.1.6.1 Aβ1–42 uptake at 4°C 
The clathrin–mediated endocytosis is blocked at 4°C (Harding et al. 1983), and the fluidity of 
membrane is limited by reducing the temperature (Uzman et al. 2000; Lodish et al. 2008). 
We, therefore, first of all tested whether cooling to 4°C leads to a cellular change that 
prevents Aβ1–42 uptake. Transferrin was used to report the inhibition of clathrin–mediated 
endocytosis pathway. Following incubation with monomeric and preaggregated Aβ1–42
565 
(150 nM, respectively) calcein (20 µM) and transferrin (10 ng / ml) at 4 °C for 45 min, fixed 
SH–EP cells were imaged by confocal microscopy (Figure 4–14). The transferrin was located 
exclusively in the cell membrane, demonstrating that clathrin–mediated endocytosis was 
efficiently inhibited.  
Under these conditions Aβ1–42 was only observed on the plasma membrane and was not 
internalized in the cells treated with Aβ1–42 monomers (Figure 4–14 a). However, the 
membrane associated Aβ1–42, which localized exclusively on the membrane at the time point 
of the cell fixation, did not colocalize with Transferrin. It suggested that the inhibition of 
monomer uptake may not due to the blocking of clathrin–dependent pathway. The down 
regulation of temperature was also unfavourable for Aβ1–42 aggregation. In this case, 
monomeric Aβ1–42 may still in monomeric or very early aggregation state, which probabely 
may not be able to be taken up.  
The uptake of preaggregated Aβ1–42 species was reduced but not totally inhibited under 
these conditions (Figure 4–14 b). Due to transferrin still located on the plasma membrane, 
internalized Aβ1–42 found in endocytic vesicles did not colocalize with them.  
 
Figure 4–13: Scheme of experimental flow. The cells were incubated with monomeric Aβ1–42at 4°C for 
loading of Aβ1–42, then cells were either imaged directly, or were washed offto remove unbound Aβ1–42 
and were further incubated in fresh medium at 37 °C. Intracellular Aβ1–42was quantified by confocal 










These data suggest that uptake of preaggregated Aβ1–42 may be independent of clathrin–
mediated endocytosis, and an efficient uptake of Aβ1–42 may depend on their aggregation 
status. 
A quantitative analysis of the amount of internalized Aβ1–42
565 aggregates at 4°C and at 37°C 
was carried out in 96–well plates by using HCS microscopy. SH–EP cells were incubated with 
preaggregated Aβ1–42
565 (as used in Figure 4–14 b) of 150 nM at 4°C and 37°C for 45 min, 
respectively (Figure 4–15). At 37°C, the total amount of more internalized Aβ1–42
565 was 
about 5 times than at 4°C. At the same time, no significant changes of cell counts were seen 
different temperatures.  
Our data suggested, while clathrin–mediated endocytosis may be the prominent mechanism 
by which both monomeric and oligomeric Aβ1–42 enters the cell, there is a secondary 
Figure 4–14: Aβ1–42 uptake at 4°C. SH–EP cells were incubated with monomeric (a) or preaggregated 
(b) Aβ1–42
565 (red) of 150 nM, calcein (20 µM, green) and transferrin (10 ng / ml, blue) for 45 min at 
4 °C, and were imaged by confocal microscopy. Transferrin and    Aβ1–42
565 monomer were observed in 
the plasma membrane. Aβ1–42
565 aggregate could be detected inside the cells. Scale bars, 10 µm. 
 
Results 61 
pathway by which Aβ1–42 oligomers can cross the cell membrane that is still functional under 
conditions when receptor mediated endocytosis of transferrin is blocked.  
A more detailed analysis of the Aβ1–42 uptake pathway is found in section 4.1.9. 
 
  
4.1.6.2 Uptake of aggregates formed on plasma membranes 
Figure 4–14 a shows that Aβ1–42, in monomeric form or in a state that cannot be taken up, is 
capable to associate with the cell membrane, even under conditions that prevented its 
endocytosis. This observation raises the question whether monomeric  Aβ1–42 is able to 
aggregate on the cell membrane. To answer this question, the formation of Aβ1–42 
aggregates on the cell membrane was quantified by using Förster resonance energy transfer 
(FRET) between two fluorophores of labeled Aβ1–42 monomers.  
SH–EP cells were incubated with two types of fluorescently labeled monomeric Aβ1–42,     
Aβ1–42
488 and Aβ1–42
633. After pre–incubation at 4 °C for 15 min, SH–EP cells were treated 
with monomeric Aβ1–42
488 and Aβ1–42
633 at 4°C for 45 min. Total Aβ1–42 concentration was 500 
nM with Aβ1–42
488 to Aβ1–42
633 ratio in 3:7. Confocal imaging showed that both Aβ1–42
488 and 
Aβ1–42
633 accumulated on the plasma membrane. Aβ1–42
488 and Aβ1–42
633 not only colocalized 
but also displayed a FRET signal, indicating direct interaction between the two–labeled    
Aβ1–42 species (Figure 4–16 a). These data demonstrate that at least a fraction of the 
monomeric Aβ1–42 peptides rapidly coaggregated on the plasma membrane.  
Next, we investigated whether the cell takes up these membrane–bound Aβ1–42 aggregates, 
rather than Aβ species that may be present extracellularly in solution.  
Under conditions like in Figure 4–16 a (4°C, 60 min incubation time with the cells), 
monomeric Aβ1–42
565 was located only on the plasma membrane even at a monomer 
Figure 4–15: Aβ1–42 uptake at 37°C vs. at 4°C. SH–EP cells were incubated with preaggregated Aβ1–42
565 
(150 nM) in 96–well plate at 37°C and at 4°C, respectively. Internalized Aβ1–42
565 was analyzed by using 
HCS microscopy. Internalized Aβ1–42
565 was decreased at 4°C. The cell counts kept stable. All results are 








concentration of 1 µM (Figure 4–16 b). No uptake of Aβ1–42
565 could be observed. Uptake of 
calcein (20 µM) exhibited that the cell still had some endocytotic activity under these 




Figure 4–16: Aggregation of Aβ1–42 occurs on the plasma membrane. (a) Aβ1–42 – to – Aβ1–42 Förster 
resonance energy transfer (FRET) on the plasma membrane. SH–EP cells were incubated with 
monomeric Aβ1–42 (500 nM total Aβ1–42) at 4 °C for 45 min, were imaged by confocal microscopy.    
Aβ1–42
488 – to – Aβ1–42
633 FRET indicated aggregates species bound to the plasma membrane. (b) After 
incubating with monomeric Aβ1–42
565 (1 µM) and calcein (20 mM) at 4 °C for 60 min, Aβ1–42 was located 
only on the plasma membrane, no uptake could be observed. Calcein indicates the cells are still active. 
(c) SH–EP cells were treated successively with monomeric Aβ1–42
488 and Aβ1–42
633 (each 500 nM in the 
medium) at 4°C for 30 min, were then incubated in fresh medium at 37 °C for 3 h. Co–localization of 
Aβ1–42
488 and Aβ1–42
633 indicates that internalized Aβ1–42 was in aggregated form. (d) SH–EP cells were 
incubated with transferrin/Alexa488 (Tf/A488, 5 ng/ml) and transferrin/Alexa647 (Tf/A647, 10 ng/ml) 
conjungates at 4 °C for 45 min. No FRET occurred between two co–localized transferrin conjungates.  
White outlines in DIC and FRET images mark cells areas. Scale bars, 10 µm. 
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In the next step, SH–EP cells were treated successively with monomeric Aβ1–42
488 and       
Aβ1–42
633, each at 500 nM concentration. First, SH–EP cells were incubated with monomeric 
Aβ1–42
488 at 4°C for 30 min. Unbound Aβ1–42
488 was removed by washing the cells with ice–
cold PBS. The cells were treated with the second labeled Aβ1–42, Aβ1–42
633, at 4°C for another 
30 min. After that, the cells were washed again to remove unbound Aβ1–42
633, were 
incubated in fresh medium at 37 °C for 3 h to permit internalization of Aβ1–42, and were 
imaged by confocal microscopy (Figure 4–16 c). Most of internalized Aβ1–42 colocalized with 
each other, suggesting coaggregations of both labeled    Aβ1–42 species. The Positive NFRET 
signals between both labeled Aβ1–42 species inside the cell confirmed that they form 
coaggregates.  
Based on the observation that by incubating <60 min, either at 500 nM or 1 µM Aβ1–42 
associated only with the plasma membrane (Figure 4–16 a & b), we conclude that Aβ1–42
488 
coaggregated with Aβ1–42
633 while located on the plasma membrane, either on the 
membrane surface or in a compartment that is localized on the membrane. The membrane 
bound aggregates were then taken up by endocytosis after the cells were returned to 37°C.  
To verify that the FRET signal is specific to coaggregation of Aβ1–42 and is not an artefact of 
the label or calculation method of FRET, we used transferrin (Tf) as a negative control.  
After incubating SH–EP cells with two types of fluorescent transferrin conjugates, 
Tf/Alexa488      (5 µg/ml) and Tf/Alexa647 (10 µg/ml), at 4°C for 45 min, colocalization of 
both Tf were observed, but no FRET between them (Figure 4–16 d). Sensitized emission FRET 
analysis were based on confocal microscopy images, and calculated using the same method 
used in Figure 4–16 a and c (Feige et al. 2005).  
These data strongly suggest that the FRET between Aβ1–42 molecules results from a specific 
aggregation process. 
For a more comprehensive analysis of the membrane assisted aggregation and subsequent 
uptake of Aβ1–42 monomers, the cells were treated with monomeric Aβ1–42
565
 at various 
concentrations (0 – 1600 nM) in 96–well plates at 4 °C for 45 min. Following a wash off 
process with ice–cold PBS to remove unbound Aβ1–42, the cells were further incubated in 
fresh medium. Subsequently, the temperature was raised to 37°C to permit internalization 
of Aβ1–42 and the cells were incubated for 24 h. Intracellular Aβ1–42
565
 was quantified by HCS 
microscopy (Figure 4–17). Intracellular Aβ1–42
565 aggregate signals could be detected at    
Aβ1–42
565 monomer concentrations above 200 nM, similar to the threshold concentration     
(~ 300 nM) we previously observed for monomer uptake at 37°C (Figure 4–12). These data 
demonstrate that Aβ1–42 binds to the plasma membrane and forms aggregates prior to 
cellular uptake, that the cell membrane assists the Aβ1–42 aggregation, and that monomer 









      
 
Conceivably, small Aβ1–42 aggregates that are competent for uptake, could be forming in 
solution and then bind to the plasma membrane. However, a comparison of conditions and 
time scales of Aβ1–42 aggregation in solution with those of the membrane binding 
experiment makes this hypothesis less likely. Incubation of cells with Aβ1–42 monomer for 45 
min at 500 nM was sufficient to initiate uptake. In this time frame, ThT positive Aβ1–42 
species did not form in solution under the same conditions (Figure 4–18). At monomer 
concentrations of 1500 nM, which is the approximate concentration used for uptake (Figure 
4–17), the conversion intoβ–sheet–rich structures took more than 3 h. 
 
      
Taken together, our results suggest that an efficient uptake required aggregated structures 
were formed on the plasma membrane. Binding of Aβ1–42 to the plasma membrane occurred 
within the lag phase of ThT aggregation kinetics, well before the formation of β–sheet–rich 
aggregates. However, the experiment cannot exclude the possibility that Aβ1–42
 formed small, 
pre–β–sheet oligomers in solution, which then bound to the plasma membrane.  
After the observation that monomers and/or small aggregates were already capable 
associated to the plasma membrane, we then examined the Aβ1–42 aggregates inside the 
cells, whether they containedβ–sheet–rich structures or not. 
The interaction of Aβ1–42
 with model membranes will be analyzed detailedly in section 4.2 of 
this thesis. 
Figure 4–18: The concentration–dependence 
manner of monomeric Aβ1–42 aggregation 
kinetics in vitro. Normalized Aβ1–42 (0.7–25 µM) 
aggregation kinetics were monitored by ThT (20 
µM) fluorescence. All results are represented as 
mean values of 3 replicate wells. Figure adapted 
from Sha Jin, Master Thesis “Cellular uptake of 
amyloid–ß aggregates”. 
Figure 4–17: The concentration–dependence 
manner of Aβ1–42 uptake at 4°C. SH–EP cells 
were treated with monomeric Aβ1–42
565 (0 – 
1600 nM) at 4°C for 45 min and then in fresh 
medium at 37°C for 24 h. Intracellular Aβ1–42
565 
was quantified by HCS microscopy. All results 




4.1.7 Internalized Aβ1–42 aggregate containβ–sheet–rich structures  
Our previous experiments found: i) monomeric Aβ1–42 is internalized at concentrations above 
~200 nM; ii) Aβ1–42 aggregates on the plasma membrane, and iii) aggregates contained β–
sheet structure were taken up very efficiently, all suggesting a possible conversion of 
monomeric Aβ1–42 into β–sheet structure during uptake. To identify the secondary structure 
of internalized Aβ1–42 in the cultured cells, we stained them by Thioflavin S (ThS) after their 
uptake.  
ThS is widely used dye to identify amyloid structure in tissue or in the cultured cells. Like 
Thioflavin T, ThS display an enhanced Em.max with red shift at 482 nm occurring β–sheet 
binding (LeVine 1993). Binding and fluorescence of ThS to β–sheet structure is less pH 
sensitivity than ThT (LeVine 1993).  
To resolve whether this conversion occurs, we performed a competitive uptake experiment 
between monomer at sub–critical concentration (Aβ1–42
565, 150 nM), which was co–
incubated with β–sheet aggregates (Aβ1–42
633, 900 nM). Both species were labeled with 
different fluorophores to track in which compartment both monomers and aggregates were 
found. In addition,β–sheet–rich structures s were recognized by ThS.  
SH–EP cells were preincubated at 4°C for 15 min, were treated with Aβ1–42
565 monomer of 
150 nM at 4°C for 20 min. Monomeric Aβ1–42
565 was removed via washing with ice–cold cell 
culture medium, and then were treated with Aβ1–42
633 aggregates of 900 nM at 4°C for 20 
min. Following remove of unbound Aβ1–42 peptide, the cells were incubated with ThS of 0.5% 
(w/v) at 4°C for 10 min. After that, the cells were further incubated in fresh cell culture 
medium with calcein ( 20 µM) at 37 °C for 1 h. After removing the calcein rich medium, the 
cells were incubated in calcein free medium at 37 °C, and live cell imaging were taken by 
spinning disk confocal microscopy at 37°C with 5 % CO2 (Figure 4–19). 
Aβ1–42
565 was observed in both state, ThS positive (Figure 4–19 circle 1) and ThS negative 
(Figure 4–19 circle 2 and 3). In Figure 4–19 circle 1 and 2 show two aggregates that 
contained both Aβ1–42
565 and Aβ1–42
633. However, only the ThS positive aggregates colocalized 
with calcein (Figure 4–19 circle 1). In contrast, ThS negative structures did not colocalize with 
calcein and were thus not inside the endocytic vesicles (Figure 4–19 circle 2). Similarly,    
Aβ1–42
565 structures that had not coaggregated with Aβ1–42
633 aggregates did not bind ThS and 











This means that ThS and calcein fluorescence signals were linked and that under these 
conditions only β–sheet aggregates located in endocytic vesicles. Sub–threshold 
concentrations of Aβ1–42 monomers were capable of binding to the plasma membrane. These 
observations strongly suggest that Aβ1–42 converted into aggregates on the membrane prior 
to uptake, coaggregation into β–sheet–rich structures was needed for their efficient uptake. 
Our previous data indicate that Aβ1–42 species with pre–β–sheet structure bound to the 
plasma membrane. Those β–sheet structures, which probably be formed directly on the 
plasma membrane, may play an important role for an efficient and successfully uptake of 
Aβ1–42 by neuroblastoma cells in culture. 
Figure 4–19: Thioflavin S (ThS) staining of internalized Aβ1–42 on living cells. SH–EP cells were treated 
with Aβ1–42
565 monomer (150 nM, red) and Aβ1–42
633 aggregates (900 nM, cyan), at 4°C for 20 min each; 
were stained with Thioflavin S (ThS, 0.5% w/v, yellow) at 4°C for 10 min; were incubated with calcein 
(20µM, green) at 37 °C for 1 h; were imaged by spinning disk confocal microscopy. Internalized 
aggregates that contained β–sheet structures showed positive ThS staining and positive calcein signals 
(circle 1). ThS negative Aβ1–42
565, co–aggregated with Aβ1–42
633 (circle 2) or by itself (circle 3), was not 
taken up into endocytic vesicles and did not co–localize with calcein. Scale bar, 10 µm. 
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4.1.8 Efficient uptake correlates with formation of β–sheet–rich 
structures  
To verify our hypothesis that formation of β–sheet structure is prerequisite of uptake and to 
determine which aggregate species could be taken up efficiently, we combined in vitro 
aggregation kinetics and cellular uptake experiments. Aβ1–42 amyloid formation is monitored 
in vitro to collect Aβ1–42 species at different stages of aggregation. Then their uptake is 
monitored through fluorescence of labeled Aβ1–42. 
Monomeric Aβ1–42 (15 µM, with 10 % Aβ1–42
565) aggregation kinetics was monitored by ThT 
fluorescence (Figure 4–20 a, red curve). Samples at four time points, which corresponded to 
different phases of peptide aggregation: initiation (t0), lag phase (t1), growth phase (t2), and 
plateau phase (t3) were collected. The samples were characterized by circular dichroism 
spectroscopy (CD, Figure 4–20 b). Within the lag phase (t0 and t1), Aβ1–42 partially lost its 
disordered state. It adopted a β–sheet structure during the growth phase (t2 and t3) of ThT 
kinetics.  
To determine which of these aggregation states are efficiently taken up, the SH–EP cells 
were incubated with these aggregates (t0 – t3) at 37 °C at a 150 nM equivalent monomer 
concentration. This is a concentration below the threshold concentration, at which Aβ1–42
565 
monomers could not be internalized but preformed aggregates could be (Figure 4–5 a and c; 
Figure 4–12 a and c). After 24 h incubation, intracellular Aβ1–42 aggregates were quantified 
by HCS microscopy (Figure 4–20 c). Intracellular Aβ1–42
565 aggregates were detected in cells 
that had been treated with growth (t2) and the steady–state phase (t3) aggregates. In 
contrast, no uptake of Aβ1–42 peptides was observed with samples from the initiation (t0) 
and lag phase (t1) of the polymerization reaction. 
These data suggest that Aβ1–42 aggregates at time points t2 and t3 that had β–sheet–rich 
structures  are efficiently internalized, while unstructured monomers (t0) or small oligomers 
(t1) without β–sheet structure are not.  
The efficient uptake of β–sheet–rich oligomers / aggregates might also explain why 
oligomeric Aβ1–42 species have many times been observed to have higher cytotoxicity (Haass 
& Selkoe 2007; Walsh et al. 2002). 
Our previous data show that neither form, monomer or small aggregates, had a strong effect 
on the count of living cells (Figure 4–12 a and c), i.e. internalized Aβ1–42
565 did not cause cell 
death. We therefore analyzed cell metabolic activities after treating with Aβ1–42 by 3–(4,5–












SH–EP cells were treated with unlabeled Aβ1–42 preparations collected at time point t0 and 
t3 from ThT kinetics (Figure 4–20 a, black curve). MTT assays were carried out after 24 h 
incubation at 37°C. Aβ1–42 aggregates formed during the growth phase (t3) were significantly 
more toxic than monomers (t0), and inhibited metabolic activity (Figure 4–20 d). Aβ1–42 
monomers became cytotoxic only at concentrations above 150 nM (Figure 4–20 e), a point 
at which they also underwent internalization (Figure 4–12 a). MTT assay was carried out 
after treating SH–EP cells with Aβ1–42 monomer at a concentration range of 0–600 nM at 
37°C for 24h.  Thus, their toxicity was correlated to their more efficient uptake. 
It should be noted that because of the dilution, the structure of aggregates at 150 nM in 
medium and at the time of uptake might be not the same as seen in the CD spectrum, which 
was measured at 15 µM (Figure 4–20 b). Nevertheless, below 300 nM only Aβ1–42 that 
contained β–sheet–rich structures (t2, t3) was internalized, while unstructured monomers 
Figure 4–20: β–Sheet structure promotes Aβ1–42 uptake. (a) Aggregation kinetics of monomeric Aβ1–42 
(15 µM) with 10 % Aβ1–42
565 in PBS were monitored by ThT fluorescence. Aggregates were collected 
from the aggregation assay at four time points (t0 – t3). (b) Secondary structures of Aβ1–42 from t0 – t3 
were measured by circular dichroism spectroscopy. (c) Aβ1–42 (t0–t3) were diluted to a final 
concentration of 150 nM, were added to SH–EP cells for 24 h incubation time at 37°C. Internalized 
Aβ1–42
565 of fixed cells was quantified by HCS. (d & e) SH–EP cells were treated with Aβ1–42 for 1 d at 
37 °C, their metabolic activities were measured by MTT assay. The cells were incubated with Aβ1–42 
monomers (t0, 150 nM), aggregates (t3, 150 nM) or without Aβ1–42 (n.c) (d); or with monomeric Aβ1–42 
at 0–600 nM (e). All results are represented as mean values ± SD of 3 replicate wells for ThT kinetics 
(a), of 6 replicate wells for uptake (c) and of 12 replicate wells for the MTT assay (d and e). 
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(t0) or small aggregates (t1) without β–sheet structure were not. This suggests that it was 
indeed the β–sheet aggregates that were taken up, rather than a different Aβ1–42 species.  
These data support the hypothesis that the formation of an ordered structure, β–sheet–rich 
structures, may be a prerequisite for efficient uptake and subsequent cytotoxicity of Aβ1–42 
aggregates in neuronal model cells. The plasma membrane may serve as a platform in 
formation of toxic aggregates. 
4.1.9 Examination of intracellular location of internalized Aβ1–42   
The observations that internalized Aβ1–42 aggregates located in endocytic vesicles raised the 
question by which endocytic pathway β–sheet–rich aggregates are internalized. 
In previous experiments (in section 4.1.6.1), we had observed that uptake of Aβ1–42 may be 
independent of clathrin–mediated endocytosis (CME, Figure 4–14). In those experiments, 
CME pathway was blocked by lowering the temperature to 4°C (Harding et al. 1983), and 
used transferrin as specific reporter to show the inhibition of CME pathway.  
We also analyzed the internalization of Aβ1–42 aggregates at 37°C under conditions, which 
permitted CME, and tested whether internalized Aβ1–42 colocalized with CME or other 
endocytic marker. 
SH–EP cells were treated with Aβ1–42
565
 β–sheet aggregates (150 nM, equivalent monomer 
concentration) at 37°C. Fixed cells were costained with endocytic markers by IF staining: 
clathrin for clathrin–mediated endocytosis; caveolin for receptor–independent endocytosis; 
early endosome antigen 1 (EEA1); Lysosome–associated membrane protein 2 (LAMP2). 
Primary antibodies were visualized by cy5 conjugated secondary antibody. Nuclei were 
stained with Hoechst 33342 (Figure 4–21). No colocalization with clathrin (Figure 4–21 a) 
and LAMP2 (Figure 4–21 b) was observed, supporting that Aβ1–42 was not internalized via 
CME. Rather, internalized   Aβ1–42
565 colocalized with caveolin (Figure 4–21 c) and EEA1 
(Figure 4–21 d), confirming that     Aβ1–42
565 was localized in endocytic vesicles and were 











In a further control experiment, the CME pathway was selectively blocked by potassium 
depletion (Ivanov 2008; Larkin et al. 1983). The effect of K+ depletion on Aβ1–42 uptake was 
compared with the internalization of transferrin.  
SH–EP cells were incubated with a hypotonic medium for 5 min, and then were incubated in 
isotonic medium with or without K+. In both of cases, with or without K+, Aβ1–42
565 β–sheet 
aggregates of 150 nM (equivalent monomer concentration) or transferrin Alexa Fluor 647–
conjugates (Tf/A647, 10 ng/ml) were added. Following the incubation at 37 °C for 1h, 
Figure 4–21: Costaining of the internalized Aβ1–42 with markers of endocytosis. SH–EP cells were 
treated with Aβ1–42
565
 aggregates (150 nM, red) at 37°C. Colocalization of internalized Aβ1–42
565 
detected by clathrin (a), LAMP2 (b), caveolin (c), EEA1 (d) by immunofluorescence staining. The 
primary antibodies of endocytic marker proteins were visualized by cy5 conjugated secondary 
antibody (green), and were imaged by confocal microscopy. Nuclei were stained with Hoechst 33342 
(blue). Part of internalized Aβ1–42
565 was colocalized with caveolin and EEA1, not with clathrin and 




565 or Tf/A647 of fixed cells were analysed by HCS microscopy (Figure 4–
22).  
Internalization of Aβ1–42
565 was not reduced by blocking CME pathway. Surprisingly, K+ 
depletion actually stimulated Aβ1–42 uptake. The increased amount of internalized Aβ1–42
565 
by incubating with K+ depleted media might be caused by a reorganization of the cortical 
actin cytoskeleton (Altankov & Grinnell 1993; Rajasekaran et al. 2001; Ivanov 2008). In 
contrast, Tf/A647 uptake was inhibited by blocking CME via K+ depletion. These results 
support our hypothesis that CME pathway does not play the primary role in the uptake of β–
sheet–rich Aβ1–42 aggregates. 
Taking together, we conclude that the cellular uptake of β–sheet Aβ1–42 aggregates was 
achieved via a clathrin independent pathway. Alternatively, internalized Aβ1–42 may have 
progressed into late endosomal compartments at the time of fixation, that may lead to only 
part of internalized Aβ1–42 colocalize with EEA1 (Figure 4–21 d). The exact mechanism and 
the precise uptake pathway of Aβ1–42 monomers via membrane–assisted aggregation should 




Figure 4–22: Blocking clathrin–mediated endocytosis (CME) pathway by potassium depletion. SH–EP 
cells were incubated with Aß1–42
565 aggregates (150 nM) or transferrin Alexa Fluor 647–conjugates 
(Tf/A647, 10 ng/ml) at 37°C for 1h in K+ depleted (–KCl) or not depleted (+KCl) medium.  Intensities of 
fluorescence in cells incubated in –KCl media were normalized of those in +KCl media. Uptake of 
Tf/A647 was reduced by blocking CME, whereas uptake of Aβ1–42
565 was increased.  All results are 








4.1.10 Inhibition of Aβ1–42 protofibril uptake by using chemical 
compound 
In studying the cellular uptake of monomeric Aβ1–42, we found their aggregation into β–
sheet–rich structures had strongly promoted their internalization. 
In this section, we changed our view from monomers to well–formed protofibrils, and 
investigated whether a structure change by treatment with a chemical compound would 
affect their uptake.  
A small hydrophobic molecule, named AMC (unpublished, provided from AG Wanker, MDC–
Berlin) was used, which may disturb the structure and change the solubility of Aβ1–42 
protofibril. We tested, whether cellular uptake of protofibrils would consequent change 
after their treatments by AMC. 
The Aβ1–42
565
 protofibrils that used were isolated by SEC, had high molecular weight, and 
were relative homogenous (Figure 4–1). This protofibrillar Aβ1–42
565
 could be internalized 
directly and more efficiently than monomeric form by SH–EP cells (Figure 4–5 a). 
To test the effect of the durg on Aβ1–42 uptake, Aβ1–42
565
 protofibrils of 15 µM (equivalent 
monomer concentration) were pretreated with AMC in buffer (DMSO) in a dose–dependent 
manner, at 3 – 1.5 – 0.75 – 0 µM, at 37 °C for 1 d, respectively, before the uptake 
experiments. The molar ratios of Aβ1–42 to AMC were in 5 – 10 – 20 – 0. In this group, both 
Aβ1–42
565
 protofibrils and AMC had relatively high concentrations. In a second group, the 
concentrations of Aβ1–42
565
 protofibril and AMC were lowered. But, their molar ratios were 
maintained at the same level as in the first group. Aβ1–42
565
 protofibrils and AMC were mixed 
and incubated in cell culture media with Aβ1–42
565
 at 150 nM (equivalent monomer 
concentration), 100 times lower than the concentration of the first group. Correspondingly, 
AMC had a concentration range at 30 – 15 – 7.5 – 0 nM. The mixtures were incubated at 
37 °C for 1 d, just as the samples in first group.  
After 1 d incubation, Aβ1–42
565
 protofibrils and AMC mixtures were added to SH–EP cells for 
uptake experiments. The samples of the first group that contained Aβ1–42
565
 protofibrils and 
AMC in higher concentrations were diluted in cell culture media and then were added to the 
cells, so that the final concentration of Aβ1–42
565
 protofibrils in the cell culture media was at 
150 nM, and AMC were at 30 – 15 – 7.5 – 0 nM. Thus Aβ1–42
565
 protofibrils and of AMC have 
the same concentration as in the second group. The Aβ1–42
565
 protofibrils and AMC mixtures 
of second group were added directly to the cells, i.e. Aβ1–42
565
 protofibrils of 150 nM and 
AMC at 30 – 15 – 7.5 – 0 nM. Additionally, in a third group as comparison experiments,    
Aβ1–42
565
 protofibrils (final concentration 150 nM in cell culture media, equivalent monomer 
concentration) and AMC (final concentration 30 – 15 – 7.5 – 0 nM in cell culture media) were 
added to the cell, namely Aβ1–42  and AMC had the same concentrations and molar ratios as 




565 of fixed cells was quantified by HCS microscopy after incubation at 37°C 
for 24h incubation time (Figure 4–23 a). The pretreatment of Aβ1–42
565
 protofibrils with AMC 
strongly reduced the uptake of Aβ in a dose dependent manner. This was especially true in 
the first group, the pretreatment of Aβ1–42
565
 protofibrils in buffer, when Aβ1–42 and AMC 
both had relatively high concentrations. Treatment with AMC showed no significant 
influence on the cell count (Figure 4–23 b).  
However, our understanding on the mechanism of AMC is still very limited. One of the 
possible reaction mechanisms might be that, AMC may bind to hydrophobic regions of Aβ1–42 
protofibrils thanks to its hydrophobic properties. This may cause a change of the solubility 
and / or surface–hydrophobicity of Aβ1–42 protofibrils, leading to a fragmentation of 
protofibrils and / or change the binding interface of the plasma membrane and Aβ1–42. 
Alternatively, altered structure of Aβ1–42 protofibrils via AMC binding may benefit its 
intracellular degradation. Therefore, a further study of AMC effect mechanism on Aβ1–42 is 
not only to be looking for a possible drug for AD, it can also promote our understandings 




Figure 4–23: Inhibition of Aβ1–42 protofibril uptake by AMC. (a) Preincubation of Aβ1–42
565 protofibril 
with AMC lead to a reduction of cellular uptake of Aβ1–42
565. (b) Average Cell count per well. All results 
are represented as mean values ± SD of 6 replicate wells. All pairwise comparisons were used t–test, 









Taken together, our data allow us to map the first steps in Aβ1–42 internalization starting 
from the monomeric peptide. First, Aβ monomers or very early disordered oligomers bind 
rapidly to the plasma membrane. Their binding partner could be either the lipid bilayer itself 
or plasma membrane proteins. Numerous studies have demonstrated interaction of Aβ with 
lipid bilayers, which will be scrutinized in section 4.2. On the plasma membrane, Aβ1–42 
peptide aggregate into β–sheet–rich structures either on the membrane surface itself or in a 
compartment that is very close to the membrane, from which they are taken up into 
endocytic vesicles. The highly efficient uptake of β–sheet–rich structures, suggests that 
aggregation into, or co–aggregation with β–sheet aggregates occurs. 
In the case of Aβ1–42 monomers uptake, the peptide concentration has to be sufficient to 
initiate the first two steps of the process, resulting in a threshold for internalization at the 
saturation concentration, or critical concentration, for Aβ1–42 aggregation (Usui et al. 2009). 
In contrast, no concentration threshold exists for the internalization of preformed Aβ1–42 
aggregates with β–sheet structure. They are internalized more efficiently and at much lower 
concentrations than the monomer.  
This has several implications for the possible mechanism of Aβ1–42 toxicity. In our 
experiments metabolic inhibition was directly correlated with the formation and/or uptake 
of β–sheet–rich aggregates. Aggregated species have been found to play a central role in Aβ 
toxicity, not all of which are large β–sheet–rich structures (Walsh et al. 2002). It is tempting 
to speculate that small oligomers may have a higher affinity to the plasma membrane than 
the monomeric peptide, facilitating the conversion to β–sheet–rich structures and 
subsequent internalization. Our results demonstrate that, unlike monomers, pre–existing Aβ 
aggregates are internalized at low nanomolar concentrations, which corresponds to 
previously observed binding of Aβ oligomers to neuronal plasma membranes at nanomolar 
concentration (Johnson et al. 2013; Johnson et al. 2011).  
Our experiments did not provide evidence that uptake of aggregated proceeds via clathrin–
mediated endocytosis. Aβ1–42 aggregates may be taken up via receptor independent 
endocytosis, as had been observed previously (Omtri et al. 2012). Other pathways for the 
internalization of amyloidogenic proteins have been discussed. Synthetic peptide aggregates 
of sizes < 500 nm were taken up into HEK cells by non–specific endocytosis whereas larger 
aggregates were internalized by a mechanism similar to phagocytosis (Couceiro et al. 2015). 
Tau aggregates can be internalized via micropinocytosis, mediated by glycoaminoglycans 
(Holmes et al. 2014). It is possible that Aβ aggregates enter the cell by the same pathway.  
Secondly, we found that Aβ aggregates can form in a concentration–dependent manner 
through self–assembly of monomers on the plasma membrane. It has long been known that 
lipid interaction promotes Aβ1–40 transition to β–sheet structure (Terzi et al. 1995) and our 
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data support the interpretation that this process is central to Aβ uptake and toxicity. Our 
data suggest the binding of Aβ1–42 monomers to the lipid bilayer or to membrane proteins 
may be the first step in the formation of cytotoxic Aβ aggregates de novo. Factors that 
increase partitioning of Aβ to the plasma membrane will likely promote the formation of β–
sheet–rich aggregates on the membrane. These include lipid peroxidation products, such as 
seco–cholesterol and 4–hydroxy–nonenal that facilitate Aβ membrane binding and 
aggregation (Bieschke et al. 2005; Siegel et al. 2007; Murray et al. 2007), divalent metal ions 
promoting Aβ membrane interaction (Curtain et al. 2003), and interaction with membrane 
proteins (Lai & McLaurin 2010).  Our data support a central role of endocytosis in Aβ 
cytotoxicity (Yu et al. 2014) and provide strong evidence that aggregation precedes 
endocytosis, a question that had previously not been conclusively resolved (Friedrich et al. 
2010; Hu et al. 2009). This experimental evidence may improve our understanding of AD 
pathology and may inform more focused therapeutic approaches targeting membrane 
binding and self–assembly of the Aβ peptide.  
4.2 Interaction of Aβ1–42 with model membrane system 
In the previous chapter (4.1) we discussed relationship of the toxicity of misfolded Aβ1–42 
aggregates and their cellular uptake, and provided evidence for the possible location of 
cytotoxic aggregates formation. Non–toxic Aβ1–42 species, including monomers and small 
aggregates, associate rapidly to the plasma membrane, where they convert into cytotoxic 
aggregates. The cellular metabolism is inhibited by internalisation those aggregates that 
contained β–sheet–rich structures. These observations raise the question how the plasma 
membrane can serve as a platform for aggregation. A possible hypothetical mechanism is 
that Aβ1–42 peptide accumulates on the plasma membrane, increasing its local concentration, 
which may lead to a rapid aggregation.  However, the plasma membrane is a very 
complicated system consisting of numerous types of lipid in different phases, a great 
number of integral and peripheral membrane proteins. Aβ1–42 might bind to lipids, proteins 
or protein receptors of the plasma membrane.  
Based on our observations that Aβ1–42 associated to the plasma membrane rapidly with 
highly affinity; and many other studies demonstrating the interaction of Aβ1–42 with lipids 
and membranes (Wood et al. 2003), the following chapter will focus on the mechanism of 
Aβ1–42–lipids interaction, specifically which Aβ1–42 aggregate species interact with lipid 
bilayers, with which lipid compositions and phases Aβ1–42 is interacting. 
For this end, giant unilamellar vesicles (GUVs) and giant plasma membrane vesicles (GPMVs) 
were used to study the interaction of Aβ1–42 with lipid bilayers. Models membrane systems, 








broadly used for investigating interactions of Aβ or another misfolded protein, e.g. α–
Synuclein, with membrane lipids (Morita et al. 2010; Wood et al. 2003; Morita et al. 2014; 
Stöckl, Fischer, et al. 2008). GUVs were prepared in varying lipid compositions, either as 
single phase vesicles or with liquid disordered (ld) and liquid ordered (lo) domains. GPMVs 
were isolated from the plasma membrane of neuroblastoma cells, the SH–EP cells, which 
were model cell line of our cellular uptake and cytotoxicity studies in chapter 4.1. As a 
consequence of their sizes Aβ1–42–lipids interactions on the membranes of GUVs and GPMVs 
can be directly visualized via fluorescently label by using confocal microscopy.  
Surprisingly, we observed that Aβ1–42 did not only bind to lipid bilayer (GUVs) and isolated 
plasma membranes (GPMVs), but were also capable of remodelling membrane curvature, 
inducing small vesicle–like invaginations in the membrane bilayer. 
4.2.1 Aβ1–42 aggregation kinetics in GUVs buffer system 
Monomeric Aβ1–42 peptides are known to form aggregates rapidly and spontaneously. Their 
aggregation kinetics are influenced strongly by changing the aggregation conditions, such as 
ionic strength and pH value of the buffers. It is essential to determine the influence of GUVs 
buffer composition on the aggregation kinetics of Aβ1–42 and to examine whether the Aβ1–42–
membranes interaction varied as a function of the peptide’s aggregation state, before 
discussing the interaction of different aggregation states of Aβ1–42 with model membranes. 
For GUVs preparations, sucrose (swelling buffer) and glucose (microscopy buffer) were used 
at high molarity, which may also affect aggregation kinetics of Aβ1–42. We first monitored the 
aggregation kinetics of Aβ1–42 monomer in sucrose and glucose buffers by using ThT 
fluorescence, and comparing them with kinetics in PBS. 
Monomerized Aβ1–42 (15 µM) was incubated in glucose buffer (280 mM), in sucrose buffer 
(280 mM), in mixture of sucrose and glucose (280 nM each, in 1:1 v/v) or in PBS, respectively. 
Na2HPO4 (5.8 mM) and NaH2PO4 (5.8 mM) were added to all the types of buffer systems to 
keep their pH values constantly at 7.4. Aggregation kinetics were carried out in a plate 
reader with shaking at 25°C and were monitored by ThT fluorescence (Figure 4–24). 
The kinetic curves have similar amplitudes of ThT fluorescence intensities at the steady state 
in glucose, sucrose and glucose/sucrose mix buffers, decreasing only slightly in PBS. However, 
the length of lag phases varies greatly. In glucose buffer, the lag phase was very short. Aβ1–42 
aggregation was accelerated in glucose buffer compared to PBS and sucrose buffer. In 
contrast, the aggregation kinetics were slowed down in sucrose buffer. The lengths of the lag 
phase were measured to be about 15 min for the glucose and about 50 min for the sucrose 
buffers, respectively. Aggregation kinetics in the 50% glucose plus 50% sucrose mix that 
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corresponded to the conditions encountered by Aβ1–42 when mixed with GUVs preparations 
was identical to those in glucose buffer.  
From these data, we conclude that the time interval between 15 min and 50 min is crucial 
for lag phase of Aβ1–42 aggregation. Membrane interaction assays will therefore concentrate 
on processes in this time interval. 
 
 
4.2.2 Aβ1–42 aggregation kinetics in presence of lipid 
According to possible influences of Aβ1–42–membrane interaction itself to Aβ1–42 monomer 
aggregation kinetics, we examined Aβ1–42 aggregation kinetics in presence of lipids in the 
buffer systems and under experimental conditions we used. For these experiments, large 
unilamellar vesicles (LUV) were used rather than GUV. Compared to GUVs, LUVs could 
provide larger lipid–water interface at the same lipid concentration as GUVs, they are more 
stable than GUVs, which would not survive the shaking during the aggregation assays.  
LUVs were prepared from pure synthetic dioleoyl phosphatidylcholine (DOPC) by using a 200 
nm membrane filter (as described in methods 3.2.2.1). Monomerized Aβ1–42 (15 µM) was 
incubated with DOPC LUVs in a lipid monomer concentration range of 0 – 750 µM in PBS. 
The molar ratios of lipid to Aβ1–42 were in the range of 0 – 50 (equivalent monomer 
concentration). Aggregation kinetics were monitored by ThT fluorescence intensity at 25 °C 
using a fluorescence plate reader.  
The kinetics displayed similar time courses, increasing the concentrations of lipid delayed 
weakly delayed the aggregation kinetics (Figure 4–25 a).  
Figure 4–24: ThT aggregation kinetic in PBS, glucose and sucrose buffer. Aβ1–42 monomer of 15 µM 
was incubated with ThT (20 µM) in different buffers at 25°C. The lengths of the lag phases are 15 min 
for the glucose and for glucose / sucrose mix; 20 min for PBS; and about 50 min for the sucrose 
buffers. n.c., negative control, without Aβ1–42 in solution. All results are represented as mean values of 








For quantitative analysis of the aggregation kinetics with different concentration, the times 
to reach 50% maximal amplitude (t50) of kinetic traces were measured (Hurshman et al. 
2004). The values of t50 were plotted in function of lipid concentrations on a logarithmic 
scale to test if the effect of lipid on aggregation of Aβ1–42 could be modelled by simple 
monomer binding (Figure 4–25 b).  
Then logarithms (to the base e) of t50 (ln(t50)) versus lipid concentration (lnC) were plotted, 
to test whether the presence of the lipid membrane changed the reaction order of 
aggregation(Figure 4–25 c) (Hurshman et al. 2004). A slope of 0.07, which was calculated by 
linear regression of the data, suggests that in this case DOPC lipid had no influence on 
reaction order and thus on the mechanism of Aβ1–42 aggregation and very little effect on the 
lag phase time of its aggregation.  
In a complementary assay the concentration dependence of Aβ1–42 aggregation kinetics were 
measured in the presence of DOPC lipid. Monomerized Aβ1–42 in a concentration range of 2 – 
20 µM (equivalent monomer concentration) was incubated with DOPC LUVs at a constant 
concentration of 150 µM (by lipid monomer concentration), i.e. with the molar ratios of lipid 
to Aβ1–42 from 7.5 to 75. Fluorescence intensities of ThT were normalized to the amplitude at 
the onset of plateau phase (Figure 4–25 d).  
Ln(t50) vs lnC (Aβ1–42 concentrations) plot shows Aβ1–42 aggregation kinetic depends on its 
own concentration (Figure 4–25 e and f). The aggregations were accelerated by increasing 
the concentration of Aβ1–42 monomer with a slope of –0.8. The concentration dependence of 
the lengths of lag phases in these kinetics data are similar to the data in the absence of lipid 
(Figure 4–18). The slope of –0.8 indicates that aggregation kinetics are dominated by 
secondary nucleation (Cohen et al. 2013), but its efficiency may be slightly reduced in the 
presence of lipids. 
Combining the data of those experiments, the concentration of Aβ1–42 monomer as variables 
at constant lipid concentration (Figure 4–25 a–c), and the concentration of lipid as variables 
at constant Aβ1–42 monomer concentration (Figure 4–25 d–f), we conclude that: i) the 
aggregation kinetics of Aβ1–42 in the presence of DOPC lipids show a dependence on 
concentration of Aβ1–42, as had been observed previously without the lipids (Figure 4–18). 
Both cases are dominated by secondary nucleation; ii) the aggregations have a very weak 
dependence on lipid concentration in lipid to Aβ1–42 molar ratios from 0 – 50, which suggests 
that the DOPC lipid membrane interacts with Aβ1–42 in its monomeric or oligomeric state but 
does not change the rate limiting step of aggregation under these experimental conditions. 
This interpretation corresponds to the model that the rate limiting step is secondary 
nucleation by fibrils, either by fragmentation or by secondary nucleation on the fibril surface 











Figure 4–25: Aggregation kinetic of Aβ1–42 monomer with DOPC large unilamellar vesicles (LUVs). (a)  
Aggregation kinetic of monomeric Aβ1–42 (15 µM) with DOPC concentrations at 0 – 750 µM were 
monitored by ThT fluorescence intensity.  (b) Half–maximal fluorescence times (t50) were plotted in 
the function of the lipid concentration (lnC). (c) Ln(t50) vs lnC (lipid concentration) plot, a slope of 0.07 
was calculated by linear regression (red line). Change of DOPC concentration shows no significantly 
influence on aggregation kinetic. (d) The ThT aggregation kinetics shows a concentration dependent 
manner of monomeric Aβ1–42 (2 – 20 µM) with constant DOPC concentration (150 µM). (e) t50 were 
plotted in the function of Aβ1–42 concentrations. (f) Ln(t50) vs lnC (Aβ1–42 concentration) plot, with a 
slope of 0.8 calculated by linear regression (red line). ThT kinetics were accelerated by increasing Aβ1–








The same general features of Aβ1–42 aggregation kinetics were observed in buffer systems we 
used: lag phase, growth phase and plateau phase. At 10 µM Aβ1–42 concentration, these 
correspond to 0–15 min, 15–90 min, and >90 min, respectively. Therefore, the studies of 
Aβ1–42 –membrane interaction would focus on these time intervals.  
Our study of Aβ–membrane relationship was then carried out in the range of Aβ1–42–lipid 
molar ratios between 0 – 50 (equivalent monomer concentration).  
Notably, the aggregation assays of Aβ1–42 in this section did not specifically probe 
aggregation in the membrane, but rather in both membrane and in bulk solution. The 
aggregation state in the membrane may be different from that of the peptide in solution, 
which may strongly affect aggregation kinetics under conditions when primary nucleation is 
rate limiting. However, this was not the case under the experimental conditions used in our 
Aβ1–42 –membrane interaction assays. 
4.2.3 Aβ1–42–lipid bilayer interaction 
Our observation showed that small Aβ1–42 aggregates in disordered state are capable to bind 
rapidly to the plasma membrane (chapter 4.1.6). Based on the amphipathic character of  
Aβ1–42, a possible interaction partner could be the membrane lipids.  
To investigate the behavior of Aβ1–42 toward lipid bilayer and to specify with which lipid 
phase Aβ1–42 interacted, GUVs of definite lipid compositions were used. Phosphatidylcholine 
(PC) is the most abundant lipid in the membranes of mammalian cells, therefore we first 
probed the interaction of Aβ1–42 with GUVs consisting 100 % DOPC, in which the lipid 
molecules adopt pure ld phase. GUVs consisting pure lo phase (raft GUVs) were prepared 
from DOPC, sphingomyelin (SSM) and cholesterol (Chol) in 1:1:8 molar ratios (Stöckl & 
Herrmann 2010). Both typs of GUVs were generated by electroformation as described in 
methods 3.2.2.2.  
To directly visualize of Aβ1–42 on the membrane by confocal microscopy, Aβ1–42 was labeled 
with fluorescence dye Atto565 and was monomerized by high pH treatment and gel 
filtration as described in methods 3.2.1.3.  
GUVs were incubated with monomeric Aβ1–42
565 at a concentration of 10 µM at RT for 30 min 
(Figure 4–26 a and c). Then Aβ1–42
565 in the outside of GUVs were diluted to 100 nM by 
adding buffer (Figure 4–26 b and d). The osmolarity of the buffer inside GUVs was 280 
mOsm/kg and outside was 200 mOsm/kg. 
An accumulation of Aβ1–42
565 on the membrane of DOPC GUVs was observed after the 
dilution of Aβ1–42
565 in outside, indicating a high affinity of Aβ1–42
565 to membrane of DOPC 
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GUVs (Figure 4–26 b). Additionally, a number of invaginations, could also be observed on the 
membrane (Figure 4–26 a).  
Comparing with DOPC GUVs, neither accumulation of Aβ1–42
565 nor invagination could be 
observed in raft GUVs (Figure 4–26  c and d, DOPC:SSM:Chol=1:1:8). DIC image verifies the 




565) was used as control, when incubating DOPC GUVs 
with sc–Aβ1–42
565 (10 µM before and 100 nM after the dilution) at RT for 30 min, the 
accumulation of sc–Aβ1–42
565 and invaginaion induction on the membrane are both negative 
(Figure 4–26 e and f). This verified that interaction with membrane of DOPC GUVs was 
specific for the Aβ sequence and not the result of the fluorescent label.  
 
 
Figure 4–26: Aβ1–42 & lipid bilayer interaction. Aβ1–42
565
 or sc–Aβ1–42
565 of 10 µM were incubated with 
DOPC GUVs (100 % DOPC) or raft GUVs (DOPC:SSM:Chol=1:1:8) at RT for 30 min. Peptides in outside of 
GUVs were diluted. GUVs were imaged by confocal microscopy. Invaginations (a) and accumulation of 
Aβ1–42 (b) were observed on membrane of DOPC GUVs, not on raft GUVs (c & d) or sc–Aβ1–42
565 treated 








These results indicate Aβ1–42 peptide accumulates specifically or preferred on the ld (DOPC 
GUVs) but not on lo phase (raft GUVs) of the GUVs membranes, and Aβ1–42 –membrane 
interaction may lead to formation of invaginations. We next investigated whether Aβ1–42 
molecule and lipids of the GUVs membrane are close enough to each other to permit a 
Förster resonance energy transfer (FRET) between them. The questions, whether the 
invaginations are specifically induced by Aβ peptide and whether they depend on the 
aggregation state of Aβ and whether they occur within a specific membrane phase, will be 
discussed in later sections.    
4.2.4 Interaction of Aβ1–42 with DOPC GUVs  
To demonstrate the interaction between Aβ and membrane lipids, we performed a FRET 
experiment between Aβ1–42 molecules and lipids of the GUVs membrane, DOPC GUVs, 
containing 1% of the green fluorescent lipid analogue 1–palmitoyl–2–[6–[(7–nitro–2–1,3–
benzoxadiazol–4–yl)amino]hexanoyl]–sn–glycero–3–phosphocholine (C6–NBD–PC, Ex.max at 
460 nm and Em.max at 535 nm), were incubated with Aβ1–42
633 monomers (4.5µM, Ex.max at 
629 nm and Em.max at 657 nm) in a 96–well plate at RT for 15 min. Fluorescence emission 
spectra were measured at 25°C by using a fluorescence plate reader at excitation of 450 nm. 
The FRET sample containing donor and acceptor displayed a decreased fluorescence 
intensity of donor emission and an increased fluorescence intensity of acceptor emission 
with a FRET efficiency approximate 0.4 (Figure 4–27 a), providing strong evidence to Aβ1–42–
membrane binding. In contrast, the donor only sample emitted at its own typical spectrum 
with an Em.max at 540 nm. The acceptor only sample was not efficiently excited at 450 nm.  
To verify that Aβ1–42–lipid interaction event indeed happened on the membrane, GUVs were 
imaged by confocal microscopy (Figure 4–27 b). Corrected FRET image was calculated from 
intensity–based images as described in methods section 3.2.12. Analysis by PixFRET showed 
a strong FRET signal on the membrane of GUV, demonstrating the interaction of Aβ1–42 with 
PC molecules on the membrane.  
The existence of the FRET signal also permits us to estimate the maximum distance between 
the Aβ1–42 and the lipid to be smaller than 10 nm. This may be due to a direct interaction of 
the N–terminus with the membrane or may be caused by a compact conformation of the 




4.2.5 Aβ1–42 induces invaginations in GUVs membrane 
As indicated in section 4.2.4, invaginations were observed in the membrane of DOPC GUVs 
when studying the Aβ1–42 –membrane interactions (Figure 4–26 a), which could be possibly 
induced by the Aβ1–42
 peptide. In the control experiment, neither invagination nor 
accumulation of peptides could be observed on DOPC GUVs membrane when incubating 
with scrambled peptide sc–Aβ1–42
565 (Figure 4–26  e & f).  
To confirm that those invaginations are specifically induced by Aβ1–42 peptide rather than the 
fluorescent dye Atto565, DOPC GUVs were incubated with unlabeled monomeric Aβ1–42 (10 
µM) at RT for 15 min and were imaged by confocal microscopy.  
A soluble but membrane–impermeable fluorescent dye, calcein (20 µM, green), was added 
to mark the buffer, to visualize the invaginations, and to demonstrate that the membrane 
bilayer remained intact. Invaginations were filled with the calcein dye. 
To ensure that invaginations are not cause by random membrane fluctuations, the 
membrane was also kept at high tension during all the experiments. To do so, GUVs were 
maintained at a higher inside pressure than outside via an osmotic pressure difference. The 
Figure 4–27: Interaction of Aβ1–42 with DOPC GUVs. (a) DOPC/C6–NBD–PC (Ex.max=460 nm, 
Em.max=535 nm) GUVs with Aβ1–42
 monomer (4.5 µM) for donor only, DOPC GUVs with Aβ1–42
633 
monomer (4.5 µM, Ex.max=629 nm, Em.max=657 nm) for acceptor only, and DOPC/C6–NBD–PC with 
Aβ1–42
633 monomer (4.5 µM, for FRET) were incubated at RT for 15 min, were measured by a 
fluorescence plate reader at excitation at 450 nm. A typical FRET spectrum, decreased donor emission 
and increased acceptor emission, with FRET efficiency ~0.4 was recorded. (b) A corrected FRET image 
of FRET sample was calculated by intensity–based images of confocal microscopy. Scale bar, 10 µm. 








osmotic gradient was achieved through different sugar concentrations. The osmolarity inside 
the GUVs was 280 mOsm/kg and osmolarity of the outside buffer was 200 mOsm/kg.  
Even under these conditions, i.e. GUVs membrane in a expansion state, small vesicle–shaped 
invaginations in a diameter of approximate 1 µm, were detected on the membrane of DOPC 
GUVs (Figure 4–28 a).  
In the absence of Aβ1–42, invaginations could not be observed (Figure 4–28 b). Likewise, no 
invaginations were observed on the membrane of DOPC GUVs when incubating with          




These data show that the formation of membrane invaginations was specific to the Aβ 
peptide, suggesting that the modulation of membrane curvature is specific to the Aβ1–42 
peptide sequence and/or the ability of Aβ1–42 to form aggregates.  
We then tested if the formation of invaginations depended on lipid composition. Aβ1–42 was 
incubated with GUVs generated from phospholipid mixtures, consisting of DOPC and 
uncharged lipid dioleyl–phosphatidylethanolamine (DOPE) in 1:1 molar ratio (PC/PE GUVs). 
The total concentrations of mixed lipids composition were identical to the DOPC 
concentration of pure DOPC GUVs. DOPC GUVs and PC/PE GUVs were incubated with       
Aβ1–42
565 monomer (10 µM) in the presence of calcein (20 µM) at RT for about 15 min, and 
were imaged by confocal microscopy.  
Figure 4–28: Aβ1–42 induces invaginations in the membrane of DOPC GUVs. (a) Monomerized Aβ1–42 
(10 µM) was incubated with DOPC GUVs and calcein (20 µM, green) at RT for 15 min. The 
invaginations, diameter about 1 µm, were observed in the membrane of DOPC GUVs by confocal 
microscopy. No invagination was detected when incubating DOPC GUVs with calcein and buffer only 
(b) or with sc– Aβ1–42 (c). Scale bars, 10 µm.  
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Invaginations, which were filled with the labeled Aβ1–42 peptide and with calcein, were 
observed on the membrane of both types of GUVs, of PE/PC GUVs (Figure 4–29 a) and of 
DOPC GUVs (Figure 4–29 a). Those vesicular shaped invaginations with a diameter of 
approximate 1 µm are quite similar to those we previously found on the membrane of DOPC 




Furthermore, to test whether the formation of invaginations is specific to the Aβ peptide, 
and whether other membrane active peptides could have the same effect in our model 
membrane system, we compared Aβ1–42 and melittin, which is an active peptide in bee 
venom. Melittin is known to insert itself into the membrane and disrupts membrane 
integrity (Lee et al. 2013). 
DOPC GUVs were imaged under the same conditions as in Figure 4–28. Membrane integrity 
of DOPC GUVs were assessed by calcein (20 µM) fluorescence and DIC imaging (Figure 4–30 
a). About 4 min after adding melittin (10 µM), calcein fluorescence was found inside the 
DOPC GUVs, indicating an increased membrane leakage induced by melittin. No invagination 
was observed (Figure 4–30 b).  
Taken together, our observations show that, Aβ1–42 peptide is capable to induce membrane 
invaginations of DOPC or PE/PC GUVs membrane, occurring Aβ1–42–membrane interactions. 
Those invaginations are induced specifically by Aβ1–42 peptide, neither by fluorescence label 
nor calcein or sc–Aβ1–42.  
Figure 4–29: Aβ1–42 induces invaginations in the membrane of PC/PE GUVs. PC/PE GUVs (a) 
DOPC/DOPE in 1:1 molar ratio) and  DOPC GUVs (b) were incubated with Aβ1–42
565
 (10 µM, red) in the 
presence of calcein (20 µM, green) at RT for about 15 min. The invaginations, diameter about 1 µm, 









4.2.6 Aβ induced invaginations specifically in Ld domains of GUVs 
membranes 
We observed Aβ1–42 preferentially accumulation and induction invagination in GUVs that 
prepared from pure ld phase, such as DOPC GUVs (Figure 4–26 a & b, Figure 4–28 a and 
Figure 4–29 b) and PC/PE GUVs (Figure 4–29 a), neither accumulation of Aβ1–42 nor 
invagination was detected on the membrane from pure lo phase, which consisted DOPC:SSM: 
chol in 1:1:8 molar ratios (Figure 4–26 c & d).  
For a more direct comparison of different behaviors of Aβ1–42 on ld and lo phases  of 
membranes, a multiphase GUV was used to model partitioning of lipids into ld and lo 
domains.  GUVs were formed from DOPC, SSM and cholesterol in 1:1:1 molar ratio (ld/lo 
GUVs), a mixture that separates into lo and ld domains. ld/lo GUVs contained 1 mol% of lipid 
analogue C6–NBD–PC, which partitions preferentially into the ld domain and can thus be 
used to visualize membrane phase partitioning (Stöckl & Herrmann 2010; Shaw et al. 2006).  
Ld/lo GUVs were incubated with Aβ1–42
565 (10 µM) at RT for 20 min and were imaged by 
confocal microscopy. Invaginations were found only in C6–NBD–PC stained phase, indicating 
they were exclusively in ld phase, whereas no invagination was detected in lo phase (Figure 
4–31).  
This result corresponds to our previous data using single phase GUVs, the invaginations were 
observed in GUVs with pure Ld phase not in GUVs with pure lo phase. 
It should be noted that GUVs did not contain membrane proteins, so that the putative 
interaction of Aβ1–42 with protein complexes in the raft domains was not probed in this 
model. We therefore probed the Aβ1–42–membrane interaction by using native neuronal 
membranes. 
 
Figure 4–30: Melittin induced membrane leakage. (a) DOPC GUVs were visualized by calcein (20 µM, 
green) fluorescence and DIC imaging. (b) Melittin (10 µM) induced membrane leakage resulting in 




4.2.7 Aβ1–42 induced invagination in giant plasma membrane vesicles  
Aβ1–42 induced invaginations exclusively on the ld phase suggesting a distinct preference 
toward ld over lo domains on GUVs model system. This observation leads to the question, 
whether this phenomena is applicable to the neuronal membrane. We therefore studied 
Aβ1–42 and membrane behavior on biological membrane systems, in which ld/lo domains 
coexist, by using giant plasma membrane vesicles (GPMVs). GPMVs are isolated from cells, 
containing the biological membrane compositions. They resemble more closely physiological 
plasma membranes, containing biological membrane lipids, raft–like microdomains and 
natural membrane proteins (Sezgin, Kaiser, et al. 2012; Baumgart, Hammond, et al. 2007). 
GPMVs were isolated from cultured neuroblastoma (SH–EP) cells (Figure 4–32 a), which had 
been used as the model cell line for cellular uptake experiments of Aβ1–42, following the 
protocol by Sezgin et al (Sezgin, Kaiser, et al. 2012) as described in methods section (section 
3.2.2.3).  
GPMVs were incubated with monomerized Aβ1–42 (10 µM) and calcein (20 µM) at RT for 15 
min. Spherical invaginations, which had a diameter of approximate 1 µm and were 
morphologically very similar to those that were found on the GUVs membrane, were imaged 
in the membrane of GPMVs by confocal microscopy (Figure 4–32 b), suggesting that Aβ1–42 is 
able to induce the negative membrane curvature in isolated cell membranes as well as in 
model membrane systems.  
 
Figure 4–31: Aβ1–42 induced invagination in ld domain. Aβ1–42
565 (red) was incubated with multiphase 
GUVs, generating from DOPC/SSM/Chol (in 1:1:1 molar ratio) and containg 1% C6–NBD–PC (green) for 
the visualization of liquid disordered (ld) phase. After 20 min incubation, invaginations were found in 











Compared with GUVs, the number of invaginations per liposome seems reduced. A possible 
reason may be the different ld/lo phases behavior and their sizes in GUVs and in GPMVs. 
Raft–like lo domains are disperse in GPMVs, whereas ld and lo domains of multiphase GUVs 
(ld/lo GUVs, from DOPC/SSM/Chol in 1:1:1 molar ratio, Figure 4–31) merge into a large 
homogenous phase at RT. In contrast, phase behavior of GPMVs shows more temperature–
dependence. Ld/lo phase separation can be imaged only at lower temperature, at which 
phases coalesce into a  larger macroscopic scale (Baumgart, Hammond, et al. 2007). Figure 
4–33 show a phase separation of GPMVs isolated from SH–EP cells. Lo domains were stained 
by merocyanine 540 in GPMV buffer, and imaged by confocal microscopy at 9 °C. 
 
 
Figure 4–33: Phase separation of GPMVs. The membrane of GPMVs were stained by merocyanine 
540. The phase separation of lo /ld phases, cross–section (left) and top view (right), were observed at 
9 °C by confocal microscopy. Scale bars, 10 µm.  
Figure 4–32: Aβ1–42 induced invagination in giant plasma membrane vesicles (GPMVs).  GPMVs were 
incubated with buffer (a) or Aβ1–42 monomer of 10 µM (b) in presence of calcein (green, 20 µM) at RT 
for 15 min. Invaginations were observed in Aβ1–42 treated GPMVs by confocal microscopy. Scale bars, 
10 µm.  
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4.2.8 Invaginations remain connected to GUVs outer lumen 
Vesicular endocytosis consists of several steps. The first step is the formation of the negative 
membrane curvature, namely the invagination, which is then in a second step pinched off 
the membrane to form a vesicle (Introduction 0 and Figure 1–12).  
We had observed that Aβ1–42 induced negative curvature in the membrane of DOPC GUVs. 
Next, we examined whether those invaginations are still connected to the outer buffer, or 
whether Aβ1–42 is also capable to drive the scission of the invaginations from membrane. To 
do this, fluorescence recovery after photobleaching (FRAP) was used.  
DOPC GUVs were incubated with Aβ1–42
565 monomer (10 µM) and calcein (20 µM), and were 
imaged by confocal microscopy. Calcein fluorescence in one of the invaginations was 
bleached by a 488 nm laser beam; the fluorescence recovery of this invagination was then 
monitored over time (Figure 4–34). Fluorescence of Aβ1–42
565 was used to identify the 
location of target vesicle during the FRAP process. A total recovery of calcein fluorescence 
was completed in about 4 min, indicating the invaginations were still connected to the 
outside solution. From these data we conclude that the invaginations are not pinched off 




Figure 4–34: Fluorescence 
recovery after 
photobleaching (FRAP) of 
invagination. 
Invaginations in the 
membrane of DOPC GUVs 
were induced after 
incubating with Aβ1–42
565 
monomer (10 µM, red). 
Calcein (20 µM, green) 
was added. Calcein 
fluorescence of the 
indicated invagination 
(white arrows) was 
bleached by 488nm laser 
beam, would be recovered 
in ca. 4 min, suggesting 
that invaginations connect 
to buffer. Fluorescence of 
Aβ1–42
565 was used to 
indicate the vesicle 
existence during the FRAP. 








4.2.9 ThT negative Aβ1–42 aggregate species bind to lipid bilayer 
Observations in the previous experiments showed that the generation of invaginations on 
the membrane of GUVs always required a certain time after adding Aβ1–42 monomers. E.g. it 
took approximate 15 min incubation time to observe invaginations at a concentration of 
Aβ1–42 monomer of 10 µM. This time lag was independent of the compositions of GUVs or 
GPMVs (Figure 4–26 a & Figure 4–28a of DOPC GUVs, Figure 4–29 of PC/PE GUVs, Figure 4–
31 of ld/lo GUVs and Figure 4–32 b of GPMVs). Referring to the aggregation kinetics 
(described in chapter 4.2.2), this time span is in lag phase at an aggregation kinetic of 10 µM 
Aβ1–42 monomer, during which aggregate species are in a ThT negative state (Figure 4–25 c). 
We hypothesize, that the Aβ1–42 aggregate species that induce invagination may be in an 
early aggregation state and their β–sheet–rich structures have not formed yet. Aβ1–42–
membrane binding may occur before the formation of β–sheet–rich structures, which may 
correspond to the formation of small Aβ aggregates directly in or on the membrane.  
To test these hypotheses, we measured the time–dependent formation of invaginations in 
two experimental designs: i) DOPC GUVs were incubated directly with monomeric Aβ1–42; ii) 
Aβ1–42 aggregates were prepared by preincubating in buffer without DOPC GUVs, and DOPC 
GUVs were then incubated with those aggregates species.  
To prepare the aggregates, monomeric Aβ1–42 (20 µM) was incubated in the glucose buffer, 
which was used for GUVs microscopy (section 4.2.1), for four time internals corresponding to 
different phases of the aggregation kinetics: 0 (monomer), 15 (15 min–aggregate), 30 (30 
min–aggregate), or 45 min (45 min–aggregate). These aggregates were then added to the 
GUVs solution at a final concentration of Aβ1–42 of 10 µM (equivalent monomer 
concentration). Calcein (20 µM) was used to visualize the GUVs and the invaginations by 
confocal microscopy.  
Figure 4–35 shows that, after treating the DOPC GUVs with monomeric Aβ1–42 (10 µM), the 
earliest time point of invagination detection was 15 min after adding Aβ1–42 monomers. This 
time matches the results of our previous experiments (Figure 4–26 a, Figure 4–28a, Figure 
4–29, Figure 4–31 and Figure 4–32 b).  
By treating DOPC GUVs with preformed Aβ1–42 aggregates, invaginations were only observed 
after addition of the 15 min–aggregates (Figure 4–35, indicated with red box). Unlike when 
incubating GUVs with monomeric Aβ1–42, the invaginations could be detected immediately 
after adding 15 min–aggregates to DOPC GUVs. In contrast, no invaginations were observed 
after incubating DOPC GUVs with the other two aggregate species, 30 min–aggregates and 
45 min–aggregates, which had been preincubated for 30 or 45 minutes in buffer and had 
therefore formed higher ordered structures than 15 min–aggregates. These observations 
strongly suggest that invaginations are induced as a result of Aβ1–42 aggregation, and there is 
a population of early aggregate species that is crucial for inducing invagination. When 
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referring to the time scale of the ThT aggregation kinetic of Aβ1–42 monomer (Figure 4–25 a), 
the time required to induce the invaginations corresponds to the end of the lag phase.  
We therefore assume that Aβ induced invagination coincides with the aggregates formed 
during the lag phase. This suggests that the Aβ1–42 aggregates into a membrane active 
species before  β–sheet–rich structures are formed; they are not the monomer nor the 




To test the validity of our hypothesis, DOPC GUVs were incubated with monomeric Aβ1–42
565 
of 10 µM until detection of invaginations (~ 15 min), or only for a short time (~5 min), before 
the invagination were observed. Then Aβ1–42
565 outside the DOPC GUVs was diluted to 100 
nM by adding buffer.  
When comparing these two time points, i.e. decreasing the concentration of Aβ1–42
565 before 
or after the formation of invaginations, a clearly visible accumulation of Aβ1–42
565 on the 
membrane of DOPC GUVs was only observed after the formation of invaginations (Figure 4–
36 a), not before (Figure 4–36 b).  
Figure 4–35: Early aggregated Aβ1–42 induces invagination in the membrane of DOPC GUVs. DOPC 
GUVs were incubated with monomer or aggregates of Aβ1–42 (10 µM), respectively. Calcein (20 µM) 
were added to visualize DOPC GUVs by confocal microscopy. Invaginations were only observed after 
15 min incubation DOPC GUVs with monomer; or directly after adding Aβ1–42 aggregates, which were 
preaggregated 15 min in buffer (both highlight in red boxes). No invagination was imaged by 
incubating with monomeric Aβ1–42 shorter than 15 min or with aggregates that were preaggregated in 










Compared the time scale of membrane interaction with the time scale of the ThT 
aggregation kinetics (Figure 4–25 a), after 15 min incubation at 10 µM concentration, the 
aggregated Aβ1–42 species are still in within the lag phase before the formation of β–sheet 
structure. This observation suggests that Aβ1–42 species that bind tightly to the membrane 
are still in a ThT negative state. Those small disordered and ThT negative aggregates are able 
to bind to the membrane of DOPC GUVs with high affinity, and are capable of inducing 
invaginations. In contrast, monomeric species seem not to have a stable binding to the 
membrane nor induce invaginations.   
4.2.10 Summary 
We observed that the plasma membrane can serve as a platform for the formation of toxic 
Aβ1–42 aggregates (chapter 4.1). This observation suggested a very close association between 
Aβ1–42–membrane interaction, Aβ1–42 aggregation, neuronal uptake of Aβ1–42 and cytotoxicity 
of Aβ1–42 and prompted us to study the membrane interaction in model membrane systems. 
To study the interaction of Aβ1–42 with lipid bilayers, we used DOPC GUVs and PC/PE GUVs 
(from DOPC/DOPE in 1:1 molar ratio) for pure ld phase, raft GUVs (from DOPC/SSM/Chol in 
1:1:8 molar ratio) for pure Lo phase, the ld/lo phase coexisted GUVs (from DOPC/SSM/Chol 
Figure 4–36: A stable binding of Aβ1–42 to membrane of DOPC GUVs benefit formation of 
invaginations. DOPC GUVs were incubated with Aβ1–42
565 monomer (10 µM). Then Aβ1–42
565 was 
diluted to 100 mM after (a) or before (b) the invaginations been detected. Accumulation of Aβ1–42
565 in 
membrane was only detected when the dilution of external Aβ1–42
565 after invaginations had been 
formed. Scale bars, 10 µm. 
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in 1:1:1 molar ratio) and GPMVs, which were isolated from SH–EP cells containing 
physiological lipids and proteins. 
We investigated the influence of lipid bilayer presence on aggregation kinetic of Aβ1–42; 
studied the Aβ1–42–membrane binding in both ld and lo phases; observed Aβ1–42 binding 
resulted membranes transformation; and examined which aggregation state of Aβ1–42 
preferentially bind to lipid bilayers. 
We found that a population of Aβ aggregate species, which had no β–sheet structures and 
formed during the lag phase of ThT aggregation kinetic, binds with high affinity to a ld phase 
as opposed to a lo phase in the GUVs membrane. The association of Aβ1–42 to membrane 
results a negative curvature in ld phase of the DOPC GUVs, DOPE GUVs and GPMVs 
membrane, which then form vesicle–like invaginations.  
4.3 Comparisons of Aβ1–42 and Aβ1–40 in membrane 
curvature modelling and in cytotoxicity 
In the previous chapters, we focused on Aβ1–42 peptide and found that, i) Aβ1–42 monomers 
and/or small aggregates associate rapidly with the plasma membrane, where they form 
aggregates and are then taken up into neuronal cells in a process that correlated with 
cytotoxicity; ii) one population of Aβ1–42 species from the late lag phase of ThT aggregation 
kinetics has high affinity with lipid bilayer of GUVs and GPMVs model membrane systems 
and induced negative curvature in the ld phase of the membrane bilayer. These data may 
suggest that membrane remodelling is coupled with cellular uptake and cytotoxicity. 
Alternatively, the membrane activity could be independent of Aβ toxicity and could have a 
yet unknown physiological role. 
Aβ peptide with 40aa, i.e. Aβ1–40, is the most common isoform in healthy and AD brain. In 
the healthy brain, the Aβ1–40 to Aβ1–42 ratio is approximately 10:1 (Simons et al. 1998; Shoji et 
al. 1992; Jarrett et al. 1993). Aβ1–42 is only prevalent in amyloid deposits in the brain of AD 
patients. It is still unknown, what, if any, is the physiological function of Aβ1–40 or Aβ1–42; why 
Aβ1–42 which has a lower synthesis rate and a lower concentration in healthy brains is 
dominantly desposited in AD brains; and what are the differences in cellular processing of 
Aβ1–40 and Aβ1–42.  
Several studies have shown the uptake (Friedrich et al. 2010) and the membrane interaction 
of Aβ1–40 (Ding et al. 2012). Here, we compared both isoforms of Aβ peptides, Aβ1–42 and 
Aβ1–40, to test whether Aβ induced membrane invagination is correlated to neuronal toxicity 








For this end, we used the two well–established model systems from the previous chapters, 
DOPC GUVs and cultured neuroblastoma cells (SH–EP cells), to examine Aβ1–40 and Aβ1–42 on 
their membrane interaction and on cell toxicity. 
4.3.1 Aβ1–40 vs. Aβ1–42 in the aggregation kinetics  
First, we compared the aggregation kinetics of Aβ1–40 and Aβ1–42. Aβ1–40 and Aβ1–42 were 
monomerized as described in the methods section (chapter 3.2.1.2). Monomerized Aβ1–40 
and  Aβ1–42 (15 µM each) were incubated with ThT (20 µM) in PBS at pH 7.4 in a 96–well 
plate. Intensities of ThT florescence were recorded at 37°C with shaking (5 s every 5 min) in a 




As expected, lag phase of Aβ1–40 took ca. 18 h, which was much longer than for Aβ1–42, and 
reached the steady state in approximate 22 h. In contrast, lag phase of Aβ1–42 was less than 1 
h. Both peptides had a similar intensity of ThT fluorescence at the end of the aggregation. 
The difference in lag phase between both isoforms allowed us to better test whether the 
increased lag phase played a role in the Aβ–membrane interaction, to investigate whether 
Aβ1–40 could also induce membrane invagination as Aβ1–42 did, and to test whether a pre–
ThT–aggregate species of Aβ induced membrane curvature or not. 
Figure 4–37: ThT Kinetic of Aß1–40 and Aß1–42.  Monomerized Aβ1–40 (red curve) or Aβ1–42 (green curve) 
at 15 µM each was incubated in PBS at 37°C with intermittent shaking, respectively. ThT fluorescence 
was measured by a plate reader.  
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4.3.2 Aβ1–40 vs. Aβ1–42 in membrane activity – induction of negative 
curvature  
Our previous data show that, Aβ1–42 aggregate from late lag phase of aggregation kinetic has 
high affinity to lipid bilayer, and is able to induce invaginations in the ld phase of GUVs and 
GPMVs membrane. The induction of negative curvature depends on the primary sequence 
of Aβ, i.e. no invaginations observed by sc–Aβ1–42 (Figure 4–28 b), and depends on the 
aggregation state (Figure 4–35).  
Here, we examined whether Aβ1–40 has the same abilities to induce invaginations in the 
same model membrane system as Aβ1–42 does, and if so, in which aggregation state.  
GUVs from 100% DOPC were generated by electroformation. DOPC GUVs were incubated 
with Aβ1–40 under the same experimental conditions that were previously used for Aβ1–42 
(Figure 4–35). Preparation of Aβ1–40 aggregates used the same protocol as used for Aβ1–42 
aggregates, monomerized Aβ1–40 of 20 µM was incubated in the glucose buffer with shaking 
at 300 rpm at 37 °C. The aggregates of Aβ1–40 were collected from different phases of 
aggregation, i.e. after 5 or 16 h incubation time. DOPC GUVs were then incubated with these 
Aβ1–40 aggregates, which had a final concentration of 10 µM (equivalent monomer 
concentration) at RT. Calcein (20 µM) was addd for imaging DOPC GUVs by confocal 
microscopy (Figure 4–38). 
 
      
 
 
We observed that Aβ1–40 peptides have very similar membrane behaviors like Aβ1–42. 
Invaginations in the membrane of DOPC GUVs could be imaged after a relative short time    
(~ 5 min) by incubating with the aggregates that collected after 16 h aggregation times 
Figure 4–38: Aβ1–40 aggregates induce the invaginations in the membrane of DOPC GUVs. Monomeric 
Aβ1–40 (20 µM) were incubated in glucose buffer with shaking at 300 rpm at 37 °C for 5 or 16 h. DOPC 
GUVs were incubated in glucose buffer with calcein (20 µM) and Aβ1–40 monomers (0 h) or aggregates 
(10µM, corresponding monomer concentration). Invaginations in approximate 1 µm diameter were 
observed in the membrane of DOPC GUVs when incubating with 16 h aggregates for 5 min by confocal 
microscopy. No invagination was observed when incubating with monomers (0 h) or 5 h aggregates. 








(Figure 4–38, 16 h), i.e. approximately from the end of lag phase (Figure 4–37). The shapes 
and the size (~ 1 µm diameter) of invaginations are very similarly to those been induced by 
Aβ1–42.  
When incubating with monomer or small aggregates, which were collected after 5 h 
aggregation times, i.e. from the middle of lag phase, no invaginations could be detected until 
45 min incubation time (Figure 4–38, 0 h & 5 h), which is our standard time duration for 
GUVs microscopy. 
The aggregation kinetics show that, Aβ1–40 monomers require much longer incubation time 
than Aβ1–42 to form the membrane active aggregate species under the same conditions, 
which corresponds to their different aggregation rates (Figure 4–37). Interestingly, the 
membrane active species of both isoforms, which induce invaginations in the membrane of 
DOPC GUVs, are in aggregated from, indicating the aggregation state is crucial to Aβ–
membrane interaction. Those aggregates of both Aβ isoforms locate at similar phases of the 
aggregation process, which are the end of the lag phase or beginning of the exponential 
growth phase. This indicates that these aggregates might have similar activity on the 
membrane of DOPC GUVs, that may be resulted by their similar sizes and/ or their similar 
surface structures, such as surface charges and hydrophobicity. 
It should be noted, in order to keep the membrane in a consistent state from the beginning 
of experiment to its end, and to prevent lipid phase transition occurred by local temperature 
increase via laser beam during microscopy, the maximum time of microscopy is limited in 45 
min for all the experiments on GUVs (both Aβ1–40 and Aβ1–42) in this study. However, if the 
membrane can be kept in an ideal constant state, we could speculate that invaginations 
would be observed after incubating with Aβ1–40 monomers for 16 h. A similar experiments 
design has been used for Aβ1–42 (Figure 4–35).  
4.3.3 Aβ1–40 vs. Aβ1–42 in the cytotoxicity  
We found that, both Aβ1–40 and Aβ1–42, which were collected from late lag phases of the 
aggregation process, could induce invaginations in the membrane of DOPC GUVs, suggesting 
those aggregates from both isoforms may have similar membrane activities. In this 
aggregation state, both isoforms may have similar structures, which result similar behaviours 
to model membrane bilayer. 
The study of Friedrich et al. has shown that Aβ1–40 can be taken up by the cells (Friedrich et al. 
2010). Here, we compared the cytotoxicity effect of Aβ1–40 and Aβ1–42 in SH–EP cells using 




In the previous chapter (chapter 4.1.8), we also found that the cytotoxicity of Aβ1–42 was 
tightly linked to its cellular uptake. The metabolism activities of the cultured neuroblastoma 
(SH–EP) cells were inhibited once Aβ1–42 was internalized by the cells (Figure 4–20). The 
internalizations of Aβ1–42 can be achieved by treating with monomeric form when its 
concentration above 150 nM.  When the concentrations of Aβ1–42 were  lower than 150 nM, 
an efficient uptake required a aggregated form simultaneously containing β–sheet structure 
(Figure 4–5, Figure 4–12).  
To compare the cytotoxicity of Aβ1–40 and of Aβ1–42, SH–EP cells were therefore 
correspondingly treated with Aβ1–40 monomer or aggregates species at 150 nM or 500 nM 
(equivalent monomer concentration), respectively. To prepare β–sheet–rich aggregate 
species, monomers were incubated in PBS for 24 h, to form mature fibrils in ThT positive 
state (Figure 4–37). In the control experiments, the SH–EP cells were treated with Aβ1–42 
under the same conditions like Aβ1–40, i.e. with monomer at 150 nM or 500 nM and with 
Aβ1–42 aggregates species from steady state phase at 150 nM or 500 nM, respectively. After 
24 h incubation with Aβ peptides at 37°C, metabolic activity of SH–EP cells was evaluated by 





Untreated cells were used as negative control for 100% metabolic activity. None of the    
Aβ1–40 species showed influence of cellular metabolic activity, regardless of their aggregation 
state. Both of Aβ1–40 species, monomer and aggregates with β–sheet–rich structures from 
the steady state of the ThT aggregation kinetic, did not change MTT reduction regardless of 
their concentrations 150 nM or 500 nM. In contrast, as in our previous experiments had 
observed, monomeric Aβ1–42 at low concentration (150 nM) displayed no inhibition effect on 
Figure 4–39: MTT assay of Aβ1–40 and Aβ1–42. SH–EP cells were incubated with Aβ1–40 and Aβ1–42 
monomer or aggregates at 37°C for 24 h, respectively. Activities of cellular metabolism were then 
evaluated by MTT assay. Monomeric Aβ1–42 at 500 nM, aggregated Aβ1–42 at 150 nM and at 500 nM 
showed inhibition of cell metabolism activities. No inhibition was detected by treating with other Aβ 








the activity of cell metabolism, but monomers at higher concentration (500 nM) inhibited 
the metabolic activity. Aβ1–42 aggregates at both concentrations, 150 nM and 500 nM, 
showed inhibition of cellular metabolism activitiy.  
4.3.4 Summary 
Aβ1–40 and Aβ1–42 are the two major isoforms from the processing of APP in the 
amyloidogenic pathway. We used ThT aggregation kinetic curves to assess the membrane 
activities and cytotoxicities of Aβ aggregate species from different phases of aggregation, 
and compared Aβ1–40 and Aβ1–42 in their membrane interaction and in cell viability within our 
established model systems. 
We found that within the lag phase, when Aβ1–40 and Aβ1–42 are in a similar aggregation state, 
they behave quite similarly with respect to the lipid bilayer. In both isoforms, one population 
of the species from the end of the lag phase induce invaginations on DOPC GUVs membrane. 
However, Aβ1–40 and Aβ1–42 have markedly different effects on cellular metabolism. 
Regardless of aggregation state, monomer or aggregate with β–sheet–rich structures, and 
regardless of concentration, 150 nM or 500 nM, Aβ1–40 shows no influence on cell 
metabolism activity, whereas Aβ1–42 monomer at 500 nM, and aggregates at both 
concentrations (150 nM and 500 nM) were toxic.  
These observations underline the pathological role of Aβ1–42, such as cytotoxicity of Aβ1–42 
aggregates.  The fact that both peptides have similar membrane activities may suggest that 
Aβ induced membrane remodelling not only plays a role in the pathological way. Rather, it 
hints at a possible physiological function of Aβ peptide membrane association and the 












Alzheimer’s disease (AD) is a highly complex neurodegenerative disorder, in which Amyloid 
beta (Aβ) peptides are deposited extracellularly in the form of amyloid plaques. A variety of 
hypotheses exists in current research for the cause of AD and the mechanisms underlying 
pathogenesis, but so far these hypotheses cannot fully explain the complexity of the 
pathogenesis of AD.  
Aβ peptides are produced both in the neurons of in AD patients and in healthy individuals. 
However, the understanding of why the cells produce this small and hydrophobic peptide, its 
physiological function, as well as the exact mechanism of pathogenesis of Aβ1–42 are still very 
limited (Jarrett et al. 1993; Knowles et al. 2014). 
The existing researches show that soluble oligomeric and/or small aggregated species are 
tightly linked to AD pathogenesis and are presumed to be the cause of neuronal damage 
(Walsh et al. 2002). However, there are still many questions, why Aβ1–42, which has only two 
amino acids (aa) more than Aβ1–40, is dominantly deposited in brain of AD patients; why the 
aggregated form of Aβ1–42 is more toxic than the monomer; how and where those 
monomers become aggregates; and how this extracellular peptide induced neurotoxicity.  
The first aim of present study is to address an important and fundamental phenomenon of    
Aβ1–42 related toxicity, specifically how the monomeric Aβ1–42 forms aggregates connected to 
the cytotoxicity, while the second part examines the interaction of Aβ1–42 with model 
membranes.  
5.1 Monomeric and aggregated Aβ1–42 species 
In the present study, monomeric Aβ and its aggregated forms from their early aggregation 
state are our main focus. Thus, it is very important to elucidate the quality of monomers, to 
prepare relatively pure and homogen monomers, and to define the aggregates before the 
studies of their behaviors.  
Comparing with monomers and well formed mature fibrils,  small aggregates including 
oligomers are believed to be central to amyloid toxicity (Haass & Selkoe 2007; Walsh et al. 
2002). Therefore, an important question in the amyloid hypothesis is the aggregation state 








factors, such as concentration of Aβ peptide, pH value of the buffer system, the temperature, 
and other components (such as sugar) of the milieu. In practice, it is very difficult to 
determine the sizes, the aggregation states, the structures of Aβ and their possible 
conformations under physiological conditions at the same time (Burke et al. 2013).  
In several studies, the solubility or the size of aggregates are broadly used to define the 
aggregation state of amyloids (Glabe 2008). Various forms of  Aβ had been observed in vitro 
and in vivo, such as disordered monomers, dimers, small oligomers, ring–like oligomers, 
protofibrils or twisted fibrils (Meinhardt & Fändrich 2009). Different types of Aβ oligomers/ 
small aggregates, which are usually in spherical form, have been described, such as SDS–
stable Aβ oligomers of 8 – 12 kD MW that were detected in cortex of AD patients (McLean et 
al. 1999); soluble oligomers of 56 kD detected in human AD brain (Kayed et al. 2003); SDS 
unstable oligomers of 20 kD that were ThT negative and cytotoxic (Ahmed et al. 2010); toxic 
Aβ–derived diffusible ligands (ADDLs, a type of soluble Aβ oligomers) (Krafft & Klein 2010); 
or cylindrin–like, out–of–register hexameric and cytotoxic oligomers (Laganowsky et al. 2012; 
Liu et al. 2012) etc.  
The confusing variety of species that were characterized as Aβ oligomers hinders our precise 
understanding of their role in AD pathogenesis and cytotoxicity. In the present study, we 
therefore focused on two easily measured parameters: the presence of aggregates as 
measured by Förster energy transfer (FRET) and the secondary structure of Aβ aggregates as 
measured by circular dichroism and by the binding of the amyloidophilic dyes ThT and ThS. 
This study investigated whether the presence of β–sheet–rich structures of Aβ aggregates 
affects the behavior of Aβ in neuronal model cells and its membrane interaction, rather than 
attempting a detailed analysis of the aggregate size or molecular weight of the Aβ species 
involved. 
To provide a clear starting point for our study, Aβ peptides were monomerized by passing 
through 30kD membrane filter, and fluorescently labeled Aβ1–42 monomers and protofibrils 
were purified by SEC to prepare a relatively homogeneous monomers and protofibrils  
(Figure 4–2 a, b, d and e). Small Aβ aggregates were then prepared in vitro (Figure 4–20 a 
and b).  
The small Aβ aggregates discussed in this study are classified in two populations: in the state 
before the formation of β–sheet structures, i.e. small aggregates without β–sheet structure, 
and in the state they just been formed, i.e. small aggregates with β–sheet structures. To 
identify and separate both types of aggregates, we used a classic tool – the ThT binding 
assay (LeVine 1993). Aggregation kinetic curve in vitro was used as a metric for the 
formation of β–sheet aggregates. During the aggregation process, different type of 
aggregated species co–existed, ThT binding assay is a very sensitive tool for grouping 
whether presence β–sheet structures of those aggregates. The majority of Aβ1–42 contains β–
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sheet structures shown by ThT binding assay and CD spectroscopy at the same time points 
(Figure 4–20 a and b, t1 vs. t2).  
In the present study, we aimed to investigate whether the presence of secondary structure 
effects on the behavior Aβ1–42 towards the cells and the membranes. Picking species from 
different time points of the ThT aggregation curve allows us to define aggregate species and  
to compare the behavior of same aggregate population in various model systems, e.g. the 
behavior of Aβ1–42 to cultured cells and to GUVs; or to observe those aggregates in same 
model systems.  
5.2 Cellular internalization of Aβ1–42 
Aβ peptide is secreted into extracellular space and amyloid plaques locate typically outside 
the cells. However, several studies have suggested that the reuptake of extracellular Aβ1–42 
into neurons may lead to the formation of intracellular aggregates, resulting in neuronal 
damage and neurotoxicity (Ida et al. 1996; Hu et al. 2009; Friedrich et al. 2010). Aβ1–42 forms 
aggregate spontaneous and rapid, at a relative high rate and relative low concentrations 
(Usui et al. 2009), and oligomers of  Aβ1–42 are observed to be central to amyloid toxicity 
(Haass & Selkoe 2007; Walsh et al. 2002). A detailed understanding of those processes and 
possible links between them should thus further our understanding in Aβ pathogenesis. 
The first goal of the present study was to investigate how monomeric Aβ1–42 becomes 
cytotoxic. Specifically, we investigated the location of Aβ1–42 aggregation, tested how 
aggregated structure is connected to uptake, examined whether internalization of Aβ1–42 is 
correlated to cytotoxicity, and investigated the pathway of Aβ1–42 uptake.  
We found that Aβ1–42 monomers as well as small aggregate species bound rapidly to the 
plasma membrane and formed β–sheet–rich aggregates. These structures were 
subsequently taken up and accumulated in endocytic vesicles. This process correlated with 
metabolic inhibition. Our data therefore imply that the formation of β–sheet–rich 










5.2.1 Uptake of Aβ1–42 monomer and the location of the aggregate 
formation 
5.2.1.1 Membrane binding and aggregation 
Aβ peptides are generated by APP and released then in a monomeric form from the plasma 
membrane into extracellular space (LaFerla et al. 2007). One of the characteristic features of 
Aβ1–42 is rapid formation of aggregates.  
The studies by Johnson et al. have described that small Aβ1–42 oligomers are capable of 
binding to the plasma membrane at nanomolar concentration in cultured neurons, and that 
Aβ1–42 oligomers can grow on the plasma membrane (Johnson et al. 2011; Johnson et al. 
2013). After adding monomeric Aβ (final monomer concentration 1 nM in cell culture 
medium), the Aβ bound in oligomeric form to membrane, and grew over the next 48 h.  
Another study by Bateman and Chakrabartty have showed that, membrane associated 
monomeric Aβ aggregates on the cell surface. The interaction of Aβ with cells mediated their 
aggregation (Bateman & Chakrabartty 2011). 
At a very low temperature (4°C), both the aggregation process of Aβ1–42 and the cell 
activities are slowed down, and the clathrin–mediated endocytosis is blocked  (Harding et al. 
1983). We observed that very small aggregates from early aggregation process, i.e. either a 
negative or positive ThT/ThS states, are capable bind rapidly on the plasma membrane 
under these conditions (Figure 4–14 a, Figure 4–16 a and b). Furthermore, when the 
concentration of added monomeric Aβ1–42 is above a threshold concentration, membrane 
bound aggregates could be taken up directly after binding to the cell membrane (Figure 4–
16 c, Figure 4–17 a, and Figure 4–19).  
5.2.1.2 Uptake by the cells 
We observed the uptake of monomeric Aβ1–42 only occurred when their concentration above 
the threshold concentration at 200–300 nM (Figure 4–12 a and b). However, the 
concentration of Aβ1–42 monomer in the medium needed for Aβ1–42–membrane binding is 
lower than the concentration needed for uptake. Aβ1–42–membrane binding can already be 
detected at 150 nM Aβ1–42 concentration (Figure 4–14 a), at which concentration the uptake 
of monomer was not observed within 24 h (Figure 4–6 c). Figure 4–14 a shows that the 
labeled Aβ1–42 peptide is located in form of isolated spots on the plasma membrane. At 
increased concentrations of Aβ1–42 in the medium (500 nM and 1 µM), membrane–bound 
Aβ1–42 formed aggregates. The aggregation process could be observed by the colocalization 
of Aβ1–42 monomers labeled with two different fluorophores and by FRET between the 
fluorophores (Figure 4–16). These data indicate that Aβ1–42 associates with the cell 
membrane in the form of small aggregates, when their concentrations are above a threshold 
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concentration (200–300 nM), the aggregated species can then be taken up (Figure 4–16 c, 
and Figure 4–17 a).  
Our FRET data provide evidence that membrane associated Aβ1–42 can be in aggregated form. 
The observations by Johnson et al. support our hypothesis, they observed that only early 
oligomers of Aβ bind to neurites (Johnson et al. 2011; Johnson et al. 2013). On the other 
hand, our data still could not completely exclude whether monomeric Aβ1–42 is also able to 
bind to the plasma membrane or not.  
Even though we cannot exclude that monomeric Aβ1–42 forms small earlier aggregates in 
solution, our data show that i) when adding the monomer of Aβ1–42 to the cell culture media 
at low concentrations (< 150 nM), Aβ1–42 peptide cannot be taken up very efficiently; and ii) 
the aggregated form, which is a requisites for cellular uptake, can be formed directly on the 
plasma membrane. 
This observation also suggests an explanation for the threshold concentration of the 
monomer uptake process. The process of nucleated polymerization is characterized by a 
threshold concentration, below which aggregation cannot occur, which is called the critical 
concentration for aggregation and is the same as the saturation concentration for 
monomeric Aβ peptide in equilibrium with aggregates (see introduction chapter 1.4). If    
Aβ1–42 needs to form defined aggregate structure before its cellular uptake, the threshold 
concentration for uptake would correspond to the critical concentration for Aβ1–42 
aggregation on the plasma membrane or in solution. Once the Aβ1–42 aggregates reached a 
certain size and/or form, they can be then taken up. The critical concentration of Aβ1–42 was 
reported to be approximate at 160 nM in solution (Usui et al. 2009). It could be considerably 
lower for membrane–bound Aβ  (Usui et al. 2009), but the aggregation of Aβ1–42 in 
equilibrium with binding to a membrane surface has not been analyzed quantitatively in this 
study. 
Friedrich et al. had speculated that, after association of soluble Aβ with the cells, the 
amyloid plaques would be formed intracellularly (Figure 1–8 b). Our data provided a more 
detailed evidence of membrane associated Aβ1–42 structures and the possible location of 
aggregate formation. Our resultes suggest that intracellular Aβ1–42 aggregate can be formed 
in the plasma membrane from soluble Aβ1–42, which can be the monomer and / or small 
aggregates in very early aggregation state. We observed FRET between labeled monomeric 
Aβ1–42 species, indicating their aggregation, in endocytic vesicles under conditions that 
permitted endocytosis (Figure 4–16 c). However, we also observed FRET between the same 
Aβ1–42 species on the plasma membrane, when blocking their uptake. These observations 
may suggest that the formation of toxic Aβ1–42 aggregates occurred membrane binding, 
rather than after entry into the endocytic vesicles. 
Hu et al. showed that Aβ1–42 (1 nM in cell culture medium) could be detected after 24 h 








concentration than our results (Hu et al. 2009). However, their study did not characterized 
the monomers they used, and did not clearly state the monomers that used were 
monomerized by specialized treatment, such as by using SEC or membrane filtration. Rather, 
the Aβ1–42 peptide was simply diluted out of DMSO solution. Without a specific 
monomerization treatment, it is likely that the Aβ1–42 was present aggregates/oligomers not 
monomers.  
Moreover, we found that preexisting Aβ1–42 aggregates could also be internalized directly. 
Our observations therefore also raise the question, what structure or size the aggregates 
need to be for a successful cellular uptake. The uptake of aggregated Aβ1–42 will be discussed 
in the next section. 
5.2.2 Uptake of Aβ1–42 aggregates  
Compared to the uptake of monomers, the cellular uptake of preaggregated Aβ1–42 species is 
more efficient (Figure 4–12). Bateman and Chakrabartty have reported similar observations. 
Aggregated species of Aβ1–42, which was a mixture with hydrodynamic radius from 10 to 
1000 nm as measured by DLS and that were ThT positive, were collected from aggregation 
assay. These aggregates (1.5 µM) were taken up more rapidly than Aβ1–42 monomers by PC12 
cells (Bateman & Chakrabartty 2011). 
Small aggregates containing preexisting β–sheet–rich structures can be internalized at very 
low concentration. The lowest concentration that we used to treat the cells in our 
experiments is 15 nM (corresponding monomer concentration, Figure 4–12 c). It must be 
noted, this is the concentration of Aβ1–42 in the cell culture media, not on the plasma 
membrane or inside the cells. 
A threshold concentrations similar to that required for monomer uptake, at approximately 
concentration range 200–300 nM, was not observed for the uptake of aggregates with β–
sheet–rich structures, supporting the mode that Aβ1–42 aggregation facilitates its cellular 
uptake.  
We hypothesize that the β–sheet–rich structures might be the key factor for cellular uptake 
of Aβ peptides. Aggregates with β–sheet structure were internalized immediately after the 
Aβ1–42–membrane binding, whereas monomers or small aggregates without β–sheet first 
had to convert into β–sheet structures on the plasma membrane before being taken up.  
We will therefore then examine and discuss the secondary structures of membrane 
associated and internalized Aβ1–42.  
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5.2.3 Secondary structure of internalized Aβ1–42 
To detect the β–sheet structure of internalized Aβ1–42 in the cultured cells, a classic thioflavin 
dyes, ThS, was used (LeVine 1993).   
ThS is widely used dye to identify amyloid structure in tissue or in the cultured cells. Similar 
to ThT, ThS binds specifically to β–sheet–rich structures and displays then an enhanced 
emission fluorescence (Sun et al. 2002; Cullen et al. 1996; Guntern et al. 1992). But unlike 
ThT, ThS is less sensitive to pH. Lowering pH (< pH 5) has no significant  influence on its 
fluorescence (LeVine 1993). Thus, ThS is better suitable for staining inside the endocytic 
vesicles. Additionally, from my observations, ThS seems to better pass through the 
membranes, and binds then selectively to Aβ aggregated form with high affinity. Therefore, 
instead of ThT that was used for reporting formation of β–sheet in vitro, ThS was used for 
recognizing the secondary structure of Aβ1–42 in cultured cells by microscopy. ThS is routinely 
used to stain deposited Amyloid–β in the visual cortex of the brains of AD patients 
(Grienberger et al. 2012).  
Our experiments combining aggregation kinetic in vitro and ThS staining of cells show that: i) 
the amount of internalized Aβ1–42 correlates with the formation of ThT positive aggregates in 
vitro, and ii) that internalized Aβ1–42 is ThS positive. 
Figure 4–20 a and c show that, the amount of β–sheet structures in the samples is correlated 
with the amount of internalized Aβ1–42, suggesting ß–sheet structure may promote the 
cellular uptake. ThS staining supports our hypothesis (Figure 4–19). By treating the Sh–EP 
cells with two types of labeled Aβ1–42, Aβ1–42
488 monomer at a concentration under the 
uptake threshold concentration (at 150 nM), and Aβ1–42
633 β–sheet aggregate (at 900 nM), 
respectively, internalization of Aβ1–42
488 occurred only via coaggregation with Aβ1–42
633 
aggregate. ThS and calcein were added to live cells to visualize β–sheet structure and 
location of Aβ1–42, i.e. on the plasma membrane or in endocytic vesicle. Our observations 
show that, ThS and calcein fluorescence signals were very closely linked. Only the aggregates 
that contained β–sheet structure (ThS positive) were internalized (calcein positive). In 
contrast, ThS negative species only associated with cell surface and could not to be observed 
in typical endocytic vesicles. 
These data demonstrate that aggregates with β–sheet structures are internalized more 
rapidly and efficiently than monomers or small aggregates without β–sheet structures, and 
support our hypothesis, that conversion into β–sheet structures facilitates the efficient 
uptake of Aβ1–42 by neuroblastoma cells via an endocytotic mechanism. 
We hypothesis that, non–β–sheet species of Aβ1–42 are capable of binding to plasma 
membrane, and converting into β–sheet–rich aggregates on the plasma membrane. To the 
best of my knowledge, the exact reason and mechanism, that the plasma membrane 








β–sheet structure on model membranes systems, which may support our hypothesis that 
lipid membranes assist β–sheet formation, but no data exist for physiological plasma 
membranes. Alternatively, Aβ1–42 could bind to a receptor or other membrane protein, Aβ–
receptor binding may facilitate Aβ aggregation and uptake. However, our data from model 
membrane systems indicate that small aggregates from early aggregation state can interact 
directly with the membrane lipids.   
The interaction of Aβ with model membrane system will be discussed in detail in section 5.3.  
These observations raise also the question, whether the uptake of Aβ1–42 correlates with 
cytotoxicity and whether the uptake of Aβ1–42 into the cells could cause an inhibition of the 
cellular metabolism activities.  
5.2.4 The causal link between Aβ1–42 uptake and its cytotoxicity  
Many studies have already shown that different aggregate species of Aβ from different 
aggregation states displayed fairly different levels of toxicity to cultured cells or in mouse 
models (Zhang et al. 2002; Glabe 2006; Barghorn et al. 2005; Stefani 2010; Ahmed et al. 
2010). In those aggregates, the soluble Aβ1–42 oligomer is commonly thought to be the most 
and primary toxic aggregate species associated with memory dysfunction in the early stage 
of AD (Ahmed et al. 2010; Klein 2006; Walsh et al. 2002). There are many hypotheses for the 
mechanism of cell / neuron death or damage, such as the interaction of Aβ with the plasma 
membrane that bind cholesterol which results in channel formation (Di Scala et al. 2014), or 
reuptake of extracellular Aβ1–42 results in neurotoxicity (Hu et al. 2009; Friedrich et al. 2010).  
We examined whether the internalization of Aβ1–42 adversely affect the activity of cell 
metabolism. For this end, MTT assay, which is a frequently used method for testing the cell 
viability and metabolic activity in the studies cited above, was used.  
Our results show that, inhibition of the cell metabolism activity and the detection of 
internalized Aβ1–42 are correlated. By treating the cells with monomeric Aβ1–42, the drop of 
the metabolism activity is proportional correlated to amount of the Aβ1–42 being taken up, 
which is in turn a dependent on the monomer concentrations in the medium. 
It should be mentioned that the threshold concentration of Aβ1–42 monomer for inhibition of 
cell metabolic activity was between 75 – 150 nM (monomer concentration in the medium, 
Figure 4–20 e), which is lower than threshold concentration observed for monomer uptake 
(200 – 300 nM). A possible explanation could be the different aggregation rate between 
labeled and unlabeled Aβ1–42. The fluorescence label had no effect on the morphology of 
formed fibril (Figure 4–3 b and c), but it slowed down slightly the aggregation kinetics 
(Figure 4–3 a). For MTT assay, the cells were treated with 100% unlabeled Aβ1–42, and 
fluoresce labeled Aβ1–42 was used for uptake experiments. Alternatively, it is possible that 
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the membrane associated Aβ1–42, may already be able to influence the cell metabolism 
before being taken up. The third possible reason could be a lack of sensitivity in the readout 
method for uptake by HCS microscopy. Intracellular aggregates need to have a certain size or 
brightness to be detected by the HCS algorithm. At the threshold concentrations, 
approximately between 100 – 200 nM, the fluorescent signal of Aβ1–42 may be too weak to 
be detected by conventional microscopy.  
Nevertheless, by treating with monomeric Aβ1–42, when their concentrations below 100 nM, 
no uptake of Aβ1–42 is detected, and cell viability by MTT assay is not changed, suggesting the 
monomeric Aβ1–42 neither convert into β–sheet aggregates, nor is the peptide cytotoxic 
below the threshold concentration for uptake. The observation that the threshold 
concentration for uptake and cytotoxicity is very close to the critical concentration for Aβ1–42 
monomer aggregation, supports the hypothesis that formation and uptake of β–sheet 
positive aggregates is the prerequisite for metabolic toxicity of Aβ1–42, while the monomeric 
peptide itself is relatively harmless. The damage of the neurons and the neurototoxicity may 
be caused by the accumulation of monomer and its aggregation products. 
However, there are data disputing that the β–sheet positive aggregates of Aβ are the toxic 
species. Ahmed et al reported that a β–sheet negative Aβ1–42 oligomer was highly neurotoxic 
(Ahmed et al. 2010). A close look at their assay conditions reveals that those oligomers were 
incubated with the neurons at 37 °C for 48 h and at a final Aβ1–42 concentration of 5 µM. Our 
data demonstrate that this concentration is more than sufficient for the formation of β–
sheet aggregates. Thus, the β–sheet negative Aβ1–42 oligomers, which were the authors 
consider form for internalization, may not be in the state as the beginning of the 
experiments. Aβ1–42 oligomers probably already convert into a higher ordered structure 
during the toxicity assay.  
Walsh et al. found that SDS–stable trimers were highly neurotoxic and that they inhibited 
long term potentiation in the synaptic transmission of hippocampal neurons (Walsh et al. 
2002). The secondary structure of those oligomers has not been characterized rigorously and 
it is not clear if the toxic species formed a larger aggregate under native conditions. Two 
possible models would reconcile the data of Walsh et al. with our results: i) the toxic species 
could be a β–sheet positive aggregate that dissociates into trimers after SDS denaturation; ii) 
there are two distinct mechanisms of Aβ toxicity affecting different neuronal processes. The 
second hypothesis is supported by the observations that two different modes of Aβ 
cytotoxicity exist, the interference with synaptic transmission and the inhibition of cellular 
metabolism activities. In the present study, we probed the second mechanisms of Aβ toxicity, 








5.2.5 Pathway of Aβ1–42 uptake 
The extracellular molecules can be internalized via different endocytotic pathways (Marsh & 
McMahon 1999), such as phagocytosis for solid particles; macropinocytosis for fluid; and the 
clathrin or caveolin mediated endocytosis for small molecules, such as peptide or proteins 
(Mayor & Pagano 2007). 
Endocytosis of misfolded proteins, such as  Aβ, tau protein, α–synuclein and huntingtin, have 
already been described in cell models (Frost et al. 2009; Brundin et al. 2010) via several 
possible endocytic pathways (Kanekiyo et al. 2013; Holmes et al. 2013; Lai & McLaurin 2010; 
Treusch et al. 2011; Yu et al. 2014). It would be plausible that the observed differences in 
cytoxicity between small disordered aggregates and aggregates containing β–sheet structure, 
the protofibril or twisted fibrils may be linked to differences in the internalization process. 
We observed internalized Aβ1–42 located in endocytic vesicles (Figure 4–5 a and b). To shed 
light on the endocytotic pathway, we examined their endocytosis by using varying methods 
to block endocytic pathways and by using immunofluorescence (IF) staining with different 
endocytosis markers.  
Clathrin–mediated endocytic pathway can be blocked via lowering the temperature to 4°C 
(Harding et al. 1983). The inhibition of the clathrin–mediated endocytosis was confirmed by 
the fact that transferrin located primarily on the plasma membrane under this condition and 
was not endocytosed (Figure 4–14). Transferrin binds to the transferrin receptor on the 
plasma membrane and can be internalized by CME via clathrin–coated pits. Fluorescent 
transferrin conjugates are therefore broadly used as marker for investigating the early phase 
of CME (Iacopetta et al. 1983; Harding et al. 1983; Jandl & Katz 1963; Laurell & Ingelman 
1947). The uptake of transferrin depends on both temperature and energy, thus can be 
blocked at low temperature (Harding et al. 1983). At 4°C, transferrin only binds to its 
receptor on the plasma membrane, and will not be taken up (Harding et al. 1983). Inhibition 
of CME pathway could be reported by the location of transferrin. However, it should be 
noted that at 4°C the fluidity of membrane is limited, which may also influence other 
endocytotic mechanisms or the aggregation of Aβ1–42 (Uzman et al. 2000; Lodish et al. 2008).  
At 4°C, the uptake of preaggregated Aβ1–42 is reduced but cannot be totally blocked. 
Compared with 37 ℃, the amount of internalized Aβ1–42 decreased by 90% at the same 
concentration (150 nM, Figure 4–15). These data suggest that a clathrin independent 
pathway of Aβ1–42 uptake may exist. Our data do not necessarily imply that 90% of Aβ1–42 is 
taken up by CME. Since other endocytic processes are also affected by the decreased 
temperature, the observed drop of uptake rate at 4°C may be caused by decreased activity 
of the cells under this non–physiological temperature.  
In another control experiment, clathrin–mediated endocytosis was selectively blocked by 
potassium depletion (Larkin et al. 1983; Ivanov 2008). Uptake of Aβ1–42 was not completely 
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blocked but rather increased by lacking of K+ (Figure 4–22), supporting the hypothesis that 
the internalization of Aβ1–42 may be achieved through a clathrin independent pathway.  
Colocalization experiments further supported our hypothesis. Interacellular Aβ1–42 colocalize 
rarely with typical markers, clathrin and LAMP2, for the clathrin–mediated endocytic 
pathway by IF staining (Figure 4–21). No colocalization between internalized Aβ1–42 and 
transferrin was detected as well (Figure 4–14).  
We therefore conclude that extracellular Aβ1–42 can enter the cells via a non–clathrin–
mediated pathway, and locate then in the endocytic vesicles. Costaining with caveolin 
suggests a possible uptake route via the caveolin endocytosis pathway (Figure 4–21). Several 
studies have reported other amyloid proteins such as tau can be endocytosed through 
micropinocytosis and proteoglycan–mediated processes (Kanekiyo et al. 2013; Holmes et al. 
2013; Lai & McLaurin 2010; Treusch et al. 2011; Yu et al. 2014). A further study may be 
needed to precisely determine the endocytosis pathway of Aβ1–42. 
Internalized Aβ1–42 was observed to colocalize with lysosome by using lysosome marker 
(Bateman & Chakrabartty 2011) and  LysoTracker (Hu et al. 2009); Friedrich et al. have 
observed internalized Aβ located within multivesicular bodies (MVBs) by Transmission 
electron microscopy (TEM) (Friedrich et al. 2010). These observations suggest those 
internalized Aβ1–42 located into endosome and/or lysosome via typical endocytic traffic 
pathway.  
Moreover, our data suggest that, internalized Aβ1–42 accumulates in endocytic vesicles 
instead of being degraded. It is possible that β–sheet rich structures of aggregated Aβ1–42 
difficult to degrade. Additionally, the increased concentration of Aβ1–42 and low pH in 
lysosome, both may facilitate the further aggregation of Aβ and stabilize their secondary 
structure, that may lead to cell damage and deposit of Aβ1–42.  
The degradation pathway of toxic Aβ1–42 if it existed and possible apoptosis mechanism 
leaded by Aβ1–42 could be the next goal. Considering that the cell damage and cell death 
might be the results of by intracellular accumulation of Aβ1–42 over the time, an animal 
model might be more suitable for a long–term observation than cultured cell. 
From what has been discussed above, we may reasonably assume that the stable and hard 
to degradad β–sheet–rich structures of internalized Aβ1–42 may be one of the possible causes, 
leading to the cytotoxicity and cell death, finally to an accumulation in the plaques on brain 








5.3 Interaction of Aβ1–42 with membranes 
The interaction of misfolded proteins with liquid / surface interfaces plays a crucial role for 
many protein–misfolding diseases, such as Alzheimer’s disease, Parkinson’s disease and 
Huntington’s disease (Burke et al. 2013).  
We have discussed that interaction of with the plasma membrane of neuronal model cells 
benefits the conversion of non–toxic Aβ1–42 species into cytotoxic aggregate. However, their 
binding partner on the plasma membrane could be either lipid bilayer itself or membrane 
proteins. 
In the following part, we therefore addressed the interaction of Aβ1–42 with lipids by using 
simplified model membrane systems, such as GUVs and GPMVs. We found that aggregated 
Aβ, which is in ThT negative state, binds to Ld phase of lipid bilayers, and induces then 
negative membrane curvature in lipid bilayers leading to invaginations that look similar to 
endocytic vesicles. 
5.3.1 Aβ–membrane binding 
Amyloid precursor protein (APP) is a transmembrane glycoprotein highly concentrated in the 
synapse of neurons. Aβ peptide is produced by APP cleavage, contains part of 
transmembrane region of APP (Olsson et al. 2014; Haass et al. 1993; LaFerla et al. 2007). The 
amphiphilic character of Aβ make it capable to interact with membrane, and may also be 
able to insert into the lipid bilayer (Williams & Serpell 2011; Lansbury & Lashuel 2006; Burke 
et al. 2013).  
5.3.1.1 Accumulation of Aβ1–42 on ld phase of GUVs 
We observed that Aβ1–42 rapidly accumulated on the plasma membrane, and then formed 
aggregates directly on the plasma membrane (Figure 4–14, Figure 4–16 a and b, Figure 4–
19). In addition, we observed preferential binding of Aβ1–42 to ld phase of GUVs model 
membrane systems (Figure 4–26). 
Model membranes have been used for the studies of interaction of Aβ with different lipid 
components, such as cholesterol (Burke et al. 2013; Yip et al. 2001; Reiss et al. 2004; Yu & 
Zheng 2012), sphingolipids (Burke et al. 2013; Van Echten–Deckert & Walter 2012), 
gangliosides (Burke et al. 2013; McLaurin & Chakrabartty 1996), and neutral or charged 
phospholipids (Burke et al. 2013; McLaurin & Chakrabartty 1997; Sabaté et al. 2005; Sabaté 
& Estelrich 2005; Sabaté et al. 2012). The accumulation of oligomeric Aβ1–40 has been 
observed in the ld phase of ld/lo phase–separated lipid monolayers (Hamada et al. 2010). A 
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selective location of Aβ1–42 oligomer and prefibrils (defined as “protofibrils” in our study) in 
the DOPC rich region, i.e. ld phase, of cell–sized ld/lo phase–separated liposomes had also 
been reported by Morita et al (Morita et al. 2012).  
Our experiments data confirmed the accumulation of Aβ1–42 in the ld phase of the 
membrane. Aβ1–42 readily accumulated in membrane of GUV that were formed from DOPC in 
pure ld phase (Figure 4–26 a). No accumulation of Aβ was observed in the GUVs containing 
100% cholesterol, GUVS in a relative pure lo phase (Figure 4–26 b) (Stöckl & Herrmann 2010). 
Correspondingly, in GUVs with coexisting ld/lo phases, Aβ1–42 only induced membrane 
negative curvature in the ld phase but not in the lo phase (Figure 4–31). Remodeling of 
membrane curvature by Aβ1–42 coincided with membrane binding. Its possible mechanism is 
discussed in more detail below. 
Several studies have reported that Aβ1–42 associates with either the lipids or protein 
complexes in raft domains and have suggested that production of Aβ1–42 and cholesterol 
levels are closely related (Lai & McLaurin 2010).  
Our observations suggest, while Aβ1–42 may interact with protein complexes in the 
cholesterol–rich lo domain in vivo, Aβ1–42 preferentially binds to the lipid in the ld phase of 
the lipid bilayer and that the invaginations are formed specifically in the Ld phase of GUVs 
membrane.  
Our observations also agree with those results that find binding of small aggregated 
(oligomeric) Aβ to the lipid bilayer. After short time (15 min) incubation of Aβ1–42 monomer 
(10 µM) with GUVs, Aβ1–42 accumulated on the membrane of DOPC GUVs (Figure 4–26 a). On 
the other hand, no Aβ1–42 binding was observed when Aβ1–42 was diluted out directly after 
addition to the GUV membrane (Figure 4–36), suggesting that aggregation was necessary for 
membrane binding. 
In our experiments, the accumulation occurred faster than the aggregation of Aβ1–42 into ThT 
positive aggregates (Figure 4–25). ThT binding is the hallmark of β–sheet–rich aggregates. 
Therefore, our results suggest that Aβ1–42 species that have higher membrane affinity are 
likely small aggregates (oligomer) from very early aggregation state and not β–sheet rich 
aggregates. However, from these experiments, we could not determine whether those small 
aggregates (oligomers) formed in solution before membrane binding or whether they had 
formed on the membrane surface.  
Also, our observations on GUV model membranes raise the question why β-sheet rich 
aggregates are internalized so much more efficiently than monomeric or early small 
aggregates of Aβ. One possibility is that binding of β-sheet aggregates to cell membranes is 
mediated by factors such as proteoglycans or membrane complexes that are not present in 
the GUV model system. Another possibility is that the concentration of Aβ used in our GUV 
membrane model (10 µM), which was much higher than the threshold concentration of 








More details of Aβ aggregation state that bound to model membrane will be discussed in 
section 5.3.3.  
5.3.1.2 Mode of Aβ1–42–membrane interaction 
We probed the Aβ1–42–membrane interaction by FRET measurement between Aβ1–42 peptide 
and lipids of GUVs membrane. C6–NBD–PC of DOPC GUVs to Aβ1–42
633 FRET verified that  
Aβ1–42 peptide is very close to GUVs membrane (Figure 4–27). Based on the fact that the 
Föster distance between the donor and the acceptor is typically smaller than 100 Å, the 
maximum distance between the Aβ1–42 and C6–NBD–PC in our experiments should be 
smaller than 10 nm.  
Base on these FRET data, we can attempt to draw conclusions about the position of the Aβ 
molecule, whether it attaches to the membrane surface or inserts into the membrane 
bilayer. Fluorophores were attached the N–terminus of the Aβ peptide. The amphiphilic 
character of the N–terminus of Aβ make it capable to interact with membrane, and may also 
enable Aβ to insert into the lipid bilayer (Williams & Serpell 2011; Lansbury & Lashuel 2006; 
Burke et al. 2013).  
As the NBD dye sits at the C6 position in the hydrophobic tail of the lipid, the FRET signal 
would suggest that Aβ1–42 had inserted into the membrane. However, the NBD label can 
adopt two possible conformations: inserted into the membrane, or looping back to head 
group of the lipid molecule or even possibly extend into solution (Huster et al. 2001). This 
prevents us from determining whether the Aβ1–42 peptide is inserted into the membrane or 
whether it remains bound to the lipid-water interface.  
A more comprehensively experiment would be helpful, in which complementary labels are 
attached to the head group and different positions of hydrophobic tail of the lipid and the 
N– and C–terminus of Aβ1–42 peptide, respectively. 
5.3.2 Induction of negative membrane curvature  
Generation of dynamic membrane curvature is one of the basic activities for the life, and is 
needed for the exchange of the substrates between in and outside the cells. Transport 
vesicles, such as endocytic or exocytic vesicles, and viral buds are typical representatives. 
The formation of dynamic membrane curvature is achieved either by lipids and proteins via 
protein–membrane interaction or via the local concentration change of membrane lipids 
(Stachowiak et al. 2013; McMahon & Gallop 2005). However, the dynamics of membranes 
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do not always have positive consequences. The membrane bending could be reduced by 
many peptides or proteins, which are involved in neurodegenerative diseases.  
Many studies have suggested that aggregation of Aβ in or near membrane might lead to 
disruption of membrane structure, change of the membrane curvature or creation of 
membrane pores (McLaurin & Chakrabartty 1997; McLaurin & Chakrabartty 1996; 
Mirzabekov et al. 1996; Gorbenko & Kinnunen 2006; Burke et al. 2013). Arispe et al and Di 
Scala et al have reported binding of Aβ to cholosterol results a channel formation of the 
plasma membrane (Di Scala et al. 2014; Arispe, Pollard, et al. 1993; Arispe, Rojas, et al. 1993); 
Vestergaard et al had observed Aβ1–42 induced membrane fusion by giant unilamellar 
vesicles (GUVs) (Vestergaard et al. 2013).  
In our study, we observed for the first time the induction of negative membrane curvature 
by Aβ peptide. Aβ1–42 is able to accumulate on ld phase of GUVs membrane. It then induces 
local negative curvature, namely invaginations, on the membrane of DOPC GUVs (from 100% 
DOPC, Figure 4–26 a & Figure 4–28a) and of PE/PC GUVs (from DOPC : DOPE in 1:1 molar 
ratio, Figure 4–29) as well. In the ld/lo phase–separated GUVs (form DOPC : SSM : Chol in 
1:1:1 molar ratio), the Aβ1–42 induced invaginations were observed exclusively in the Ld 
phase (Figure 4–31). Furthermore, Aβ1–42 induced invaginations could also be observed in 
GPMVs that isolated from SH–EP cells (Figure 4–32 b).   
Combined with the previously results that Aβ1–42 accumulate only in ld phase, not in Lo 
phase (Figure 4–26 a and b), our results suggest that both Aβ1–42 binding and Aβ1–42 induced 
membrane remodeling are primarily located to ld phase.  
Membrane remodelling by Aβ1–40 in SUVs model membrane system has been hypothesized 
by Matsuzaki and Horikiri from Fourier transform infrared spectroscopy with polarized 
attenuated total reflection (FTIR–PATR) data (Matsuzaki & Horikiri 1999). They investigated 
the Aβ1–40–lipid interaction by a shift in IR resonances, and the molecular orientations were 
evaluated by polarization. Their CD and FTIR–PATR spectroscopy data suggest Aβ1–40 may 
induce negative curvature strain on the ganglioside–containing membrane of SUVs (PC : 
GM1 in 4:1 molar ratio). However, Morita et al have recently reported a contrary 
observation by Aβ1–42 using GUVs, that the location of oligomeric Aβ1–42 (5 µM) was observed 
in the ld phase of cell–sized lo/ld phase–separated liposome, which were formed from DPPC, 
DOPC, cholesterol (Chol), fluorescent lipid analogs rhodamine–DHPE (Rho–PE) for ld and 
NBD–DPPE (NBD–PE) for lo phases. They observed that Aβ1–42 (5 µM) oligomers induced the 
exo– and endo–buds from lo domains and enhanced the fluctuation of the ld phase by 
microscopy. They speculated that Aβ1–42 oligomers may induce a change in the motion of lo 
domains (chol) that float within the ld phase (PC), and caused the budding of lo domains 








(SUVs and GUVs), or the different aggregation states of Aβ peptide or different preparations 
of samples. 
α–Synuclein, another protein tightly associated with neurodegenerative disorders which 
accumulates in Parkinson’s disease, is also able to associate with membrane (Jao et al. 2008; 
Stöckl et al. 2010). Braun et al shown the interaction of α–Synuclein with membrane can 
result both positive and negative curvature by molecular dynamics (MD) simulation 
calculations that were based on NMR data (Braun et al. 2012). α–Synuclein was found to 
increase positive membrane curvature on pure DOPS GUVs (Shi & Baumgart 2015; Shi et al. 
2015). The authors speculate that this process may play a role in neurotoxicity in Parkinson’s 
disease. However, the mechanism of this process is not yet well understood. 
We observed, the induction of invaginations is related to the binding of Aβ1–42 to membrane. 
This indicates that the remodelling of membrane curvatures is the result of the Aβ1–42 
/membrane binding and interaction. Those observations raise then an important question, 
namely which aggregates species of Aβ peptide interact with then membrane and whether 
these are the same species that induce negative membrane curvature.  
5.3.3 ThT negative Aβ1–42 aggregates induced membrane remodeling 
In our study, we noted that there is always a time interval between adding Aβ1–42 monomer 
to GUVs and the detection of invaginations (fig. 4–28). This time interval can be omitted by 
incubating GUVs with preaggregated Aβ. However, the spectrum of aggregate populations 
that are capable to induce membrane inagination is not very broad, i.e. Aβ preaggregated 
for 45 min or more seems to lose its membrane remodelling activity. When comparing this 
time window to the time scale of the ThT aggregation kinetic (Figure 4–25), we found that 
membrane activity coincides with the lag phase of aggregation. Neither monomer nor big 
aggregates, but only small ThT negative aggregate from the end of the lag–phase of ThT 
kinetics bind to ld phase (DOPC) with high affinity, and are capable to induce invaginations. 
This interpretation is reinforced our data from Aβ1–40 aggregation (Figure 4–38). Here, it was 
also species from the end of the lag phase at 16 h incubation, which had membrane activity. 
Matsuzaki and Horikiri have observed that Aβ1–40 would be in different conformations when 
binding to different lipids. Aβ1–40 was in an unordered structure in solution examined by CD 
and ThT assay. After membrane associations, Aβ1–40 bound to membrane of PC SUVs was 
measured in unstructured form by CD spectroscopy, whereas Aβ1–40 formed α–helix upon 
association with membrane of negatively charged PG SUVs and formed β–sheet 




Different to the conclusions from Morita et al (Morita et al. 2014), our data support that 
membrane transformations are induced by aggregated species not by monomers.  
5.3.4 Possible mechanism of Aβ1–42 induced membrane remodeling  
Our results show that, Aβ aggregates are able to induce negative membrane curvature 
leading to the formation of spherical invaginations in GUVs model systems. Since no other 
components are present in the system, negative membrane curvature has to result from the 
Aβ–membrane interaction, but the mechanism is not known yet. Possibly, membrane 
curvature is induced by inserting Aβ aggregates into the membrane.  
A spontaneous incorporation of Aβ1–40 into neural liposomes (soybean PC, in average 
diameter about 200 nm) was reported by Sabaté et al (Sabaté et al. 2005).  
Braun et al have reported the membrane remodeling effects of other amyloid protein, α–
synuclein, using combination of experimental data from X–ray scattering and fluorescence 
correlation spectroscopy, coarse–grained molecular dynamics (MD) simulations and 
potential of mean force calculations, found that α–synuclein could induce both positive and 
negative curvature in membranes. They have suggested that curvature–generating 
amphipathic α–helices of α–synuclein to induce the negative Gaussian curvature on 
POPS/POPC (at a 1:3 mole ratio) bilayers (Braun et al. 2012).  
Additionally, in our experiments, the osmotic pressure of buffer inside GUVs is larger than 
the outside. Due to the osmotic pressure difference between the in– and outside, 
membranes should be in an expanded state, which suggests the force generated from Aβ–
lipid interaction has to be relatively large in order to overcome the osmotic pressure.   
5.3.4.1 General principles for generating the negative membrane curvature by 
peptide action 
In  the normal, i.e. the relaxed, state of bilayers, the sum of lateral pressure is close to zero 
(Iversen et al. 2015). Koller and Lohner have sketched how a inserted molecule induce 
membrane curvature (Figure 5–1) (Koller & Lohner 2014). The insertion of protein or peptide 
into one monolayer of the membrane exerts a lateral pressure. This force probably arises 
from peptide–lipid interactions as well as peptide–peptide interactions. Those interaction 
processes induce then membrane curvatures. A lateral pressure on the hydrophobic tail 
region of phospholipids results negative curvature, i.e. curvature < 0, the lipid tails are 
pushed outward more than headgroups. A positive curvature is resulted by lateral pressure 











By integration of a protein into the lipid bilayer (Figure 5–2), such as a transmembrane 
protein or transmembrane protein domain, the lateral pressure results deformation of 
membrane and  protein oligomerization and conformation change (Iversen et al. 2015).     
 
 
5.3.4.2 Possible structure of inserted Aβ1–42  
In the present study, we provide evidence that Aβ–membrane interactions can generate 
invaginations in the membrane of model membrane systems. Their interactions may have 
two effects on the membranes. On one hand, they may lead to a reorganization of 
membrane lipids to minimize their hydrophobic area. This may result a physical shape 
changes of membranes. On the other hand, the deformation of membrane, i.e. formation of 
Figure 5–2: Membrane curvature is induced by lipid–protein interaction. Left: The conformation of 
transmembrane proteins is coupled to membranes via the lateral pressure profile. Right: the lateral 
pressure profile, which measured alone the bilayer, black, before and green, after the conformation 
changes of transmembrane protein. Figures adapted from Iversen et al (Iversen et al. 2015). 
Figure 5–1: Definitions of negative and positive membrane curvature, which are driven by insertion of 
molecules (light grey) into monolayer that change the lateral pressure and induce the membrane 
curvatures. Figures adapted from Koller and Lohner (Koller & Lohner 2014). 
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membrane negative curvature, may change the local physical properties of membrane and/ 
or lipids, which could then promote and modulate Aβ aggregation process. In other words, it 
can be thought that Aβ reorganizes its structure, especially the Aβ–lipid (in tail region of lipid) 
and Aβ–lipid–water (in lipid headgroup region) interface structures, to fit for surrounding 
ecology. This may also give Aβ a new biological activity. Additionally, our observations shown 
that Aβ aggregates in ThT negative state induced a negative membrane curvature in GUVs 
and GPMVs.  
Following the model outlined above, in Figure 5–3 we hypothesize that those Aβ aggregates 
embed into membranes, which induce and stabilize the negative membrane curvature, i.e. 
an invagination in the membrane (gray). Aβ peptides in an aggregated form embed into the 
lipid bilayer (green). Each Aβ peptide (orange) is in a hairpin structure, with the hydrophobic 
C–terminal part in the hydrophobic tail region of phospholipids, and N–terminal probably 
outside the membrane toward to the buffer. The hairpin structures of many single peptides 
may make the aggregate have a trapezoid shape. The longer base part of the trapezoid 
formed by the C–terminal part inserts into one monolayer of the membrane, while the 
shorter base part of the trapezoid formed by N-terminal part is toward to the buffer. By 
insertion of trapezoid shaped Aβ aggregate and Aβ–lipid interactions, the lateral pressure on 
the hydrophobic tail region of phospholipids may push the lipid tails outward more than 
headgroups, i.e. negative curvature is formed. The negative curvature may be enhanced 
through multiple insertion of Aβ aggregate and the reorganization of membrane lipids, i.e. 
an invagination is formed.  
 
         
 
A similar model of Aβ1–40, which insert C–terminal into the membrane, has been used by 
Lemkul et al to study the Aβ–membrane behavior by MD simulations (Figure 5–4), which 
found that the aggregates of Aβ1–40 stably bind to membrane (Lemkul & Bevan 2013).  
 
Figure 5–3: Schema of one invagination (grey) induced by 
embedded Aβ aggregate (green). Single Aβ aggregate 
embedded into the membranes, which induces and 
stabilizes the negative membrane curvature. Each Aβ 
peptide (orange) is in a hairpin structure, with hydrophobic 
C–terminal part in the hydrophobic tail region of 
phospholipids, and N–terminal probably outside the 








   
 
 
Zhao et al. have investigated membrane interaction of Aβ1–42 fragments using mix 
membrane from DPPC, chol., Cl- and Na+ by MD study (Figure 5–5). Aβ1–42 fragment contains 
residues 1–27 (N–terminus) interact with the lipid‐aqueous interface region, whereas 




Based on those MD studies, we may imagine that part of Aβ aggregates insert into 
membrane, so that the embedded Aβ aggregates have their hydrophobic C–terminal part in 
the hydrophobic tail region, and, hydrophilic N–terminal probably remains contact with lipid 
headgroup. Within the bilayers, the Aβ1–42 peptides might forms similar structures as were 
proposed for oligomeric Aβ1–42 complexes in vitro (Figure 5–6 a). Alternatively, the Aβ 
peptides could form a hairpin structure as in amyloid fibrils model (Figure 5–6 b) (Ahmed et 
al. 2010).   
 
Figure 5–5: MD study of Aβ1–42 fragments membrane interactions. Residues 1‐27 (left) interact with 
the lipid‐aqueous interface region. Residues 28‐42 (right) inside the hydrophobic tail region. 
Membrane contained DPPC, chol., Cl- and Na+. Figure adapted from Zhao et al. (Zhao et al. 2011). 
Figure 5–4: Configurations of Aβ1–40 monomer (black) and aggregate (colored) with POPC membrane 





In our hypothetical membrane interaction model (Figure 5–3), Aβ aggregates embed into 
the membranes, and induce the negative membrane curvature. Each Aβ peptide is in a 
hairpin structure, with the hydrophobic C–terminal part embedded in the tail region of the 
lipids and N–terminal close to lipid headgroup (Figure 5–3). The localization of the 
hydrophobic hairpin structures makes the C–terminal part of Aβ1–42 bulkier than the N–
terminus, which leads to a wedge (trapezoid) shaped structure of the aggregates/oligomers 
in the membrane.   
Several possible orientations of the C–terminus within Aβ1–42  aggregate have been 
suggested by Ahmed et al for pentamers (Figure 5–7) and by Bernstein et al for haxamers 




We measured an average diameter about 1 µm for a typical spherical invagination in GUVs 
that was induced by Aβ1–42 (Figure 4–28). This is about 100–fold larger than the size of a 
single early Aβ oligomers (Ahmed et al. 2010). Based on the suggestion of possible size and 
structure of Aβ aggregates/oligomers by Ahmed et al (Figure 5–7) (Ahmed et al. 2010), we 
Figure 5–7: Schematic of the Aβ1–42 pentamer based on SEC and AFM data. Figure adapted from 
Ahmed et al (Ahmed et al. 2010). 
Figure 5–6: Schematic structure of Aβ1–42 monomers, within the oligomer (left) and within fibrils 








assume that those invaginations, i.e. negative membrane curvatures, may be induced 
through embedding of multiple wedge shaped oligomers as shown in Figure 5–3.  
Further mechanical details, such as the depth of Aβ insertion, the internal packing of insert 
Aβ aggregates complex contains only Aβ or it is an Aβ–lipid mixture, or the way of Aβ–
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6 Conclusion and outlook 
One of the pathological hallmarks of Alzheimer’s disease (AD) is deposits of the protein 
fragment β–amyloid in the form extracellular plaques (George G. Glenner & Wong 1984). 
Amyloid–beta peptides (Aβ) between 38–43 amino acids in length are formed by proteolytic 
cleavage of a membrane protein, the amyloid precursor protein (APP). Aβ is released as a 
monomer and tends to form aggregates spontaneously. The oligomeric species of Aβ1–42 are 
tightly linked to AD pathogenesis and are presumed to be the cause of neuronal damage 
(Walsh et al. 2002). Many studies have suggested that the reuptake of extracellular Aβ1–42 
and subsequent formation of intracellular aggregates might be one pathway that leads to 
neuronal damage and neurotoxicity (Friedrich et al. 2010; Hu et al. 2009). However, 
questions remain as to where aggregates form, how the state of aggregation of Aβ1–42 
relates to its internalization, and why aggregated species (oligomer) are far more toxic than 
monomers and large fibrils. Clearly the aggregation and internalization of Aβ1–42 and the 
connections between these processes may be vital in understanding the ultimate toxic 
effects of this peptide.  
My thesis project aims to understand the structural and mechanistic details of Aβ1–42 
internalization. We used fluorescently labeled Aβ1–42 to visualize the aggregation state of 
peptides and track their neuronal uptake in a human neuroblastoma (SH–EP) cell model. We 
examined the relationship between the aggregation state of extracellular Aβ1–42 and the 
efficiency of its internalization to determine whether the formation of aggregates is a 
prerequisite to or the consequence of its neuronal uptake, and found that the cells very 
efficiently internalized β–sheet positive aggregates of Aβ1–42 that form early in its 
aggregation kinetics. The cellular uptake was correlated with cytotoxicity. These results 
suggest that aggregate formation is the prerequisite rather than the consequence of Aβ1–42 
uptake and that interaction of the Aβ1–42 oligomers with the membrane is the first step of 
the endocytotic process.  
The second aim of my thesis is therefore to characterize Aβ membrane interaction in detail. 
By using two species of Aβ1–42 monomers that were each labeled with a different 
fluorophore, we could track Aβ self–association by Förster resonance energy transfer (FRET). 
The FRET experiment showed that Aβ1–42 aggregates form on the plasma membrane of the 
neuronal model cells, confirming that oligomer formation precedes cellular uptake of Aβ1–42. 
This also suggests that the membrane serves as a platform for highly efficient aggregation.  
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A key reaction in these processes is the binding and aggregation of Aβ1–42 on the plasma 
membrane. Therefore, next goal is to study the interactions of Aβ1–42 with lipid bilayers in 
vitro by confocal microscopy using model membrane systems, such as various types of giant 
unilamellar vesicles (GUVs) and giant plasma membrane vesicles (GPMVs) isolated from the 
plasma membrane of neuroblastoma (SH–EP) cells. Surprisingly, we found that a population 
of Aβ species from the end of the lag phase of Thioflavin T aggregation kinetics has a very 
high affinity to the lipid of membranes and induces negative membrane curvature in both 
GUVs and GPMVs membranes. Both, the Aβ1–40 and Aβ1–42 induced membrane invaginations 
the liquid disordered (Ld) phase, whereas a control peptide, scrambled–Aβ1–42, that was 
aggregation–incompetent did not.  
Additionally, blocking the clathrin–mediated endocytosis pathway could not fully inhibit the 
uptake of Aβ1–42. There was no colocalization of plasma membrane–bound Aβ1–42 and 
transferrin, which implies that Aβ1–42 did not localize into clathrin–coated pits. These 
observations suggest that there may be a route of Aβ1–42 endocytosis that is independent of 
the clathrin–mediated process and that Aβ1–42 may catalyze its own endocytosis. 
While the steps that lead to the initial production of Aβ1–40 and Aβ1–42 from APP have been 
intensively studied, many questions remain about the roles the peptides play in healthy 
neurons and in the pathophysiology of AD. Here we hypothesized that cytotoxicity might be 
linked to an uptake of extracellular Aβ1–42. Our experiments addressed two essential 
components of this hypothesis: i) that the β–sheet structure is possible a prerequisite for 
Aβ1–42 internalization; and ii) that Aβ1–42 oligomers can facilitate their own endocytosis 
resulting intracellular accumulation and cytotoxicity. We mapped out one of the mechanism 
by which Aβ1–42 could be efficiently internalized: demonstrating the disordered aggregate 
species without β–sheet structure has a very high lipid affinity, bind rapidly to plasma 
membrane, where they aggregate, and are then taken up in endocytic vesicles. The cytotoxic 
effect is positively correlated with monomer uptake in a concentration–dependent manner, 
suggesting not only that the internalized Aβ1–42 aggregates are more toxic, but also that the 
formation of higher aggregates species is the first step by which Aβ1–42 leads to cytotoxicity. 
These experimental evidences may improve our understanding of Aβ toxicity and AD 
pathology, and suggest new approaches for potential therapies. 
Moreover, our experimental evidence may permit us to recognize a possible physiological 
function of non–toxic Aβ1–40. Aβ1–40 has been observed in very close association with 
synaptic activity and neuron survival (Plant et al. 2003), but the understanding about 
mechanistic details is still limited. Very recently, a new ultrafast endocytosis of synaptic 
vesicles was characterized that is 200 times faster than clathrin–mediated endocytosis 
(Watanabe et al. 2013). APP is concentrated on the synaptic plasma membrane, where 
cleavage could occur and Aβ could be release at relatively high local concentrations. Aβ1–40 
might support the formation of invaginations in the presynaptic active zone. The 
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characterization of a possible role of Aβ1–40 and Aβ1–42 in synaptic vesicle endocytosis will be 
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